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SUMMARY 
Gamma-aminobutyric acid type A (GABAA) receptors are the major inhibitory 
neurotransmitter receptors in the central nervous system (CNS). These heteropentameric 
transmembrane proteins act as chloride ion channel upon activation by the endogenous ligand γ-
amino butyric acid (GABA). Until now, 11 distinct GABAA receptor subtypes have been 
identified in the human brain. They differ in their subunit stoichiometry, tissue localization, 
functional characteristics, and pharmacological properties. Many CNS depressant drugs, such as 
the benzodiazepines exert their action via enhancement of the GABAergic neuronal inhibition. 
However, therapy may be accompanied by unwanted side-effects and specific clinical action is 
precluded due to the lack of GABAA receptor subtype selectivity.  
In a preliminary screen the lipophilic extracts of Piper nigrum fruits, Angelica pubescens 
roots, Acorus calamus roots, Biota orientalis leaves and twigs, and Kadsura longipedunculata 
fruits had shown positive GABAA receptor modulating activity in an in vitro functional, 
automated two-microelectrode voltage clamp assay with Xenopus laevis oocytes, which 
transiently expressed α1β2γ2S GABAA receptors.  
Aiming at the discovery of new scaffolds which act at the GABAA receptor, the active 
constituents of these five plant extracts were identified by means of an HPLC-based activity 
profiling approach. In total, we discovered 28 secondary metabolites with positive GABAA 
receptor modulating properties belonging to the structural classes of coumarins, monoterpenes, 
sesquiterpenes, diterpenes, phenylpropanes, piperamides, and lignans. Their structures were 
elucidated by a combination of powerful analytical methods such as HPLC-PDA-TOF-MS, 
highly sensitive microprobe NMR, and for chiral compounds, polarimetry and ECD. 
Determination of relative and absolute configuration was supported by conformational analysis 
and quantum chemical calculations. Furthermore, three yet unknown natural products could be 
identified.  
HPLC-based activity profiling with P. nigrum enabled the identification of 13 structurally 
related piperamides with minimum amount of extract. This allowed us to draw preliminary 
structure activity considerations for the scaffold of piperine, which was the main α1β2γ2S GABAA 
receptor modulator in this plant (EC50: 52.4 ± 9.4 μM, maximal stimulation of GABA induced 
chloride currents (IGABA) by 302% ± 27%). 
9
  
Sandaracopimaric acid and isopimaric acid from B. orientalis were tested for subtype 
selectivity at α1-3,5β1-3γ2S subtypes which revealed a comparatively high efficiency of both 
compounds at α2/3-subunit containing receptors. Additionally, sandaracopimaric acid exerted 
superior efficiency at receptors comprising β2-subunits. It showed EC50 values from 24.9 ± 6.3 
μM to 82.2 ± 46.6 μM, and efficiencies ranging between 502% ± 56% to 1101% ± 98% 
potentiation of IGABA at the subtypes of investigation. A decrease of locomotor activity in the 
Open Field behavioral model was observed after intraperitoneal injection of 3 to 30 mg 
sandaracopimaric acid per kg bodyweight in mice. A trend towards anxiolytic-like activity could 
be observed with 1 and 3 mg/kg.  
Further “drug-like” GABAA receptor modulating scaffolds were discovered among the 
lignans from K. longipedunculata (potencies down to 12.8 ± 3.1 μM and efficiencies up to 886 ± 
291% stimulation of IGABA) and among the sesquiterpenes from A. calamus (potencies down to 
34.0 ± 6.7 μM and efficiencies up to 886 ± 105% stimulation of IGABA).  These substances have 
potential for the further development as therapeutics acting at the GABAA receptor. 
10
  
ZUSAMMENFASSUNG 
Gamma-Aminobuttersäure Typ A (GABAA) Rezeptoren sind die wichtigsten inhhibitorischen  
Rezeptoren im zentralen Nervensystem. Neunzehn verschiedene GABAA Rezeptor 
Untereinheiten können in unterschiedlicher Stöchiometrie zu Heteropentameren (GABAA 
Rezeptor Subtypen) konglomerieren und so transmembranäre Chloridionenkanäle bilden, die 
durch den endogenen Liganden γ-Aminobuttersäure (GABA) aktiviert und dadurch geöffnet 
werden. Bisher konnten 11 verschiedene GABAA-Rezeptor-Subtypen im menschlichen Gehirn 
identifiziert werden. Diese unterscheiden sich in ihrer Gewebe-Lokalisierung und ihren 
funktionellen und pharmakologischen Eigenschaften. Viele zentraldämpfende Medikamente, wie 
z.B. die Benzodiazepine üben ihre Wirkung über die Verstärkung der GABAergen Hemmung 
neuronaler Schaltkreise aus. Die Therapie mit diesen Wirkstoffen ist jedoch oft von 
unerwünschten Nebenwirkungen begleitet, und eine spezifische klinische Wirkung kann 
aufgrund der fehlenden Selektivität für einzelne GABAA-Rezeptor-Subtypen nicht erreicht 
werden. 
Im Rahmen eines vorausgehenden Screenings riefen lipophile Extrakte aus den Früchten von 
Piper nigrum und Kadsura longipedunculata, aus Wurzeln von Angelica pubescens und Acorus 
calamus, sowie aus Zweigen und Blättern von Biota orientalis eine Verstärkung des GABA-
induzierten Chloridionen Stroms durch GABAA Rezeptoren des α1β2γ2S Subtyps hervor. Als 
Testsystem diente ein automatisiertes Zwei-Mikroelektroden-Spannungsklemme Verfahren an 
Xenopus Oozyten. Die aktiven Inhaltsstoffe der fünf Pflanzenextrakte wurden mittels HPLC-
basiertem Aktivitäts Profiling identifiziert, mit dem Ziel neuartige Verbindungen mit GABAA 
Rezeptoraktivität zu entdecken. 
Insgesamt wurden 28 Naturstoffe aus verschiedenen Strukturklassen (Coumarine, 
Monoterpene, Sesquiterpene, Diterpene, Phenylpropane, Piperamide und Lignane) isoliert, 
welche alle positiv GABAA-Rezeptor modulierende Eigenschaften aufwiesen. Für deren 
Strukturaufklärung wurden analytische Methoden wie HPLC-PDA-TOF-MS, ‘Microprobe’ NMR 
(Mikro-Probenkopf) und, für chirale Verbindungen, Polarimetrie und Zirkulardichroismus 
eingesetzt. Die Bestimmung der relativen und absoluten Konfiguration wurde dabei durch 
Konformationsanalysen und quantenchemische Berechnungen unterstützt. Darüber hinaus 
konnten drei bisher unbekannte Naturstoffe identifiziert werden. 
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Neben Piperin, das am α1β2γ2S-Subtyp eine Wirkstärke von 52.4 ± 9.4 μM (EC50) und eine 
maximale Stimulation der GABA-induzierten Chloridströme von  302% ± 27% aufwies, konnten 
aus Piper nigrum mithilfe des HPLC-basierten Aktivitäts Profiling noch weitere strukturell 
verwandte, unterschiedlich stark aktive Piperamide identifiziert werden. Dadurch konnten erste 
Voraussagen bezüglich Struktur-Wirkungs Beziehungen dieser neuartigen GABAA Rezeptor 
Modulatoren zu getroffen werden. 
Sandaracopimarsäure und Isopimarsäure aus B. orientalis wurden an α1-3,5β1-3γ2S Subtypen auf 
mögliche Subtyp-Selektivität hin getestet. An Rezeptoren mit α2/3-Untereinheiten trat bei beiden 
Substanzen ein vergleichsweise hoher Maximaleffekt auf. Die Wirkstärken von 
Sandaracopimaric variierten zwischen 24.9 ± 6.3 μM und 82.2 ± 46.6 μM, die Maximaleffekte 
zwischen 502% ± 56% und 1101% ± 98% an den verschiedenen Subtypen. Zusätzlich konnte für 
diese Substanz ein vergleichsweise starker Maximaleffekt an Rezeptoren mit β2-Untereinheiten 
gemessen werden.  
Im Open-Field-Test mit Mäusen wurde nach intraperitonealer Injektion von 3 bis 30 mg 
Sandaracopimarsäure pro Kilogramm Körpergewicht eine Abnahme der lokomotorischen 
Aktivität beobachtet. Bei niedrigeren Dosierungen (1 und 3 mg/kg) war ein Trend hin zu 
anxiolytischer Aktivität festzustellen.  
Weitere, aus pharmakologischer Sicht interessante, Naturstoffe mit vielversprechender 
GABAA-Rezeptor Aktivität, konnten aus K. longipedunculata isoliert werden. Die Lignane 
wiesen EC50 Werte ≥ 12.8 ± 3.1 μM und Maximaleffekte ≤ 886% ± 291% auf. Auch unter den 
Sesquiterpenen aus A. calamus fanden sich einzelne interessante Verbindungen (EC50 ≥ 
34.0 ± 6.7 μM, Maximaleffekte ≤ 886% ± 105%). Diese Substanzen sind geeignete Kandidaten 
für die Entwicklung neuer Wirkstoffe mit GABAA-Rezeptor Aktivität. 
12
  
1. AIM OF THE WORK 
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Therapy with drugs acting at the GABAA receptor has been hampered by serious unwanted 
side effects such as cognitive impairment, tolerance, and drug dependence. These are partly 
caused by insufficient GABAA receptor subtype selectivity. Current development of subtype-
specific GABAA receptor modulators with a beneficial clinical profile largely focuses on 
exploring the benzodiazepine binding pocket using medicinal chemistry on known drugs. There 
is an urgent need for novel scaffolds acting at the GABAA receptor with potential for drug 
development. Moreover, such substances might enhance understanding of drug interaction with 
this complex target.  
Nature provides a wealth of small molecules with huge structural diversity. Therefore a 
promising approach in lead discovery is to screen for new GABAA receptor ligands in biogenic 
material. Numerous studies have reported interaction of extracts or purified natural products with 
the GABAA receptor [1, 2]. However, many are limited to data from binding assays and hence 
only allow restricted estimation of a compound’s potential as a lead candidate.  
The starting point of this work was a screen of 982 plant and fungal extracts in an automated 
two-microelectrode voltage clamp in vitro assay using Xenopus laevis oocytes which transiently 
expressed GABAA receptors of the α1β2γ2S subtype. A total of 101 extracts potentiated GABA 
induced chloride currents by more than 30% at 100 µg/ml, which was set as a threshold for 
sufficient activity.  
As a first step, promising extracts had to be selected for isolation of their active principles. 
Selection criteria included sufficient positive GABAA receptor modulatory activity, expected 
chemical diversity based on taxonomic considerations, and contingently traditional usage.  
In a next step, constituents responsible for the activity within active extracts had to be 
identified and evaluated according to their lead potential. The aim was to isolate the most 
interesting molecules with the aid of diverse chromatographic methods and to fully elucidate their 
structure by means of spectrometric and spectroscopic methods. The focus, however, had to be 
kept not solely on the isolation and characterization of the major bioactive compounds, but also 
on structurally related constituents occurring in the same plant to evaluate structure-activity 
relationships. 
The activity of the compounds was to be reassessed in the Xenopus assay by complete 
pharmacological characterization at the α1β2γ2S GABAA receptor subtype (that is the 
determination of potency by measuring EC50 values and efficiency by recording maximal 
potentiation of the GABA induced chloride current). Pronounced modulatory activity at the main 
14
  
GABAA receptor subtype and structural “drug-likeness” were criteria for targeted selection of 
novel scaffolds that were to be tested for GABAA receptor subtype selectivity and, in a next step, 
for in vivo pharmacological effects. 
References 
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natural products of plant origin. Adv Pharmacol 2006; 54: 286-316 
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alternatives. Curr Pharm Design 2004; 10: 1035 
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2. INTRODUCTION 
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 2.1. Lead Finding from Nature  
Nature has been a generous source for remedies for thousands of years. All over the world 
people have been treating their illnesses and diseases by using medicinal preparations from 
natural origin. While in western countries phytotherapeutics currently experience a renaissance as 
“soft medicine”, nature has not ceased to be an important source for modern drug discovery [1]. 
Historically, many ground-breaking drugs were discovered from nature: penicillin from the 
fungus Penicillium notatum, morphine from the opium poppy (Papaver somniferum) or digoxin 
from the foxglove (Digitalis purpurea) to mention a few. These were, however, marketed in 
times when safety requirements for drug approval were at a much lower level than today. If 
Aspirin®, a derivative of salicylic acid from willow bark, had not been registered as a drug 
already in 1899 it would probably not cure billions of people’s headaches today since it would 
have failed preclinical tests due to gastric toxicity in rats and dogs [2]. Despite constantly 
increasing regulatory requirements, nearly 30% of the new chemical entities (NCE) approved by 
the U.S. Food and Drug Administration (FDA) within more than two decades (1981-2006) were 
natural products or semi-synthetic derivatives thereof [3]. In March 2008, there were 37 new drug 
approvals (NDA) or close to NDA (late-stage clinical development) falling into this class [4]. Of 
these, 8 have been launched or are in registration with the (FDA) as at April 2011 (Table 1).  
Table 1: Natural products and natural product derivatives which have been launched or 
are in registration with the FDA since March 2008 [4, 7]. 
Drug Lead compound Year introduced Disease area Classification 
Launched 
Eribulin Halichondrin B  2010 Oncology  NP-derived 
Everolimus  Rapamycin 
(Sirolimus) 
2009 
2010 
Oncology 
Immunosuppression 
Semi-synthetic 
NP 
Telavancin Vancomycin 2009 Antibacterial Semi-synthetic 
NP 
Methylnaltrexone Morphine 2008 Opioid-induced 
constipation and pain 
NP-derived 
Fingolimod Myriocin 2010 Multiple sclerosis NP-derived 
Cabazitaxel Paclitaxel 2010 Oncology Semi-synthetic 
NP 
NDAs 
Dapagiflozin Phlorizin 2011 Type 2 diabetes NP-derived 
Fidaxomicin Tiacumicin B 2010 Antibacterial NP 
NDA: New drug approval; NP: Natural Products 
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Figure 1: Drug discovery and development from natural origins. The upper bar shows the general steps in the drug 
discovery and development process. The lower bar highlights steps within the hit-to-lead process which need to be 
accomplished when screening is performed with crude extracts or fractions. On the basis of Koehn, F.E., 2008 [5] 
Even though potent drugs recently have been developed from natural sources (for extensive 
reviews see Potterat and Hamburger, 2008 [1] and Newman and Cragg, 2007 [3]), drug discovery 
and development from natural sources seem to be less and less attractive for pharmaceutical 
companies [5]. Competitive marketing, laborious litigation, and the above mentioned increasing 
regulatory and public requirements concerning drug safety, have made drug discovery and 
development an extraordinarily cost-intensive business while pharmaceutical companies must 
calculate carefully cost-benefits ratios of each drug candidate to hold their ground [6]. 
Several “challenges facing drug discovery from natural sources” have been listed by Li and 
Vederas in 2009 [6]. They include disadvantages of high-throughput screening (HTS) of natural 
sources over HTS of synthetic compound libraries (poor solubility, complex mixtures, 
synergisms/antagonisms, poor compound stability). Moreover, traditional isolation strategies of 
bioactive natural products such as bioassay-guided isolation (see Chapter 2.2) are accompanied 
by a high probability of hit duplication [6, 8]. Further challenges in drug discovery from natural 
origin are characterization of the complex structures of natural products, cost-intensive 
development of synthesis strategies, difficulties in access and resupply of source material, and 
intellectual property issues [1, 6]. However, apart from various efforts undertaken in 
revolutionizing drug discovery from natural origin [6, 9], the traditional approach of lead 
discovery from nature is still pursued and therefore constantly being optimized [1, 8]. The most 
important steps in screening of biogenic material and hit-to-lead development with natural 
products (Figure 1) are described in Chapter 2.2.  
19
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 2.2. Identification and Structural Characterization of Bioactive 
Plant-derived Natural Products 
Screening of Plant Extracts for Bioactivity 
After target identification and establishment of a suitable bioassay, different approaches for 
lead discovery from plant material may be chosen. While prefractionated extracts or purified 
natural product libraries are preferred by pharmaceutical companies, a reasonable, less costly 
alternative is screening crude extracts. The latter provides a much greater structural diversity than 
a pure compound library and includes fewer samples to screen compared to prefractionated 
extracts [1]. Different strategies are pursued to assemble extract libraries. Source material may be 
collected randomly or in a targeted manner with a focus on chemotaxonomic relationships. 
Ethnomedicinal and traditional usage is another criterion for selection since traditional medicines 
are rich in pharmacologically active compounds [2], and phytotherapeutical resources like 
European folk medicine, traditional Chinese medicine (TCM), or Ayurvedic medicine are readily 
accessible. 
Isolation of Bioactive Natural Products 
Bioassay-guided isolation is the classical approach used to unravel the identity of bioactive 
natural products simultaneously with their exhaustive isolation from the source material. It 
usually begins with open column chromatography of an active extract followed by consecutive 
chromatographic steps with increasing separation performance. The isolation of the active 
principles is guided by intermediate testing of chromatographic fractions in the particular 
bioassay. Complete structure elucidation and compound identification is often done at the end of 
the process (Figure 2). Immediate large scale isolation without the possibility of linking the 
activity to single compounds makes this strategy extremely cost-intensive and time-consuming, 
especially if in the end known or otherwise uninteresting compounds are identified. Moreover, 
bioactivity is often lost during the purification process. These are the major drawbacks of this 
approach, often referred to as a “search for the needle in the haystack”, making it little applicable 
for the high-throughput environment of modern drug discovery [3]. 
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Figure 2: A search for the “needle in the haystack”: the bioassay-guided approach. An 
active extract is separated in a large scale in a series of chromatographic steps starting 
with low resolution separation methods such as open column chromatography. Each 
fraction of every step is tested in the bioassay to track the active compound(s). Note that 
structure elucidation and hence compound identification is done at the end of the 
process. 
The constant evolution of powerful analytical technologies like MS and NMR combined with 
the increasing performance of separation techniques has enabled a very elegant, miniaturized 
approach to accelerate dereplication1 of bioactive compounds in crude extracts, namely HPLC-
based activity profiling (Figure 3). Briefly, a minute amount of a bioactive extract is separated 
over analytical or semi-preparative HPLC and divided into microfractions which are to be tested 
in the particular bioassay. Simultaneously, on-line or off-line chemical analysis allows direct 
allocation of the activity to single constituents which is in contrast to the classical approach of 
bioassay-guided isolation [3, 4]. An on-line HPLC-MS system is the basic equipment for HPLC-
                                                 
1 Identification of known or otherwise uninteresting compounds early in the isolation process in order to avoid 
duplication. 
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 based activity profiling since it provides UV-VIS absorbance spectrum, mass abundance, 
molecular mass, and even molecular formula in case of high accuracy mass detectors in a single 
run [5]. Simple quantitative information may also be obtained by hyphenated evaporative light 
scattering detection (ELSD) [3]. Detailed structural information is achieved by NMR 
measurements of peak-resolved HPLC-fractions containing the compounds of interest, and even 
determination of absolute configuration is possible by on-line HPLC-CD [6]. Comparison of 
combined spectral data with natural products databases allows rapid dereplication of interesting 
constituents. Hence, promising secondary metabolites can be distinguished from uninteresting 
ones. Based on these results, a project can be discontinued or further pursued by beginning large-
scale isolation.  
 
 
 
 Figure 3: A schematic view of the miniaturized HPLC-based activity profiling 
approach. High performance chromatography allows early dereplication, and highly 
sensitive and accurate analytical instruments enable structure elucidation by using only 
minute amounts of an extract. Figure kindly provided by M. Hamburger. 
 
Recently, a variety of innovative methodologies for tracking bioactivity within complex 
mixtures have been established, but they have not yet found broad application. These include 
diverse MS-based methods mostly detecting ligands binding to a specific immobilized target, 
NMR-based methods revealing ligand interaction with soluble proteins, and investigations on a 
microchip format such as in vitro or in vivo gene expression profiling on microarrays [3]. HPLC 
is the most widespread method for separation of extracts and it has been hyphenated to bioassays 
23
 (mostly receptor or enzymatic binding assays) to track bioactivity. However, such fully on-line 
strategies cannot be broadly applied since the number of bioassays compatible with HPLC 
separation conditions is limited. Moreover, post-column diffusion lowers peak resolution and 
every set-up using a different bioassay must be validated separately [3]. In principle, 
microfractionation such as in HPLC-based activity profiling and subsequent off-line sample 
testing allows combination with all cell-based and molecular assays which are usable in a 
microscale. This approach has been proven to be well suited to high throughput settings [7-10]. 
HPLC-based activity profiling is a cost-efficient and time-saving strategy to detect robust hits 
from natural origin. Early dereplication and complete structure elucidation using minimum 
amounts of extract is only possible due to a variety of high performance analytical methods 
which provide complementary data on the constitution and configuration of a compound. The 
most widely used methods combined with HPLC-based activity profiling are described briefly in 
the following section. 
Structure Elucidation of Natural Products 
A PDA detector is standard to modern HPLC equipment providing the spectral profile of a 
compound with a chromophore absorbing light from UV to near IR. The specific pattern of 
maximal absorptions, which for most natural products occurs between 200 and 550 nm, often 
allows relating them to classes of secondary metabolites with characteristic chromophores from 
the beginning [11]. Mass spectrometers with accuracy in the low ppm range provide accurate 
masses to calculate the molecular formula of a compound. Adequate equipment for the detection 
of accurate masses of non-volatile and thermally labile natural products consists of an ion source 
like electrospray ionization (ESI) or atmospheric-pressure chemical ionization (APCI), and a 
mass analyzer such as time-of-flight (TOF). Lower cost and lower accuracy ion trap analyzers are 
often coupled to HPLC and are suitable for MSn experiments (repeated tandem mass 
spectrometry) which give insight into connectivity of atoms in a molecule [12]. Knowing the 
molecular formula is crucial for correct interpretation of NMR spectra, recorded in a next step for 
establishing a natural product’s structure.  
The technical advances made since the implementation of NMR into compound identification 
afforded the continuous generation of higher magnetic fields (currently, 23.5 Tesla can be 
reached with 1 GHz instruments), and high performance probes, such as capillary NMR flow 
probes and 1 mm microprobes with an active sample volume in the single-digit μL range, or 
24
 cryogenically cooled microprobes (down to 1.7 mm, active sample volume 30 μL). As a result, 
sensitivity and signal-to-noise ratio increased dramatically, allowing higher sample throughput 
and smaller sample quantities. This is very important for structure elucidation of natural products, 
since limited amount is one of the major issues [13]. The above mentioned technical 
preconditions enabled on-line interfacing NMR and chromatography. Sample application has 
been achieved by loop-transfer, on-flow, or stop-flow methods. In these cases, however, 
deuterated solvents are necessary for chromatography, and if undeuterated solvents are used, 
inevitable solvent suppression might interfere with analyte signals. Moreover, sample 
concentration is bound to natural abundance of the compound in the extract. At-line solid-phase 
extraction has been implemented to overcome these issues [11] but sample loss due to 
insufficient trapping/elution efficiency [14] remains a drawback. Off-line HPLC 
microfractionation and subsequent sample preparation by parallel drying and redissolving into an 
appropriate concentration for high sensitivity NMR, is a convenient, less costly alternative which 
is not hampered by concentration or passive diffusion issues, nor by sample loss. 
A broad range of NMR experiments is available and the nature of the molecule dictates which 
ones are the most suitable for elucidation of constitution and configuration. One-dimensional 1H-
NMR and 13C-NMR experiments, and two-dimensional homonuclear (1H,1H-COSY) and 
heteronuclear (1H,13C) correlation experiments such as HSQC and HMBC are standard in 
determining the covalent structure of a small molecule with limited signal overlap. For more 
complex structures with several overlapping spin systems, additional experiments like e.g. 
(1H,1H)-TOCSY or (1H,13C)-HSQC-TOCSY are recommended. While these experiments detect 
scalar couplings between two nuclei, NOESY and ROESY experiments provide stereochemical 
information by displaying through space correlations to determine the complete 3D-structure of a 
molecule. These experiments, however, only disclose the relative configuration [13].  
The Challenge of the Absolute Configuration 
The determination of the absolute configuration of a natural product is indispensable since 
bioactivity as a cause of ligand-protein interactions is stereoselective. Therefore, for chiral 
compounds, structure elucidation is only complete if the absolute configuration is assigned. In 
rare cases, it can be determined by NMR experiments after esterification of the compound with 
Mosher’s acid or by application of chiral lanthanide shift reagents [13, 15, 16]. An alternative 
analytical method to determine the absolute configuration is X-ray diffraction, which requires the 
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 natural product in crystallized form. Crystallization, however, depends on the compound’s nature 
and is therefore not always possible [17]. In such cases, chiroptical methods such as optical 
rotation and circular dichroism (CD) may be essential to determine absolute configuration. CD 
provides information about conformation and absolute configuration but is restricted to 
compounds that have a chromophore in sufficient proximity to a stereocenter. Furthermore, its 
analysis relies largely on the comparison with reference spectra [18]. The emergence of high-
performance computing allows prediction of CD spectra by quantum chemical calculations. This 
is especially valuable for the analysis of new molecular entities when chemical synthesis of the 
reference compound is not an alternative [19]. In 2008, Bringmann et al. suggested a solid 
approach (Boltzmann-approach) for in silico simulation of CD spectra (Figure 4).  
 
 
Figure 4: Overview of the Boltzmann-approach to determine the absolute configuration of a chiral compound by 
conformational analysis and CD calculations (adapted from Bringmann et al., 2008 [6] 
Because flexible chromophores strongly influence the CD spectrum, a careful conformational 
analysis of an arbitrarily chosen enantiomer of the chiral compound is inevitable. This can be 
done by molecular mechanics. The most predominant conformers occurring within a specified 
energy window are then geometrically minimized by means of more sophisticated, quantum 
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 chemical calculation methods, for example density function theory. Finally, time-dependent 
calculations of electronic transitions with each minimized conformer provide UV and CD spectra 
to be Boltzmann-weighted according to each conformer’s energy. Superimposing these spectra 
results in an overall curve that can be compared with the experimental data. Computational errors 
sometimes make it necessary to slightly correct the calculated curve by adjusting it to the 
experimental spectrum based on the absorption maximum (UV-correction; Figure 4) [6].  
Each of these calculation steps can be performed at different levels of accuracy and the best 
one depends on the nature of the investigated molecule [20]. An increase in accuracy usually 
corresponds to a longer calculation time and it is a challenge to find the right balance between 
sufficient accuracy and expenditure of time.  
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 2.3. The GABAA Receptor 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the central 
nervous system (CNS). It is biosynthetically formed by simple decarboxylation of the major 
excitatory neurotransmitter, glutamate. GABA activates ionotropic GABAA receptors and 
metabotropic GABAB receptors. The GABAA receptors are the main inhibitory receptors in the 
CNS. They are primarily neuronal2 transmembrane proteins of the cys-loop pentameric ligand-
gated ion channel (LGIC) superfamily, with synaptic, extrasynaptic, and perisynaptic locations. 
Upon activation by GABA, the integral chloride channels of the GABAA receptors open. 
Resultant increase in membrane chloride permeability leads to an inhibitory postsynaptic 
potential (hyperpolarization of the neuronal membrane) that reduces triggering of further action 
potentials [1, 2].  
The GABAA receptor is an assembly of five distinct subunits. Sequencing of the human 
genome revealed the existence of 19 different GABAA receptor subunits (Figure 5) [3]. They are 
classified according to their primary structure into α(1-6), β(1-3), γ(1-3, including splice variants 
γ2S and γ2L), δ, ε, π, θ, and ρ(1-3), the latter being able to form homopentamers formerly referred 
to as GABAC receptors [1]. The expression profile of the subunits varies depending on tissular 
and cellular region. This provides the basis for the putative existence of a huge variety of 
different heteropentameric GABAA receptor subtypes. So far, 11 functional GABAA receptor 
subtypes have been identified in the CNS. The exact physiological role of only a few is known. 
Moreover the number of native GABAA receptor subtypes will further rise as more information 
on subunit expression becomes available through, for example, in situ hybridization (on the 
mRNA level) in combination with coimmunoprecipitation methods (on the protein level). 
Furthermore, studying the coregulation of subunits in cells, and genetically engineered animals 
can help to enlarge the list of identified GABAA receptor subtypes [1, 4]. The α1, β2, and γ2 
subunits are chromosome partners and ubiquitously coexpressed [3, 5]. Accordingly, the most 
prominent GABAA receptor subtype, accounting for about 40% of all GABAA receptors, consists 
of 2 α1, 2 β2 and 1 γ2 subunit [6]. The amounts of minor subtypes are still comparable with the 
                                                 
2 GABAA receptors also have been detected in pancreatic tissue. However, their physiological role in this 
location is still under investigation. [1]Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes 
of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and 
function. Update. Pharmacol Rev 2008; 60: 243-60. 
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 expression level of other CNS receptors, for example, for the biogenic amines or acetylcholine, 
reflecting the importance of the GABAergic system in neuronal circuits [1].  
  
 
Figure 5: Dendrogram showing the sequence 
identity of the 19 genes encoding for human 
GABAA receptor subunits. The Greek letters 
(αβγ specify the 8 homologous 
subunit families which share high (>70%) 
sequence identity. The length of the horizontal 
branches connecting any two subunits reflects 
the partial divergence in their particular amino 
acid sequence. The scale bar indicates 20% 
sequence divergence (reproduced from Simon et 
al., 2004 [3]) 
Many clinically relevant drugs treating psychiatric diseases, but also various model drugs 
used in research, exert their action via the GABAA receptors (Figure 6) [2, 7-9].  
The barbiturates were the tranquilizers of the first hour targeting the GABAA receptor. 
Barbital, introduced to the market by Bayer as Veronal® at the beginning of the twentieth century, 
was the first in a long series of barbituric acid derivatives. Probably due to their unrestricted 
prescription later on [11], they became notorious as “mother’s little helpers” (The Rolling Stones, 
on their album “Aftermath”, released 1966). In current clinical use, barbiturates have almost 
completely been substituted by the much safer benzodiazepines (BZD), which were launched first 
in the 1960’s (Librium® in 1960 and Valium® 1962) [12]. Currently, BZD are probably the best 
studied GABAA receptor ligands. Their site of interaction with the GABAA receptor lies in the 
interface between the α and γ subunit [13].  
Drugs acting at the BZD-binding site can be subdivided into three groups based on their mode 
of action: (i) positive allosteric modulators or BZD-site agonists, such as diazepam, (ii) negative 
allosteric modulators or BZD-site inverse agonists, such as methyl-6,7-dimethoxy-4-ethyl-β-
carboline-3-carboxylate (DMCM; a β-carboline), and (iii) null modulators or BZD-site 
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 antagonists like flumazenil. BZDs are not able to directly activate the target – a property which 
precludes lethal overdoses known from agonistic barbiturates. They have been prescribed to treat 
anxiety, panic and mood disorders, alcohol withdrawal symptoms, insomnia, and epilepsy [2]. 
Benzodiazepines modulate GABAA receptors comprising α1-3, or α5 subunits. Pharmacological 
 
 
Figure 6: The GABAA receptor as a drug target. Various clinical and model drugs exert their activity via the 
GABAA receptor (list not complete): GABA (natural agonist), its competitive agonist muscimol and competitive 
antagonist bicuculline; benzodiazepines (allosteric modulators; e.g. diazepam); picrotoxin and 
t-butylbicyclophosphorothionate (TBPS) (allosteric antagonists); barbiturates, general anesthetics e.g. propofol and 
etomidate, and neurosteroids, e.g. alfaxalone (mixed allosteric modulators/agonists); loreclezole (allosteric 
modulator); miscellaneous substances binding to the GABAA receptor, not shown: furosemide (loop diuretic; 
inhibitor of GABA), Zn2+ (inhibitor of GABA), La3+ (stimulator of GABA), penicillin (antibiotic; open channel 
blocker in high concentrations), ethanol. The binding sites are able to interact with one another upon drug binding. 
Adapted from Belelli et al. [10]. 
functions evoked by the modulation of receptors comprising one of these subunits have been 
studied extensively ([1, 12] and citations therein). The α1 containing receptors are responsible for 
the sedative action of diazepam [14-16], whereas anxiolytic-like and analgesic activity could be 
attributed to α2 and α3 containing subtypes by investigating GABAA receptor point mutated mice 
[17-20]. Moreover, drugs with preferential α5 subunit efficiency positively influenced learning 
and memory in rodents [21-24] and humans [25]. Particular properties of other GABAA receptor 
subunits are still under investigation (their tentative physiological role has been listed by Korpi 
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 and Sinkkonen, 2006 [5]). These and related findings on subtype-related pharmacological 
properties initiated the development of subtype-specific drugs with more selective 
pharmacological profiles and hence less unwanted side effects that arise due to insufficient 
GABAA receptor subtype selectivity [12]. The mechanism of long-term side effects of the BZDs, 
such as tolerance and dependence, is not yet fully understood but different subtypes seem to have 
different timescales for the onset and offset of these side-effects [26].  
The complexity of the GABAergic system with its numerous distinct GABAA receptor 
subtypes varying in their tissular, cellular, and subcellular localization is an opportunity to 
develop highly subtype specific drugs with distinct pharmacological profiles. Most recent 
findings have shown that such drugs might not only be substitutes for the widely prescribed 
benzodiazepines but also help to further understand the physiological role of the diverse GABAA 
receptor subtypes [12]. The development of highly subtype–specific GABAA receptor ligands 
remains a challenge due to the lack of a crystal structure of the GABAA receptor. Comparative 
modelling (homology modelling) of the extracellular domain, mostly based on the X-ray 
crystallographic structure of a soluble acetylcholine binding protein and recently additionally on 
the electron microscopy structure of the n-Acetylcholine receptor and the X-ray structure of 
bacterial pentameric ion channels, has provided a certain insight into the quaternary structure of 
the GABAA receptor and the BZD binding site [4, 27, 28]. Most of the current subtype-selective 
drugs which are either on the market or still in clinical trials act via the BZD binding site [12]. 
Little is known about novel structural scaffolds binding to distinct binding sites, although these 
might provide yet unknown modes of action at the target and hence might bear a different clinical 
profile.  
In vitro Bioassays to Assess GABAA Receptor Activity 
Receptor binding assays using either native tissue, or human endothelian kidney cells 
(HEK293) or mouse fibroblast leukocyte tyrosine kinase cells (LTK- cells) that are transfected 
with specified GABAA receptor subunits, are used frequently in in vitro test methods to measure 
the GABAA receptor affinity of a compound by competitive or noncompetitive displacement of a 
radiolabelled or fluorescent reference ligand [4]. Such assays are site-specific, depending on the 
labelled ligand used, and can therefore not be used to detect scaffolds for unknown binding sites. 
The informative value is, moreover, limited, since intrinsic activity (chloride permeability) 
cannot be observed directly. Substances allosterically modulating GABA binding in a negative, 
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 positive, or neutral manner, may be differentiated in experiments observing shifts of the 
concentration response curve for GABA binding [4]. Direct agonistic activity or antagonistic 
activity, however, is not revealed.  
From the perspective of developing CNS depressant drugs acting via the GABAA receptor, it 
is crucial to know whether a compound acts as agonist, antagonist, or modulator at the GABAA 
receptor. Several functional high-throughput assays have been used to obtain such information. 
These include radioactivity-based ion flux assays (measuring intracellular 36Cl concentration 
before and after drug application), fluorescence-based assays (either measuring chloride 
concentrations after quenching by fluorescent compounds or recording indirect changes in 
membrane potential), or microphysiometry studies (measuring extracellular or intracellular 
acidification rates, based on bicarbonate permeability of GABAA receptors). However, these 
techniques do not allow the membrane potential to be controlled: if electrochemical gradients are 
eliminated, electric transfer through ion channels is no longer driven which may lead to false 
negative responses. Furthermore, in the particular assays, artefacts may occur during fluorescence 
read-out, applied samples may themselves quench chloride ions impairing correct concentration 
measurements and cells cannot be continuously perfused which may lead to ligand accumulation 
in the cell. Hence, the gold-standard to study ion channel function, are electrophysiological 
techniques in which charge transfer is recorded directly and quantitatively [4, 29]. Automated 
patch-clamp instruments, demanding preferably stable cell lines and highly specialized 
consumables, are time-consuming, costly, and labor-intensive systems for electrophysiological 
measurements. The two-microelectrode voltage clamp (TEVC) technique is a convenient, more 
flexible, robust method using Xenopus oocytes (Figure 7) 
to directly measure current changes through ion channels 
such as GABAA receptors. This is done under permanent 
control of the membrane potential by a feedback circuit 
(Figure 8) [4, 29, 30]. Although less suitable for high-
throughput, it is a cost-effective technique and the data 
obtained are highly reproducible and accurate [29].  
Other expression systems for functional studies on 
recombinant GABAA receptors of basically any adequate 
subtype include mouse fibroblast LTK-cells, Chinese 
Hamster Ovary cells (CHO), and human endothelial 
Figure 7: Enzymatically defolliculated 
oocytes from Xenopus laevis. A 
diameter of about 1-1.2 mm makes these 
cells very easy to handle for 
electrophysiological measurements. 
(Picture J. Zaugg, Vienna)  
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 kidney cells (HEK293) [4]. Xenopus oocytes, however, are able to transiently express various 
molecular targets in parallel (also antitargets such as hERG K+-channels used to preliminarily 
evaluate potential for side effects and drug-drug interactions [31]) and are therefore more flexible 
than the above mentioned cell lines. Furthermore, they are favorable because they are well-
documented, and advantageous due to high expression, low endogenous expression of membrane 
proteins, and easy maintenance (Figure 7 and Figure 8). 
 
Figure 8: Schematic workflow of two-microelectrode voltage clamp studies using Xenopus oocytes for measuring 
GABAA receptor activity. The oocytes are surgically removed from female Xenopus laevis. After enzymatic 
defolliculation of the oocyte, cRNAs, transcripted from cDNA of adequate GABAA receptor subunits, are injected 
in a proper ratio to ensure subtype expression (e.g. 1:1:10 for α1β2γ2S subtypes). After 24 to 48 hrs of incubation, the 
oocytes can be used for voltage clamp measurements (Figure by Kvist et al., 2011 [29]). 
GABAA receptor activation, and opening and closure of the chloride channel is characterized 
by complex kinetics including receptor desensitization after activation [2]. Therefore, fast and 
timed sample application as well as fast perfusion of the oocyte are essential  for assessing 
reproducible data with the TEVC technique [30]. Moreover, slow false-positive currents, likely 
resulting from detergent-like compounds that have a tendency to disrupt the membrane and are 
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 quite common among natural products (saponins, fatty acids) [32], can be better distinguished 
from fast GABA or drug-induced currents. These conditions are ensured by the use of a medium-
throughput automated fast perfusion system and a sampling robot such as implemented by the 
Hering group in Vienna (Figure 9) [30].  
Figure 9: Cross-section view (a) and 
top view (b) of the oocyte perfusion 
chamber of the automated two-
microelectrode voltage clamp assay as 
implemented by the Hering group in 
Vienna [30]. Two microelectrodes (1 
and 2) are inserted via the sloping 
access inlets (8) through a glass cover 
plate (7) into the small (∼15 μL) oocyte 
chamber (c). Samples are applied by 
the tip of the liquid handling arm (3) of 
a TECAN Miniprep 60 to a funnel 
reservoir made of quartz (6) 
surrounding the microelectrode access 
holes. Perfusion of the oocyte (10, c) 
that is placed on a cylindrical holding 
device (15) is enabled by means of the 
syringe pump (9) of the Miniprep 60 
connected to the chamber body (11) via 
the outlet (12). Residual solution is removed from the funnel before drug application via the funnel outlets (4 and 5). 
In addition to the ground reference electrode (13), the cylindrical holder for the oocyte contains a reference electrode 
(14) that serves as an extracellular reference for the potential electrode. Salt bridges can be inserted into the side 
outlet for the ground electrode (13). c Schematic drawing of the solution flow inside the perfusion chamber and in 
the annular gap around the cylinder with oocyte. d Photo of the oocyte perfusion chamber. An oocyte (10) is placed 
on a cylinder and impaled with two microelectrodes (1,2) surrounded by the funnel (6). Figure and figure caption 
kindly provided by I. Baburin [30] 
Behavioral Models for GABAA Receptor Related Pharmacological Effects 
Animal models provide preliminary ideas of how a drug might act in humans. They are 
standard to preliminary assessments of the pharmacological effect of a drug in vivo that has been 
previously identified as active at a specific target in an appropriate in vitro assay. Inclusively, 
animal tests can give insight into pharmacokinetic and toxicological properties of a drug. Various 
behavioral models are used to study anxiolytic-like3 properties of a drug. The predictive value of 
most of them has been validated with BZDs [33]. Animal models of anxiety are grouped into two 
main classes (i) involving conditioned responses to stress (often painful events such as electric 
shocks used in the four-plates test or in the Vogel drinking conflict test [33] or (ii) ethology-
                                                 
3 ‘Anxiolytic-like’, ‘sedative-like’, and ‘anticonvulsant-like’ are terms for pharmacological effects of a drug in 
animals. The terms ‘sedative’, ‘anxiolytic’, and ‘anticonvulsant’ refer to pharmacological effects in humans. 
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 based models exploring spontaneous and natural reactions such as flight, avoidance, and freezing 
as a cause of stressful challenges [33]. In natural product research the most popular anxiety 
models investigating unconditioned responses have been the Elevated plus maze (measuring 
conflict between exploration and aversion to elevated open places [33, 34]), followed by the hole-
board test (measuring the response of the animal to an unfamiliar setting such as holes in the 
ground) [34], and the open field test [35]. The open field test, sensitive to BZDs and 5-HT1A 
receptor agonists [36], is based on the natural agoraphobia of rodents. The ratio of time spent in 
the periphery of an illuminated open field over time spent in the centre is measured to evaluate 
the influence of potentially anxiolytic drugs on stress-induced inhibition of exploration behavior 
[33]. Other in vivo paradigms used in relation to GABAergic activity include the accelerating 
rotating rod (rotarod) measuring motor incoordination [37], and the horizontal wire test to assess 
neuromuscular strength [37]. Both tests have been applied to detect substance induced 
myorelaxation [38]. The actimeter test independently evaluates locomotor activity and has been 
used as a control for anxiety paradigms where locomotion could influence explorative behavior 
[39]. Studies evaluating antiepileptic potential of a drug have been performed by induction of 
seizures either by convulsant drugs such as the GABAA receptor antagonists picrotoxin, 
bicuculline, and pentylenetetrazole [40-42], or by electroshocks [43]. Other experiments evaluate 
influence on hypnotic-induced sleeping time [44, 45]. Seizure activity is directly recorded during 
electroencephalographic (EEG) measurements [46], which are as well beneficial to observe 
electrical activity in the animal’s brain during experiments investigating the anxiolytic-like and 
sedative-like effect of a drug [47]. 
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2.4. Natural Products as GABAA Receptor Modulators 
In Switzerland, one of the first choices to treat weak forms of insomnia, panic attacks, and 
mood disorders is an over-the-counter sedative or tranquillizing phytotherapeutical preparation. 
These comprise medicinal plants such as valerian roots (Valeriana officinalis) or passionflower 
(Passiflora incarnata) [1]; one possible mechanism of action has been related to the GABAA 
receptor [2, 3]. Also in other health systems, such as in traditional Chinese medicine (TCM) and 
Ayurveda, one can find herbal preparations with reports of in vitro GABAAergic activity 
(Ziziphus jujuba or Withania somnifera) [4]. Regarding prescription drugs against severe CNS 
related pathologies, only 1 natural product and 6 natural product derivatives of a total of 85 drugs 
were approved by the FDA between 1981 and 2006 [5]. Those having a specific indication 
related to the GABAA receptor were synthetic compounds mostly deriving from the BZD 
scaffold. This situation has not changed much recently, as mentioned in the previous chapter. In 
contrast, there is a multitude of scientific publications that report on structurally diverse natural 
products from plant origin that act at GABAA receptors [4, 6-8]. The quality of the data, however, 
largely relies on the type of bioassay which is applied for gathering in vitro data and of the 
animal model which is chosen to confirm these data in vivo (Chapter 2.3).  
A selection of important natural products acting at the GABAA receptor as control drugs or 
compounds which qualify as lead structures and are currently being investigated for the 
development of novel therapeutic agents is provided in the following section.  
Flavonoids with GABAA Receptor Activity 
Flavonoids are a class of ubiquitously occurring polyphenols of plant origin. Many biological 
functions have been attributed to them, both in vitro and in vivo [9-11]. Some 20 years ago 
GABAA receptor activity was discovered for chrysin (1) and for the biflavone amentoflavone (2) 
[12, 13]. Flavonoids have demonstrated inter alia anxiolytic-like, sedative-like, and 
anticonvulsant-like properties and it is now known, that they exert their action via diverse 
mechanisms in the CNS [14]. Today, they are the most extensively studied GABAA receptor 
modulators from plant origin. Pharmacophore models have been generated to investigate their 
binding site [15-17] and they have served as a scaffold for medicinal chemistry [14, 18, 19]. 
6,3’-Dinitroflavone (3) is a flavonoid derivative with similarly high affinity to the GABAA 
receptor as diazepam in a [3H]-flunitrazepam binding assay. At a 30-100 times lower 
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concentration than diazepam it had highly selective anxiolytic-like effects in mice [19, 20]. 
However, a recent study with 3 on GABAA receptor subtype selectivity proved controversial for 
the current understanding of α2/3-subunit-mediated anxiolytic-like effects. This raised the theory 
of active flavonoid metabolites [21] which is in accordance with the yet limited information 
about brain bioavailability of most flavonoids [22]. Furthermore, discussions on the 
bioavailability of flavonoids in humans are controversial [14, 23].  
The mode of action of flavonoids at the GABAA receptor varies strongly with the substitution 
pattern which originates from different hydroxylation, C-prenylation, O-methylation, C- and O-
glycosidation, and/or polymerization [14, 18, 24]. Currently, two proposed distinct flavonoid 
binding sites are under discussion: a high affinity site identical with the BZD-binding site and an 
alternative low-affinity site [14]. Very recently, a second-order positive modulation 
(metamodulation) of diazepam action was observed for apigenin (4) and hesperidin (5) at 
concentrations too low for the flavonoids to show their own modulatory effects. [14, 25, 26]. 
These findings revealed an interesting, new aspect of GABAA receptor modulation by natural 
products, namely the interaction with established therapeutics. In conclusion, flavonoids are a 
very interesting class of natural products with high potential as lead compounds for developing 
drugs with GABAA receptor activity.  
 
Chart 1: Flavonoids with GABAA receptor activity 
Terpenoids with GABAA Receptor Activity 
Probably the most important terpenoid with GABAA receptor activity is picrotoxin. It is an 
equimolar mixture of two convulsant sesquiterpene lactones, picrotoxinin (6) and picrotin (7). 
Picrotoxin and pure picrotoxinin (6), which is the stronger convulsant of the two compounds 
[CD50 1.5 mg/kg BW (6) vs. 80 mg/kg BW (7)] [27], are used as controls as potent GABAA 
receptor channel blockers in vitro, and in animal convulsion studies. 
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From the perspective of lead discovery for novel therapeutic agents, valerenic acid (8) (a 
sesquiterpene with a structure reminiscent of etomidate or loreclezole; Figure 6) must be 
mentioned. In thorough investigations of GABAA receptor subtype selectivity, Khom et al. found 
that 8 specifically modulates GABAA receptors comprising β2/3 but not β1 subunits in 
concentrations between 0.1 and 30 μM. No pronounced selectivity was found for the different α-
subunits tested [28]. Later on, behavioral studies confirmed the in vitro data of 8 by showing 
anxiolytic-like activity in mice at a concentration range of 1-6 mg/kg BW [29, 30]. This effect 
was mediated by β3-subunit containing GABAA receptors as studies with point-mutated mice 
revealed [29]. Valerenic acid (8) served as a scaffold for medicinal chemistry to develop 
derivatives with higher GABAA receptor efficiency and potency [30, 31]. Although 8 was shown 
to likely be able to cross the blood-brain barrier in an in vitro cell culture model [32], it needs to 
be clarified to what extent 8 and its synthetic derivatives are bioavailable and whether 
metabolites might be responsible for GABAAergic activity in vivo.  
1S2R5S-(+)-Menthol (9), a monoterpene found in many essential oils, was shown to be a 
superior positive GABAA receptor modulator in vitro than its enantiomer (-)-menthol. This study 
on stereoselective activity at the GABAA receptor nicely shows the importance of correctly 
determining the absolute configurations of natural products.  
Miltiron (10) is a promising diterpene from the Chinese medicinal herb Salvia miltiorrhiza 
exerting anxiolytic-like behavior but not sedative-like behavior or addictive effects in mice [33]. 
Whether the mechanism of action is via direct activity at the GABAA receptor is, however, 
unclear [34].  
 
Chart 2: Terpenoids with GABAA receptor activity 
Alkaloids with GABAA Receptor Activity 
Bicuculline (11), a phtalide isoquinoline and muscimol (12), an isoxazole from fly agaric 
(Amanita muscaria), are alkaloids that bind to the GABA binding site with antagonistic (11) and 
agonistic (12) intrinsic activity. Accordingly, they exhibit convulsant (11) and anticonvulsant-like 
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(12) activity in vivo [35, 36]. These two natural products have served for many years as reference 
compounds for GABAA receptor research. Synthetic but also natural β-carboline alkaloids such 
as harmane (13) are full, partial or mixed agonists, antagonists, or inverse antagonists at the 
GABAA receptor. This is concurrent with their either CNS depressant or CNS stimulating effects 
in vivo [37]. The β-carboline scaffold has served for the development of the anxiolytic compound 
abecarnil which, however, failed to show superiority over placebo in clinical trials phase II and 
III [38]. In contrast to the nitrogen-bearing BZD or nonbenzodiazepines, most natural alkaloids 
with identified GABAA receptor activity are inhibitors of the chloride current and convulsant in 
animal models and therefore less interesting for drug development [4]. 
 
Chart 3: Alkaloids and other miscellaneous natural products with GABAA receptor activity 
Miscellanous Structural Classes with GABAA Receptor Activity 
Honokiol (14), a neolignan from Magnolia officinalis showed an anxio-selective effect in 
mice [39, 40] and has already served for medicinal chemistry efforts [41]. It has been shown to 
interact with the GABAA receptor in binding studies [42] and recent investigations using a 
functional assay revealed its β2/3 subunit selectivity for positive allosteric modulation efficiency 
[43].  
The comprehensive list of nearly 200 natural products with in vitro and/or in vivo 
GABAAergic activity composed by Moser in 2009 include the structural classes of flavonoids, 
terpenoids, alkaloids, coumarins, neolignans, diverse phenolics, polyacetylenes, pyrones, 
naphtodianthrones, and phtalides [4]. This review revealed that most studies are restricted to in 
vitro binding assays. These provide information on affinity at the GABAA receptor; however, as 
mentioned earlier, this is insufficient for a proper evaluation of the compound’s lead potential, 
since intrinsic activity is not detected in functional assays.  
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3. RESULTS AND DISCUSSION 
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3.1. HPLC-BASED ACTIVITY PROFILING: DISCOVERY OF PIPERINE AS A 
POSITIVE GABAA RECEPTOR MODULATOR TARGETING A 
BENZODIAZEPINE-INDEPENDENT BINDING SITE 
Zaugg J, Baburin I, Strommer B, Kim HJ, Hering S, Hamburger M. J Nat Prod 2010; 73; 
785-191  
 
 
 
Piperine was identified as main positive α1β2γ2S GABAA receptor modulatory constituent 
of Piper nigrum fruits by HPLC-based activity profiling. On-line high-resolution mass 
spectrometry and off-line microprobe NMR provided the analytical basis for the 
identification of another 12 structurally related piperamides with less or no activity in the 
functional assay with Xenopus oocytes. Preliminary structure-activity relationships could 
be observed using minute amounts of extract. 
 
 
 
 
 
 
 
 
Extraction of plant material for isolation, isolation of the piperamides, recording and 
interpretation of analytical data for structure elucidation (HPLC-PDA-ESI-TOF-MS and 
semipreparative HPLC – off-line microprobe NMR), writing of the manuscript, and 
preparation of figures (except for Fig. 3 and 4) were my contributions to this publication.
        
Janine Zaugg 
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HPLC-Based Activity Profiling: Discovery of Piperine as a Positive GABAA Receptor
Modulator Targeting a Benzodiazepine-Independent Binding Site
Janine Zaugg,†,§ Igor Baburin,‡,§ Barbara Strommer,‡ Hyun-Jung Kim,† Steffen Hering,‡ and Matthias Hamburger*,†
Institute of Pharmaceutical Biology, UniVersity of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland, and Departement of Pharmacology
and Toxicology, UniVersity of Vienna, Althanstrasse 14, 1090 Vienna, Austria
ReceiVed October 17, 2009
A plant extract library was screened for GABAA receptor activity making use of a two-microelectrode voltage clamp
assay on Xenopus laeVis oocytes. An ethyl acetate extract of black pepper fruits [Piper nigrum L. (Piperaceae) 100
μg/mL] potentiated GABA-induced chloride currents through GABAA receptors (composed of R1, 2, and γ2S subunits)
by 169.1 ( 2.4%. With the aid of an HPLC-based activity profiling approach, piperine (5) was identified as the main
active compound, together with 12 structurally related less active or inactive piperamides (1-4, 6-13). Identification
was achieved by on-line high-resolution mass spectrometry and off-line microprobe 1D and 2D NMR spectroscopy,
using only milligram amounts of extract. Compound 5 induced a maximum potentiation of the chloride currents by
301.9 ( 26.5% with an EC50 of 52.4 ( 9.4 μM. A comparison of the modulatory activity of 5 and other naturally
occurring piperamides enabled insights into structural features critical for GABAA receptor modulation. The stimulation
of chloride currents through GABAA receptors by compound 5 was not antagonized by flumazenil (10 μM). These data
show that piperine (5) represents a new scaffold of positive allosteric GABAA receptor modulators targeting a
benzodiazepine-independent binding site.
Gamma-aminobutyric acid type A (GABAA) receptors are the
major inhibitory neurotransmitter receptors in the brain. The
assembly of five subunits forms a central pore that is permeable
for chloride ions upon activation by the endogenous ligand
γ-aminobutyric acid (GABA). A total of 19 different subunit
isoforms have been identified in the human genome, which form
GABAA receptors in numerous combinations.1 The most abundant
GABAA receptor subtype consists of 2 R1, 2 2, and 1 γ2 subunits,
and more than 10 subtypes composed of other subunit combinations
have been identified.2 GABAA receptor subtypes differ in tissue
localization, functional characteristics, and their pharmacological
properties.3,4
The therapeutic action of the benzodiazepines and other phar-
macological compounds used to treat anxiety, panic, insomnia, and
epilepsy is mediated by an enhancement of GABAergic neuronal
inhibition through GABAA receptors.5,6 Various natural products
modulating GABAA receptors (e.g., flavonoids, monoterpenes,
diterpenes, neolignans, and -carbolines) have been identified.7,8
Little is known in most cases, however, about their subunit
selectivity, and presently no natural product derived compound is
in clinical development.
We recently embarked on a project aimed at the discovery of
GABAA receptor modulating compounds with scaffolds new for
the target. In a screening of 880 plant and fungal extracts with an
automated functional assay using Xenopus oocytes expressing
GABAA (R12γ2S) receptors, an ethyl acetate extract of Piper nigrum
showed promising activity. This observation was intriguing insofar
as it somehow seemed to corroborate traditional use of pepper in
Asian folk medicine as antiepileptic, antianxiety, sedative, and sleep-
inducing herbal preparations.9-11 Therefore, we deemed this extract
sufficiently interesting to identify the constituent(s) responsible for
the GABAA receptor modulating activity with the aid of HPLC-
based activity profiling. HPLC-based activity profiling is a rapid
and miniaturized approach for localization, dereplication, and
characterization of bioactive natural products in extracts.12 We have
successfully used it with various cell-based and biochemical
assays13-15 and recently developed and validated a profiling
protocol for the discovery of new GABAA receptor ligands.16 Here,
we describe the identification of piperine (5) as a new scaffold of
positive allosteric modulators of the GABAA receptor targeting a
benzodiazepine-independent binding site.
Results and Discussion
Extracts were screened by means of an automated, fast perfusion
system during two-microelectrode voltage clamp measurements in
Xenopus oocytes expressing functional GABAA receptors with
defined subunit composition (R12γ2S).17 When tested at 100 μg/
mL, the P. nigrum ethyl acetate extract enhanced GABA-induced
chloride ion current (IGABA) by 169.1 ( 2.4%. The extract was
submitted to HPLC-based activity profiling using a validated
protocol.16 The chromatogram of a semipreparative separation of
extract (5 mg) and the corresponding activity profile of the time-
based fractionation (22 microfractions of 90 s each) are shown in
Figure 1.
A prominent peak of activity was found in fractions 7 and 8
(potentiation of IGABA by 316.1 ( 7.0% and 248.1 ( 10.6%,
respectively), which contained the major compound of the extract.
Fraction 9 showed moderate activity (35.5 ( 1.1%), while fractions
6, 10, and 13 were only marginally active. However, nonresolved
peaks occurred in the chromatogram, in particular in the time
window of the activity peak. Therefore, separation conditions were
optimized for full resolution of the critical HPLC peaks. These
conditions were then used to measure high-resolution LC-MS data
and for peak-based microfractionation by semipreparative HPLC
for subsequent off-line microprobe NMR.
The semipreparative HPLC chromatogram obtained with 10 mg
of extract is shown in Figure 2A. A total of 30 peaks were collected
and submitted to parallel evaporation. For each peak a 1H NMR
spectrum (128 scans) was recorded with a 1 mm TXI probe. For
13 peaks, the spectra were of sufficient quality for reliable structure
identification. Molecular formulas were calculated for compounds
1-13 using accurate mass data obtained by HPLC-PDA-ESI-
TOFMS analysis of the extract. Since P. nigrum is phytochemically
well studied (95 compound entries in the Chapman and Hall
Dictionary of Natural Products18), 1-4 entries were found for each
* To whom correspondence should be addressed. Tel: ++41-61-267-
1425. Fax: ++41-61-267-1474. E-mail: matthias.hamburger@unibas.ch.
† University of Basel.
‡ University of Vienna.
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of the 13 molecular formulas. Results of the HPLC-PDA-ESI-
TOFMS analysis and database search are summarized in Table 1.
Compounds 1-13 were unambiguously identified with the aid
of 1H NMR data and comparison with published reference
data.19-29 The major peak was piperine (5), the main pungent
piperamide in P. nigrum,30 and the remaining compounds were all
structurally related amides (Chart 1). Data for 1-13 are provided
as Supporting Information. Figure 2B shows 1H NMR spectra of
minor amides 3 and 4, and 5 collected from the peak-based
microfractionation. Representative HSQC and HMBC spectra of
compounds 4 and 5, respectively, are shown in Figure 2C to provide
an impression of the quality of spectra that can be obtained with
this off-line HPLC-microprobe NMR approach.
For a quantitative determination of GABAA receptor activity of
compounds in the active time window, piperlonguminine (3),
piperanine (4), and piperine (5) were purified at preparative scale,
along with structurally related trichostachine (2) and piperettine
(7). These compounds were tested at a concentration of 100 μM in
the oocyte assay. Piperine (5) was most efficient, as it potentiated
IGABA by 226( 26%, while piperanine (4) at the same concentration
was less efficient (potentiation of IGABA by 138 ( 20%). Weak
enhancement of IGABA (32 ( 24%) was observed for 7, and
compounds 2 and 3 slightly inhibited IGABA (-29 ( 13% and -10
( 3%, respectively) (Chart 1). Given the lack of IGABA potentiation
in other fractions of the activity profile (Figure 1A), the other amides
must be considered inactive.
As shown in Figure 3, both piperanine (4) and piperine (5)
enhanced IGABA at a GABA EC5-10 in a dose-dependent manner.
The currents were stimulated at concentrations g 1 μM. Maximum
IGABA enhancement by 4 and 5 (187 ( 10%, n ) 3, and 302 (
26%, n ) 3, respectively) occurred at ∼300 μM with EC50 values
of 56 ( 19 and 52 ( 9 μM, respectively. The application of 5
prior to GABA showed no activity, indicating an allosteric
modulation of the receptor (response to application of 100 μM 5
in the absence of GABA is shown in Figure 3C). Furthermore, the
application of 100 μM trichostachine (2), piperlonguminine (3),
piperanine (4), and piperettine (7) in the absence of GABA
displayed as well no activity on GABAA receptors composed of
R12γ2S subunits (see Figure 3C).
To investigate a possible interaction of 5 with the benzodiazepine
binding site, we analyzed its effect on IGABA in the presence of the
benzodiazepine receptor antagonist flumazenil (10 μM). Potentiation
of IGABA by 300 μM piperine (5) was not significantly affected by
flumazenil (304 ( 40%, n ) 3 control vs 334 ( 108% in the
presence of flumazenil, n ) 3) (Figure 4A and B). Figure 4C
illustrates the additive effects of 100 μM 5 (180 ( 69%, n ) 3)
and diazepam (1 μM) (204 ( 48%, n ) 3) on IGABA when coapplied
(391 ( 104%, n ) 3) (Figure 4C and D).
The example of piperamides highlights the advantages of an
HPLC-based approach and, in particular, the possibility of obtaining
valuable preliminary structure-activity information via the char-
acterization of focused compound subsets without a need for
preparative purification. Activity can be easily localized in the
extract, and all peaks in the critical time window rapidly separated
by semipreparative HPLC under optimized conditions (Figures 1
and 2). A series of compounds structurally related to 5 could be
identified by a combination of on-line (HPLC-PDA-HRMS) and
off-line (microprobe NMR) requiring only milligram amounts of
extract. Off-line NMR with disposable 1 mm tubes has several
attractive features for profiling. Collected HPLC peaks can be
processed in parallel (evaporation, sample preparation for NMR).
An NMR autosampler permits unattended measurement of 1D 1H
NMR spectra, on the basis of which the need for more advanced
NMR experiments can be checked. The microtubes can be stored
for a certain time similar to classical NMR tubes, and time-
consuming experiments can be performed at a later moment. By
extending the profiling beyond the active compounds toward
inactive but structurally related molecules, small focused “virtual”
libraries are generated that provide valuable information for
preliminary structure-activity considerations. In the present case
it was clear that the nature of the amide moiety and the chain length
between the aromatic ring and the amide were critical for the
observed allosteric modulation of GABAA receptors. Rigidity of
the chain might also be important for the efficiency, as the 4,5-
dihydro derivative 4 was significantly less efficient in stimulating
IGABA compared to 5 (Figure 3).
Very recently, Pedersen et al. reported 5 as a GABAA receptor
ligand presumed to bind to the benzodiazepine binding site.31
However, only low affinity (IC50 of 1.2 mM in a [3H]-flumazenil
binding assay) was reported. We assume that the activity observed
by Pedersen et al.31 was due to low-affinity binding to the
benzodiazepine binding site at very high compound concentrations.
Besides the fact that the affinity was extremely low, a binding assay
provides neither information on the intrinsic activity of a compound
nor insights into the molecular mechanism of its action.
In contrast, our functional assay clearly demonstrated a positive
allosteric modulation of the GABAA receptor by 5 and 4 with
comparable potencies and revealed a higher efficiency of 5 in
stimulating IGABA (Figure 3). Studies with the benzodiazepine
receptor antagonist flumazenil (Figure 4A and B) and the additive
Figure 1. HPLC-based activity profiling of the black pepper extract
for GABAA receptor modulating properties. The HPLC chromato-
gram (254 nm) of a semipreparative separation of 5 mg of extract
is shown in B. Peak numbering corresponds to compounds 1-13.
The 22 collected time-based fractions, 90 s each, are indicated with
dashed lines. The potentiation of the GABA-induced chloride
current in Xenopus oocytes (IGABA) by each fraction is shown in A.
Part C shows typical traces for the modulation of GABA-induced
chloride currents through GABAA (R12γ2S) receptors by fractions
7 and 8 of the P. nigrum EtOAc extract.
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effects of 5 and diazepam (Figure 4C and D) clearly demonstrate
that 5 does not interact with the benzodiazepine binding site.
Benzodiazepines may cause undesirable effects including reduced
coordination, cognitive impairment, increased accident proneness,
physiological dependence, and withdrawal symptoms.5,32 GABAA
receptor ligands with fewer side effects are, therefore, an unmet
medical need.5,33
Our data show that 5 represents a new scaffold for positive
allosteric GABAA receptor modulators interaction with a benzo-
diazepine-independent binding site. Our study provides a molecular
basis for earlier reports on the antidepressant34,35 and anticonvulsant
activity of piperine (5)9,36,37 in rodents and corroborates traditional
uses of Piper nigrum and other Piper species.9-11,38 Even though
a number of other pharmacological properties have been repor-
ted,39-42 5 may represent an interesting lead structure. It complies
in all respects with Lipinski’s “rule of five” (MW: 285 g/mol,
ClogP: 3.31, H-bond-donor/acceptor sites: 0/4.),43 is orally bio-
available, and is readily accessible. Piperine (5) is, however, known
Figure 2. Part A shows the chromatogram (254 nm) of the optimized, semipreparative HPLC separation of the active P. nigrum extract (10
mg in 100 μL of DMSO). A total of 30 peaks were collected for off-line microprobe NMR. Peak labeling corresponds to compounds 1-13.
Part B shows 1H NMR spectra of selected compounds obtained by the separation mentioned above, whereas part C shows the spectra of
two representative 2D NMR experiments.
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to activate TRPV1 receptors40 and is a general inhibitor of both
phase I and phase II metabolism,44 which might cause side effects
and drug interactions. It should be explored to what extent
pharmacological promiscuity of piperamides can be reduced through
structural modifications.
Experimental Section
General Experimental Procedures. NMR spectra were recorded
at room temperature with a Bruker Avance III spectrometer operating
at 500.13 MHz. Proton NMR experiments and 1D and 2D homonuclear
and heteronuclear NMR spectra were measured with a 1 mm TXI probe.
Table 1. Data of HPLC-PDA-TOFMS Analysis and Associated Database Findings of Compounds 1-13, Which Were Purified from
the Active Ethyl Acetate Extract by Semipreparative HPLC
cpd tR1 (min)a tR2 (min)b λmax (nm) acc. mass found acc. mass calcd calcd formula DNP hitsc
1 6.1 6.6 221, 294, 316 313.1295 313.1308 C18H19NO3 2
2 21.5 20.6 241, 309, 342 271.1195 271.1202 C16H17NO3 1
3 26.8 25.4 243, 309, 338 273.1346 273.1359 C16H19NO3 2
4 27.9 26.2 232, 285 287.1513 287.1515 C17H21NO3 2
5 29.0 27.1 255, 310, 338 285.1361 285.1359 C17H19NO3 4
6 36.3 33.7 213, 263, 305 313.1673 313.1672 C19H23NO3 2
7 36.9 34.5 348 311.1512 311.1515 C19H21NO3 1
8 39.2 36.4 210, 263, 310, 358 315.1826 315.1828 C19H25NO3 2
9 41.7 38.7 261 327.1816 327.1828 C20H25NO3 2
10 44.9 41.6 268, 305 339.1837 339.1828 C21H25NO3 2
11 50.4 47.3 261, 307 343.2145 343.2141 C21H29NO3 2
12 51.4 48.0 213, 263, 303 355.2141 355.2141 C22H29NO3 3
13 61.1 58.5 261, 303 383.2460 383.2454 C24H33NO3 3
a Retention time in the HPLC-PDA-ESITOFMS analysis. b Retention time in the semipreparative HPLC separation (Figure 2A). c Hits in the natural
products database (Chapman and Hall Dictionary of Natural Products); search query limited by the term “piper”.
Chart 1. Structures of Piperamides 1-13 and Potentiation of
GABA-Induced Chloride Current (IGABA) in Xenopus Oocytes by
100 μM 2-5 and 7
Figure 3. Part A shows the concentration-response curves for
compounds 4 and 5 on GABAA receptors composed of R1, 2, and
γ2S subunits using a GABA EC5-10. Part B displays typical traces
for modulation of chloride currents through R12γ2S GABAA
receptors by piperine (5). In part C representative currents illustrate
the absence of direct activation of GABAA receptors (R12γ2S) by
piperine (5), trichostachine (2), piperlonguminine (3), piperanine
(4), and piperettine (7) at 100 μM in comparison to a GABA-
induced current at 1 μM.
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Spectra were analyzed using Bruker TopSpin 2.1 software. High-
resolution mass spectra (HPLC-PDA-ESITOFMS) were obtained on a
micrOTOF ESI-MS system (Bruker Daltonics) connected via a T-splitter
(1:10) to an HP 1100 series system (Agilent) consisting of a binary
pump, autosampler, column oven, and diode array detector (G1315B).
Data acquisition and processing was performed using HyStar 3.0
software (Bruker Daltonics). Semipreparative HPLC separations for
activity profiling and off-line microprobe NMR was performed with
an HP 1100 series system (Agilent) consisting of a quaternary pump,
autosampler, column oven, and diode array detector (G1315B). Parallel
evaporation of microfractions and semipreparative HPLC fractions was
performed with a Genevac EZ-2 plus vacuum centrifuge (Avantec).
SunFire C18 (3.5 μm, 3.0 × 150 mm) and SunFire Prep C18 (5 μm,
10 × 150 mm) columns (Waters) were used for HPLC-PDA-
ESITOFMS and semipreparative HPLC, respectively. HPLC-grade
acetonitrile (Scharlau Chemie S.A.) and water were used for HPLC
separations. Solvents used for extraction and column chromatography
were of analytical grade. Petroleum ether of technical grade was purified
by distillation for extraction and column chromatography. Silica gel
(63-200 μm, Merck) was used for column chromatography.
Plant Material. Dried fruits of P. nigrum L. were purchased from
the Juhuayuan Herbal Market in Kunming (Yunnan Province, China).
A voucher specimen (00 286) is deposited at the Institute of
Pharmaceutical Biology, University of Basel.
Extraction. The plant material was frozen with liquid nitrogen and
ground with a ZM1 ultracentrifugal mill (Retsch). The extract for the
screening and HPLC-based activity profiling was prepared with an ASE
200 extraction system with solvent module (Dionex) by extraction with
ethyl acetate. Extraction pressure was 120 bar, and the temperature
was set at 70 °C. For isolation of the piperamides, 343 g of ground
fruits was extracted by maceration at room temperature with petroleum
ether (4 × 2.5 L, 2 h each), followed by ethyl acetate (4 × 2.5 L, 2 h
each). The solvents were evaporated at reduced pressure to yield 14.22
and 18.84 g of petroleum ether and ethyl acetate extract, respectively.
The extracts were stored at -20 °C until use.
Microfractionation for Activity Profiling. Microfractionation for
GABAA receptor activity profiling was performed as previously
described,16 with minor modifications: separation was carried out on a
semipreparative HPLC column with acetonitrile (solvent A) and water
(solvent B) using the following gradient: 30% A to 100% A for 30
min, hold for 10 min. The flow rate was 4 mL/min, and 50 μL of extract
(100 mg/mL in DMSO) was injected. A total of 22 time-based
microfractions of 90 s each were collected. Microfractions were
evaporated in parallel and submitted to activity testing.
HPLC-PDA-ESITOFMS. The ethyl acetate extract of P. nigrum
was analyzed with acetonitrile (solvent A) and water containing 0.1%
formic acid (solvent B) using an optimized gradient profile: 30% A
isocratic for 5 min, 30% to 80% A in 65 min, 80% to 100% A in 1
min, hold for 9 min. The flow rate was 0.5 mL/min. The sample was
dissolved in DMSO at a concentration of 10 mg/mL, and the injection
volume was 200 μL. Conditions for ESITOFMS were as follows:
spectra were recorded in the range m/z 100-600 in positive mode.
Nitrogen was used as a nebulizing gas at a pressure of 2.0 bar and as
a drying gas at a flow rate of 9.0 L/min (dry gas temperature 240 °C).
Capillary voltage was set at 4500 V, hexapole at 230.0 Vpp. Instrument
calibration was performed using a reference solution of sodium formiate
0.1% in 2-propanol/water (1:1) containing 5 mM NaOH.
Semipreparative HPLC and Off-Line Microprobe NMR. Separa-
tion of P. nigrum ethyl acetate extract was carried out with the same
solvent system and gradient elution as for HPLC-PDA-ESITOFMS.
The flow rate was set at 4 mL/min, and the injected volume of extract
was 100 μL at a concentration of 100 mg/mL in DMSO. A total of 30
peak-based fractions were collected manually, evaporated in parallel,
and redissolved in d4-methanol, d1-chloroform, or d6-DMSO. For NMR
experiments of the collected fractions, the following settings were used:
64 or 128 scans to record 1H spectra; 8 scans for 1H1H-COSY spectra
using the cosygpqf pulse program; 32 scans and 256 increments to
record HSQC experiments using the hsqcedetgp or hsqcetgpsi2 pulse
program, and for HMBC-NMR, 64 scans, 128 increments, and the
hmbcgplpndqf pulse program.
Isolation of Piperamides. A portion (16.6 g) of the ethyl acetate
extract was separated by chromatography on a silica gel column (70
× 6.5 cm i.d.) using a step gradient of petroleum ether (solvent A) and
ethyl acetate (solvent B) in ratios of 10:0, 8:2, 6:4, 4:6, 2:8, and 10:0
(2 L each), respectively, to yield 20 fractions (1-20). Fractions 10
and 11 (2.02 and 9.02 g, respectively) were used for crystallization of
5 (7.16 g). The residue of the mother liquor of fraction 10 (830 mg)
was separated into 18 fractions (10A-10R) by medium-pressure liquid
chromatography on a silica gel cartridge (40-63 μm, 150 × 40 mm
i.d.). A gradient of 10% B to 50% B in 95 min and 50% B to 100% B
Figure 4. Effect of (5) on IGABA in the presence of flumazenil and
diazepam. (A) Stimulation of IGABA by 5 in the presence of
flumazenil (10 μM). The left bar shows the positive allosteric
modulation of the GABA (EC5-10)-induced chloride current by 300
μM piperine (5). The right bar illustrates that flumazenil does not
antagonize the 5-induced enhancement of IGABA. (B) Typical
GABA-induced chloride currents in the absence and presence of
the indicated concentrations of 5, or 5 and flumazenil, respectively.
(C) Additive effects of 5 and diazepam on IGABA. The left bar
illustrates the enhancement of IGABA by 100 μM (5); the bar in the
middle, by 1 μM diazepam, and the right bar illustrates enhancement
of IGABA when both compounds were coapplied. (D) Representative
chloride currents induced by 5 μM GABA (corresponding to
EC5-10), current enhancement by 5 (100 μM) and diazepam (1 μM),
and IGABA during coapplication of both compounds.
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in 60 min was applied at a flow rate of 20 mL/min. From fraction 10L
(140 mg), a total of 65.3 mg was separated by injecting different
volumes of a concentration of 10 mg/mL DMSO onto the semiprepara-
tive HPLC column in order to isolate 4 (1.5 mg) and 7 (13.4 mg). The
gradient profile using acetonitrile (solvent C) and water containing 0.1%
formic acid (solvent D) was 40% C to 55% C in 25 min. The flow rate
was set at 4 mL/min. Further on, a total of 68.3 mg of fraction 19 (1.2
g) and 56.2 mg of fraction 9 (60 mg) were separated using the
semipreparative HPLC system by repeated injection of different
volumes of 10 mg/mL DMSO dilutions. Separation of fraction 19
yielded compound 2 (10.5 mg) using the following gradient system:
40% isocratic C for 2 min, followed by 40% C to 45% C in 18 min.
Fraction 9 was separated isocratically at 50% C to yield compound 3
(6.5 mg). The flow rate for both separations was 4 mL/min. Compounds
2-4 and 7 were identified by comparison of physicochemical data (1H
NMR and UV-vis) with published values20,23,24,27 and recorded data
for the peaks in the off-line HPLC microprobe NMR approach. The
purity of the compounds was >95% (1H NMR).
Expression of GABAA Receptors. Stage V-VI oocytes from
Xenopus laeVis were prepared, and cRNA was injected as previously
described by Khom et al. (2006).45 Female Xenopus laeVis (NASCO,
Fort Atkinson, WI) were anesthetized by exposing them for 15 min
to a 0.2% MS-222 (methanesulfonate salt of 3-aminobenzoic acid
ethyl, Sigma) solution before surgically removing parts of the
ovaries. Follicle membranes from isolated oocytes were enzymati-
cally digested with 2 mg/mL collagenase (Type 1A, Sigma).
Synthesis of capped runoff poly(A+) cRNA transcripts was obtained
from linearized cDNA templates (pCMV vector). One day after
enzymatic isolation, the oocytes were injected with 50 nL of DEPC-
treated water (Sigma) containing different cRNAs at a concentration
of approximately 300-3000 pg/nL per subunit. The amount of
injected cRNA mixture was determined by means of a NanoDrop
ND-1000 (Kisker Biotech). To ensure expression of the gamma
subunit in R12γ2S receptors, rat cRNAs were mixed in a 1:1:10
ratio. Oocytes were then stored at 18 °C in ND96 solution.46 Voltage
clamp measurements were performed between days 1 and 5 after
cRNA injection.
Two-Microelectrode Voltage Clamp Studies. Electrophysiological
experiments were performed by the two-microelectrode voltage clamp
method making use of a TURBO TEC 03X amplifier (npi electronic
GmbH) at a holding potential of -70 mV and pCLAMP 10 data
acquisition software (Molecular Devices). Currents were low-pass-
filtered at 1 kHz and sampled at 3 kHz. The bath solution contained
90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM
HEPES (pH 7.4). Electrode filling solution contained 2 M KCl. Oocytes
with maximal current amplitudes > 3 μA were discarded to exclude
voltage clamp errors.
Fast Solution Exchange during IGABA Recordings. Test solutions
(100 μL) were applied to the oocytes at a speed of 300 μL/s by means
of an automated fast perfusion system.17 In order to determine GABA
EC5-10 (typically between 3 and 8 μM), a dose-response experiment
with GABA concentrations ranging from 0.1 μM to 1 mM was
performed. Stock solution of P. nigrum (10 mg/mL in DMSO) was
diluted to a concentration of 100 μg/mL with bath solution and then
mixed with GABA EC5-10. As previously described, microfractions
collected from the semipreparative HPLC separations were dissolved
in 30 μL of DMSO and subsequently mixed with 2.97 mL of bath
solution containing GABA EC5-10.16 Stock solutions of compounds 2-5
and 7 (10 mM in DMSO) were diluted to a concentration of 100 μM
with bath solution and then mixed with GABA EC5-10 or applied alone.
For dose-response experiments, bath solution containing compound
4 or 5 in concentrations ranging from 1 to 300 μM was applied to the
oocyte 90 s prior to application of the corresponding compound solution
containing GABA EC5-10. Diazepam and flumazenil (Sigma) were
dissolved in DMSO (10 mM) and subsequently diluted in bath solution
or bath solution containing GABA EC5-10. Oocytes were preincubated
for 90 s with flumazenil or diazepam before the corresponding GABA
EC5-10 containing test solution was applied.45
Data Analysis. Enhancement of the chloride current (IGABA) was
defined as I(GABA+Comp)/IGABA - 1, where I(GABA+Comp) is the current
response in the presence of a given compound, and IGABA is the control
GABA-induced chloride current. Data are given as mean ( SE of at
least two oocytes and g2 oocyte batches.
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 Table S1. NMR spectroscopic data (500 MHz, MeOD) for (1) 
(E)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenethyl)acrylamide  
(syn.: moupinamide) (1) b 
CAS Nr. 66648-43-9 
 
 
 
position δCa δH (J in Hz) 
2 140.42 7.43, d (15.7) 
3 117.52 6.40, d (15.7) 
2’ 110.46 7.11, d (1.8) 
3’-MeO 54.97 3.89, s
5’ 115.09 6.80, d (8.2) 
6’ 121.82 7.02, dd (8.2, 1.8) 
1’’ 40.94 3.47, t (7.3) 
2’’ 34.31 2.76, t (7.3) 
2’’’ 129.21 7.05, d (8.5)
3’’’ 114.95 6.72, d (8.5)
5’’’ 114.95 6.72, d (8.5) 
6’’’ 129.21 7.05, d (8.5) 
a 13C chemical shifts deduced from HSQC-NMR spectrum 
b δC and δH reference data can be found in Hussain, S. F.; Goezler, B.; Shamma, M.; Goezler, T. 
Phytochemistry 1982, 21, 2979-2980 
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 Table S2. NMR spectroscopic data (500 MHz, CDCl3) for (2) 
(2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(pyrrolidin-1-yl)penta-2,4-dien-1-one  
(syn.: trichostachine) (2) b 
CAS Nr. 25924-78-1 
 
 
 
position δCa δH (J in Hz) 
2 - 6.23, d (14.7) 
3 - 7.42, dd (14.7, 10.4) 
4 - 6.71, dd (14.7, 10.4) 
5 - 6.73, d (14.7) 
2’ - 5.95, s 
4’ - 6.96, d (1.3)
6’ - 6.88, dd (8.0,1.3) 
7’ - 6.75, d (8.0) 
2’’ - 1.91, m 
3’’ - 3.54, t (6.6) 
4’’ - 3.54, t (6.6)
5’’ - 1.91, m 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Olsen, R. A.; Spessard, G. O. J. Agric. Food Chem. 1981, 29, 
942-944 
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 Table S3. NMR spectroscopic data (500 MHz, CDCl3) for (3) 
(2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-N-isobutylpenta-2,4-dienamide 
(syn.: piperlonguminine) (3) b 
CAS Nr. 5950-12-9 
 
 
 
position δCa δH (J in Hz) 
2 - 5.89, d (14.5)
3 - 7.33, dd (14.5,11.0) 
4 - 6.65, dd (15.2, 11.0) 
5 - 6.76, d (15.2) 
2’ - 6.95, s 
4’ - 6.88, d (1.5) 
6’ - 6.88, dd (8.0, 1.5)
7’ - 6.76, d (8.0) 
2’’ - 3.17, t (6.5) 
3’’ - 1.81, m (6.5) 
4’’ - 0.93, d (6.5) 
5’’ - 0.93, d (6.5)
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Olsen, R. A.; Spessard, G. O. J. Agric. Food Chem. 
1981, 29, 942-944 
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 Table S4. NMR spectroscopic data (500 MHz, CDCl3) for (4) 
 
(E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)pent-2-en-1-one 
(syn.: piperanine) (4) b 
CAS Nr. 23512-46-1 
 
 
 
position δCa δH (J in Hz) 
2 121.45 6.18, d (15.0) 
3 143.61 6.77, dt (15.0, 7.0) 
4 34.36 2.45, dt (15.0, 7.5)
5 34.42 2.68, t (7.5) 
2’ 100.58 5.89, s 
4’ 108.76 6.65, d (1.5) 
6’ 121.13 6.60, dd (8.0, 1.5) 
7’ 108.00 6.70, d (8.0)
2’’ n.d. 3.48, broad
3’’ 26.02 1.54, m 
4’’ 24.51 1.62, m 
5’’ 26.02 1.54, m 
6’’ n.d. 3.48, broad 
a 13C chemical shifts deduced from HSQC-NMR spectrum 
b δH reference data can be found in Traxler, J.T. J. Agr. Food Chem., 1971, 19, 
1135-1138 
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 Table S5. NMR spectroscopic data (500 MHz, CDCl3) for (5) 
(2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one  
(syn.: piperine) (5) b 
CAS Nr. 94-62-2 
 
 
 
position δCa δH (J in Hz) 
1 166.01 - 
2 120.12 6.32, d (15.0) 
3 142.16 7.27, dd (15.0, 10.0) 
4 125.25 6.72, dd (15.0, 10.0
5 137.92 6.69, d (15.0) 
1’ 148.38 - 
2’ 101.14 5.95, s 
3’ 148.38 - 
4’ 105.59 6.84, d, (1.5)
5’ 132.40 -
6’ 122.21 6.75, d (8.0, 1.5) 
7’ 108.15 6.63, d (8.0) 
2’’ 43.01 3.45, broad  
3’’ 24.54 1.45, m 
4’’ 24.48 1.53, m
5’’ 25.97 1.45, m 
6’’ 46.74 3.45, broad 
a 13C chemical shifts deduced from HSQC- and HMBC-NMR spectra 
b δH and δC reference data can be found in De Araujo-Junior, J.X.; Da-Cunha, E.V.L.; Chaves, 
M.C.; Gray, A.I. Phytochemistry 1997, 44, 559-561 
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 Table S6. NMR spectroscopic data (500 MHz, CDCl3) for (6) 
(2E,6E)-7-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one 
(syn.: 4,5-dihydropiperettine; pipersintenamide) (6) b 
CAS Nr. - 
 
 
 
position δCa δH (J in Hz) 
2 121.29 6.25, d (15.0) 
3 n.d. 6.81, dt (15.0, 6.9) 
4 31.98 2.34, m 
5 31.98 2.34, m 
6 n.d. 6.01, dt (15.7, 7.0) 
7 130.28 6.31, d (15.7)
2’ 100.87 5.91, s 
4’ 105.41 6.85, d (1.5) 
6’ 120.31 6.73, dd (7.9, 1.5) 
7’ 108.10 6.70, d (7.9) 
2’’ n.d. 3.51, broad
3’’ 25.96 1.52, m 
4’’ 24.53 1.63, m 
5’’ 25.96 1.52, m 
6’’ n.d. 3.51, broad 
a 13C chemical shifts deduced from HSQC-NMR spectrum 
b δH and δC reference data can be found in Chen, J.J; Huang, Y.C.; Chen, Y.C.; Huang, Y.T.; 
Wang, S.W.; Peng, C.Y.; Teng, C.M.; Chen, I.S. Planta Med. 2002, 68, 980-985 
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 Table S7. NMR spectroscopic data (500 MHz, CDCl3) for (7) 
(2E,4E,6E)-7-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4,6-trien-1-one 
(syn.: piperettine) (7) b 
CAS Nr. 583-34-6 
 
 
 
position δCa δH (J in Hz) 
2 - 6.34, d (14.5) 
3 - 7.33, dd (14.5, 11.3) 
4 - 6.41, dt (11.3, 13.4) 
5 - 6.62, dt (10.5, 13.4) 
6 - 6.66, dd (15.0, 10.5) 
7 - 6.58, d (15.0)
2’ - 5.94, s 
4’ - 6.93, d (1.5) 
6’ - 6.84, dd (8.0, 1.5) 
7’ - 6.74, d (8.0) 
2’’ - 3.55, m
3’’ - 1.57, m 
4’’ - 1.64, m 
5’’ - 1.57, m 
6’’ - 3.55, m 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in De Araujo-Junior, J.X.; Da-Cunha, E.V.L.; Chaves, M.C.; Gray, 
A.I. Phytochemistry 1997, 44, 559-561 
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 Table S8. NMR spectroscopic data (500 MHz, CDCl3) for (8) 
(E)-7-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)hept-6-en-1-one 
(syn.: piperolein A) (8) b 
CAS Nr. 30505-92-1 
 
 
 
position δCa δH (J in Hz) 
2 - 2.32, t (8.0) 
3 - 1.67, m 
4 - 1.50, m 
5 - 2.20, dt (7.3, 7.1) 
6 - 6.02, dt (7.3, 15.8) 
7 - 6.28, d (15.8)
2’ - 5.90, s 
4’ - 6.85, d (1.5) 
6’ - 6.73, dd (8.1, 1.5) 
7’ - 6.70, d (8.1) 
2’’ - 3.46, m
3’’ - 1.53, m 
4’’ - 1.65, m 
5’’ - 1.53, m 
6’’ - 3.46, m 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Strunz, G.M.; Finlay, H. Tetrahedron, 1994, 50, 
11113-11122 
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 Table S9. NMR spectroscopic data (500 MHz, CDCl3) for (9) 
(2E,4E,8E)-9-(benzo[d][1,3]dioxol-5-yl)-N-isobutylnona-2,4,8-trienamide 
(syn.: retrofractamide A) (9) b 
CAS Nr 94079-67-1 
 
 
 
position δCa δH (J in Hz) 
2 - 5.72, d (15.0) 
3 - 7.16, dd (15.0, 10.5) 
4 - 6.15, dd (15.0, 10.5)
5 - 6.07, m 
6 - 2.30, m 
7 - 2.30, m 
8 - 6.01, m 
9 - 6.30, d (15.4)
2’ - 5.92, s 
4’ - 6.86, d (1.4) 
6’ - 6.73, m 
7’ - 6.73, m 
2’’ - 3.15, t (6.3)
3’’ - 1.79, m
4’’ - 0.91, d (6.5) 
5’’ - 0.91, d (6.5) 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Park, I.K.; Lee, S.G.; Shin, S.C.; Park, J.D.; Ahn, Y.J. J. 
Agric. Food Chem. 2002, 50, 1866-1870 
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 Table S10. NMR spectroscopic data (500 MHz, CDCl3) for (10) 
(2E,4E,8E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)nona-2,4,8-trien-1-one 
(syn.: dehydropipernonaline) (10)b 
CAS Nr 107584-38-3 
 
 
 
position δCa δH (J in Hz) 
2 - 6.24, d (15.3) 
3 - 7.21, dd (15.3, 11.7) 
4 - 6.20, dd (15.0, 11.0)
5 - 6.07, m
6 - 2.30, m 
7 - 2.30, m 
8 - 5.99, m 
9 - 6.29, d (15.2) 
2’ - 5.90, s
4’ - 6.85, m 
6’ - 6.73, dd (7.8, 1.5) 
7’ - 6.71, d (7.8) 
2’’ - 3.53, m 
3’’ - 1.56, m
4’’ - 1.63, m 
5’’ - 1.56, m 
6’’ - 3.53, m 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Lee, S.W.; Rho, M.C.; Parl, H.R.; Choi, J.H.; Kang, J.Y.; Lee, J.W.; 
Kim, K.; Lee, H.S.; Kim, Y.K. J. Agric. Food Chem. 2006, 54, 9759-9763 
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 Table S11. NMR spectroscopic data (500 MHz, CDCl3) for (11) 
(E)-9-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)non-8-en-1-one 
(syn.: piperolein B) (11)b 
CAS Nr 30505-89-6 
 
 
 
position δCa δH (J in Hz) 
2 - 2.30, t (7.4) 
3 - 1.62, m 
4 - 1.35, m
5 - 1.35, m
6 - 1.45, m 
7 - 2.16, dt (7.5, 7.5) 
8 - 6.02, dt (15.8, 7.4) 
9 - 6.27, d (15.8) 
2’ - 5.90, s
4’ - 6.86, d (1.5) 
6’ - 6.73, dd (8.1, 1.5) 
7’ - 6.71, d (8.1) 
2’’ - 3.45, m 
3’’ - 1.53, m
4’’ - 1.62, m 
5’’ - 1.53, m 
6’’ - 3.45, m 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Wei, K.; Li, W.; Koike, K.; Pei, Y.; Chen, Y.; Nikaido, T. J. Nat. 
Prod. 2004, 67, 1005-1009, supporting information 
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 Table S12. NMR spectroscopic data (500 MHz, CDCl3) for (12) 
(2E,4E,10E)-11-(benzo[d][1,3]dioxol-5-yl)-N-isobutylundeca-2,4,10-trienamide 
(syn.: pipercide) (12)b 
CAS Nr 54794-74-0 
 
 
 
position δCa δH (J in Hz) 
2 - 5.72, d (15.0) 
3 - 7.16, dd (15.1, 10.4) 
4 - 6.11, m
5 - 6.13, m 
6 - 2.16, m 
7 - 1.46, m 
8 - 1.46, m 
9 - 2.18, m
10 - 6.00, dt (15.7, 6.7) 
11 - 6.27, d (15.6) 
2’ - 5.90, s 
4’ - 6.86, d (1.5) 
6’ - 6.73, dd (7.4, 1.5)
7’ - 6.71, d (7.4)
2’’ - 3.15, t (6.3) 
3’’ - 1.79, m 
4’’ - 0.91, d (6.7) 
5’’ - 0.91, d (6.7) 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Park, I.K.; Lee, S.G.; Shin, S.C.; Park, J.D.; Ahn, Y.J. J. Agric. Food 
Chem. 2002, 50, 1866-1870 
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 Table S13. NMR spectroscopic data (500 MHz, CDCl3) for (13) 
(2E,4E,12E)-13-(benzo[d][1,3]dioxol-5-yl)-N-isobutyltrideca-2,4,12-trienamide 
(syn.: guineensine) (13)b 
CAS Nr. 55038-30-7 
 
 
 
position δCa δH (J in Hz) 
2 - 5.72, d (15.0) 
3 - 7.16, dd (15.3, 10.8) 
4 - 6.10, m
5 - 6.07, m 
6 - 2.14, m 
7 - 1.43, m 
8 - 1.32, m 
9 - 1.32, m
10 - 1.43, m 
11 - 2.14, m 
12 - 6.02, dt (15.7, 7.3) 
13 - 6.26, d (15.7) 
2’ - 5.90, s
4’ - 6.86, d (1.5)
6’ - 6.73, dd (7.4, 1.5) 
7’ - 6.71, d (7.4) 
2’’ - 3.15, t (6.3) 
3’’ - 1.79, m 
4’’ - 0.91, d (6.7)
5’’ - 0.91, d (6.7) 
a no heteronuclear 2D-NMR spectra were recorded 
b δH reference data can be found in Park, I.K.; Lee, S.G.; Shin, S.C.; Park, J.D.; Ahn, Y.J. J. Agric. Food 
Chem. 2002, 50, 1866-1870 
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3.2. HPLC-BASED ACTIVITY PROFILING OF ANGELICA PUBESCENS 
ROOTS FOR NEW POSITIVE GABAA RECEPTOR MODULATORS IN 
XENOPUS OOCYTES 
Zaugg J, Eickmeier E, Rueda DC, Hering S, Hamburger M. Fitoterapia 2011; 82; 434-440  
 
 
 
Five coumarins and bisabolangelone were identified as positive α1β2γ2S GABAA receptor 
modulating constituents of Angelica pubescens roots by HPLC based activity profiling. 
Structures were elucidated by high resolution mass spectrometry and microprobe NMR. 
Osthol and cnidilin were identified as main active compounds in the functional assay with 
Xenopus oocytes. 
 
 
 
 
 
Eva Eickmeier did upscaled extraction of plant material, isolation of compounds, 
recording and interpretation of analytical data for structure elucidation (HPLC-PDA-
ESI-TOF-MS, microprobe NMR, optical rotation) as part of her master’s thesis under my 
direct supervision. HPLC microfractionation, Xenopus surgery, preparation of oocytes 
for electrophysiological measurements, two-microelectrode voltage clamp studies on 
fractions and pure compounds (except for direct activation studies), data analysis, writing 
of the manuscript, and preparation of figures were my contribution to this publication. 
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A petroleum ether extract of the traditional Chinese herbal drug Duhuo (roots of Angelica
pubescens Maxim. f. biserrata Shan et Yuan), showed significant activity in a functional
two-microelectrode voltage clamp assay with Xenopus oocytes which expressed recombinant
γ-aminobutyric acid type A (GABAA) receptors of the subtype α1β2γ2S. HPLC-based activity
profiling of the active extract revealed six compounds responsible for the GABAA receptor
modulating activity. They were identified by microprobe NMR and high resolution mass
spectrometry as columbianetin acetate (1), imperatorin (3), cnidilin (4), osthol (5), and
columbianedin (6). In concentration-dependent experiments, osthol and cnidilin showed
the highest potentiation of the GABA induced chloride current (273.6%±39.4% and
204.5%±33.2%, respectively at 300 μM). Bisabolangelone (2) only showed minor activity at
the GABAA receptor. The example demonstrates that HPLC-based activity profiling is a simple
and efficient method to rapidly identify GABAA receptor modulators in a bioactive plant extract.
© 2011 Elsevier B.V. All rights reserved.
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1. Introduction
Angelica pubescensMaxim. f. biserrata Shan et Yuan belongs
to the Apiaceae family and mainly grows in Chinese provinces
such as Hubei and Sichuan [1]. Roots of the species are used in
Traditional Chinese Medicine (TCM) as herbal drug Duhuo.
Coumarins and furanocoumarins are the main constituents of
this drug [2–4]. In TCM, Duhuo is used to treat pain, fever,
rheumatism, heaviness of the low-back and knees, and
contracture of the limbs [4,5]. In vivo studies also reported
sedative and hypnotic activities of the fluid extract and
decoction of A. pubescens in mice or rats [5,6]. In a screening
of herbal drugs, a petroleum ether extract of Duhuo positively
modulatedGABAA receptors. For assessmentof activityweused
an established functional two-microelectrode voltage clamp
assay with Xenopus oocytes which transiently express GABAA
receptors of the subunit combination α1β2γ2s [7].
GABAA receptors are the most important inhibitory ion
channels in the central nervous system. A total of 19 different
GABAA receptor subunits have been identified in the human
genomewhichmay form pentameric assemblies in numerous
combinations resulting in functional chloride channels [8,9].
These differ in tissue localization, functional characteristics,
and their pharmacological properties [10,11]. GABAA recep-
tors are targeted by many clinically used drugs to treat
insomnia, panic disorders, epilepsy, and also to induce
anesthesia. The benzodiazepines which are widely prescribed
GABAA receptor modulators are clinically used as sedative-
hypnotics, anxiolytics and anticonvulsants. However, their
long-term-use leads to development of tolerance and
physical dependence [12]. Thus, there is a need for the
development of novel GABAA receptor modulators which
are devoid of these adverse effects. Natural compounds from
plant extracts may represent interesting scaffolds for
Fitoterapia 82 (2011) 434–440
Abbreviations: GABA, γ-aminobutyric acid; IGABA, GABA induced chloride
ion current; GABA EC5–10, GABA concentration reaching 5–10% of maximal
activity elicited by GABA; TCM, Traditional Chinese Medicine.
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development of new subunit selective GABAA receptor
modulators [13]. In the present study we have identified
the compounds in the Duhuo extract responsible for GABAA
receptor modulation.
Activity in the Duhuo extract was tracked with the aid of
HPLC-based activity profiling. HPLC-based activity profiling is
a miniaturized and rapid approach for the localization,
dereplication and characterization of bioactive natural pro-
ducts in crude extracts [14], which has been successfully used
with various cell-based and biochemical assays [15–20].
Subsequent preparative separation of the active extract
yielded the sesquiterpene bisabolangelone (2), two linear
furanocoumarins, imperatorin (3) and cnidilin (4), two
angular furanocoumarins, columbianetin acetate (1) and
columbianedin (6), and the isoprenylated coumarin osthol
(5). The compounds were fully characterized by high
resolution mass spectrometry, 1D and 2D microprobe NMR
experiments, polarimetry, and by comparison with literature
data [21–28]. Compounds 1–6 were tested at three different
concentrations in the oocyte assay to investigate their
individual GABAA receptor modulatory activities.
2. Experimental
2.1. General experimental procedures
NMR spectra were recorded at room temperature with a
Bruker Avance III spectrometer operating at 500.13 MHz. 1H
NMR, COSY, DEPT-edited HSQC, and HMBC spectra were
measured with a 1 mm TXI probe. Spectra were analyzed using
Bruker TopSpin 2.1 software. HPLC-PDA-ESI-TOF-MS spectra
were obtained on amicrOTOF ESI–MS system (Bruker Daltonics)
connected via T-splitter (1:10) to an HP 1100 series system
(Agilent) consisting of a binarypump, autosampler, columnoven
and diode array detector (G1315B). The petroleum ether extract
was analyzed with methanol (solvent A) and water (solvent B),
both containing0.1% formic acidwithgradient elutionof 50%A to
100% A in 30 min, hold for 10 min at a flow rate of 0.4 mL/min.
The sample concentration was 10 mg/mL in DMSO, and the
injection volumewas 5 μL. Spectrawere recorded in the range of
m/z100–700 inpositivemode.Nitrogenwasused as anebulizing
gas at a pressure of 2.0 bar and as a drying gas at a flow rate of
9.0 L/min (dry gas temperature 240 °C). Capillary voltagewas set
at 4500 V, hexapole at 230.0 Vpp. Instrument calibration was
performed using a reference solution of sodium formiate 0.1% in
isopropanol/water (1:1) containing 5 mM sodium hydroxide.
Data acquisition and processing was performed using HyStar 3.0
software (Bruker Daltonics). Optical rotationwasmeasured on a
Perkin Elmer polarimeter (model 341) equipped with a 10 cm
microcell. The optical rotation for the Na-D-line (589) was
extrapolated from the lines of a mercury lamp using the Drude
equation [29]. Semi-preparative HPLC separation for activity
profilingwas performedwith anHP1100 series system(Agilent)
consisting of a quaternary pump, autosampler, columnoven, and
diode array detector (G1315B). SunFire C18 (3.5 μm,
3.0×150 mm) and SunFire Prep C18 (5 μm, 10×150 mm)
columns (Waters) were used for HPLC-PDA-ESI-TOF-MS and
semi-preparative HPLC, respectively. Medium pressure liquid
chromatography (MPLC) was done on a pre-packed normal
phase cartridge (40–63 μm, 40×150 mm) using a Sepacore
system (Buchi) consisting of a control unit C-620, two pump
modules C-605, and a fraction collector C-660. The MPLC unit
was controlled with the SepacoreControl software (version
1.0.3000.1). Preparative HPLC separation was performed with a
SunFire Prep C18 OBD (5 μm, 30×150 mm) column using a
Shimadzu LC-8A preparative separation chromatograph
equipped with a SPD-M10A VP diode array detector. HPLC-
grademethanol (Scharlau Chemie S.A.) andwater were used for
HPLC separations. Deuterated chloroform was purchased from
Armar Chemicals. Solvents used for extraction, open column
chromatography, andMPLCwere of technical grade and purified
by distillation. Silica gel (63–200 μm, Merck) was used for open
column chromatography.
2.2. Plant material
Duhuo (dried roots of A. pubescensMaxim. f. biserrata Shan
et Yuan) was purchased from sinoMed GmbH & Co. (Bad
Kötzting, Germany) for screening and HPLC-based activity
profiling (batch K26.04.2004), and from Complemedis AG
(Schönenwerd, Switzerland) for compound isolation (batch
051459). Voucher specimens (00 378 and 00 596, respec-
tively) are deposited at the Institute of Pharmaceutical
Biology, University of Basel.
2.3. HPLC microfractionation
An aliquot (ca. 20 g) of ground roots was macerated at room
temperature with petroleum ether (3×0.5 L, 1 h each). Micro-
fractionation for GABAA receptor activity profiling was per-
formed as previously described [18,30,31], with minor
modifications: separation was carried out on a semi-preparative
HPLC column with methanol (solvent A) and water (solvent B)
using the following gradient: 50% A to 100% A in 30 min, hold for
10 min. The flow rate was 4 mL/min, and 100 μL of the extract
(100 mg/mL in DMSO) were injected. A total of 28 time-based
microfractions of each 90 s were collected. Microfractions were
evaporated in parallel with a Genevac EZ-2 plus vacuum
centrifuge (Avantec). The dry films were redissolved in 1 mL of
methanol; aliquots of 0.5 mL were dispensed in two vials, dried
under N2 gas, and submitted to bioassay.
2.4. Extraction and isolation
The plant material was ground with a ZM1 ultracentrifugal
mill (Retsch). For compound isolation, 884 g of ground roots
were extracted by maceration at room temperature with
petroleumether (4×2.5 L, 1 heach). The solventwasevaporated
at reduced pressure to yield 21.8 g of petroleum ether extract. A
part of the extract (19.3 g) was separated by open column
chromatography (9×80 cm, 1.2 kg silica gel) using a step
gradient of hexane–chloroform–methanol (20:80:0, 3 L;
15:85:0, 2 L; 10:90:0, 2 L; 5:95:0, 2 L; 0:100:0, 2 L; 0:99:1, 4 L;
0:90:10, 1 L; 50:50, 1 L). Theflowratewas approximately 15 mL/
min. The effluentwas combined to 15 fractions (1–15) according
to TLC patterns (detection at 254 nm and at daylight after
staining with anisaldehyde-sulphuric acid reagent). Recrystalli-
zation of fraction 10 (3.80 g) afforded 5 (2.32 g). A portion of the
mother liquor of fraction 10 (0.9 g)was separated byMPLCusing
a toluene–ethyl acetate gradient (100:0 to 70:30 in 2 h) with a
flow rate of 30 mL/min. A total of 16 fractions (10A–10P) were
collected based on TLC analysis. Fractions 10E (57.1 mg), 10 L
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(48.2 mg), 10 N (33.6 mg), and a portion of fraction 10 G
(50 mg) were each dissolved in 800 μL DMSO–methanol (1:1)
and separated by preparative HPLC using a gradient of
methanol–water (50:50 to 100:0 in 30 min, flow rate 20 mL/
min). Columbianetin acetate (1) (11.1 mg) was obtained from
fraction 10 L, bisabolangelone (2) (2.6 mg) from fraction 10 N,
imperatorin (3) (0.61 mg) and cnidilin (4) (0.48 mg) from
fraction 10E, and columbianedin (6) (22.8 mg) from fraction 10E
(18.3 mg)and10 G(4.5 mg). Compounds1–6were identifiedby
comparison of 1D and 2D NMR, HPLC-PDA-ESI-TOF-MS and
polarimetry data with published values [21–28]. For complete
data see the supporting information in the Appendix.
2.5. Expression of GABAA receptors
Stages V–VI oocytes from Xenopus laevis were prepared
and cRNAwas injected as previously described by Khom et al.
[32]. Female X. laevis (NASCO) were anesthetized by exposing
them for 15 min to a 0.2%MS-222 (3-aminobenzoic acid ethyl
ester methanesulfonate, Sigma) solution before surgically
removing parts of the ovaries. Follicle membranes from
isolated oocytes were enzymatically digested with 2 mg/mL
collagenase from Clostridium histolyticum (Type 1A, Sigma).
Synthesis of capped run-off poly(A+) cRNA transcripts was
obtained from linearized cDNA templates (pCMV vector). One
day after enzymatic isolation, the oocytes were injected with
50 nL of DEPC-treated water (Sigma) containing different
cRNAs at a concentration of approximately 300–3000 pg/nL
per subunit. The amount of injected cRNA mixture was
determined by means of a NanoDrop ND-1000 (Kisker
Biotech). Rat cRNAs were mixed in a 1:1:10 ratio to ensure
expression of the gamma subunit in α1β2γ2S receptors.
Oocytes were then stored at 18 °C in an aqueous solution of
90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2 and 5 mM
HEPES (pH 7.4), containing 1% of Penicillin–Streptomycin
solution (Sigma) [33]. Voltage clamp measurements were
performed between days 1 and 5 after cRNA injection.
2.6. Two-microelectrode voltage clamp studies
Electrophysiological experiments were performed by the
two-microelectrode voltage clamp method making use of a
TURBO TEC 03X amplifier (npi electronic, Tamm, Germany) at
a holding potential of −70 mV and pCLAMP 10 data
acquisition software (Molecular Devices, USA). Currents
were low-pass-filtered at 1 kHz and sampled at 3 kHz. The
bath solution contained 90 mMNaCl, 1 mM KCl, 1 mMMgCl2,
1 mM CaCl2 and 5 mM HEPES (pH 7.4). Electrode filling
solution contained 2 M KCl.
Fig. 1. HPLC-based activity profiling of A. pubescens petroleum ether extract for GABAA receptor modulating properties. B: HPLC chromatogram (240 nm) of a
semipreparative separation of 10 mg of extract. Peak numbering corresponds to compounds 1–6. The 28 collected time-based microfractions, 90 s each, are
indicated with dashed lines. A: The potentiation of the GABA-induced chloride current in Xenopus oocytes (IGABA) by each fraction. A current elicited by a GABA
EC5–10 was used as control current.
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2.7. Fast solution exchange during IGABA recordings
Test solutions (100 μL) of extracts, fractions and pure
compounds were applied to the oocytes at a speed of 300 μL/s
bymeansof theScreeningTool automated fast perfusion system
[7]. In order todetermineGABAEC5–10 (typically between3 and
10 μM for receptors of the subunit combination α1β2γ2S), a
concentration–response experiment with GABA concentra-
tions ranging from 0.1 μM to 1 mM was performed. Stock
solution of A. pubescens extract (10 mg/mL in DMSO) was
diluted to a concentration of 100 μg/mL with bath solution
containing GABA EC5–10 according to a validated protocol [18].
As previously described, microfractions collected from the
semi-preparative HPLC separations were dissolved in 30 μL
DMSO and subsequently mixed with 2.97 mL of bath solution
containingGABAEC5–10 [18]. Stock solutions of compounds1–6
(100 mM in DMSO) were diluted to a concentration of 30, 100,
and 300 μMwith bath solution for measuring direct activation,
or with bath solution containing GABA EC5–10 for measuring
modulation of the GABAA receptors. The final DMSO concen-
tration in all samples including the GABA control samples was
adjusted 1% to avoid solvent effects at the GABAA receptor.
Enhancementof theGABA induced chloride current (IGABA)was
defined as I(GABA+Comp)/IGABA−1, where I(GABA+Comp) is the
current response in the presence of a given compound, and
IGABA is the control GABA-induced chloride current. Data were
analyzed using the ORIGIN 7.0 SR0 software (OriginLab
Corporation) and are given as mean±S.E. of at least 2 oocytes
and ≥2 oocyte batches.
3. Results and discussion
Pharmacological studies were performed on Xenopus
oocytes expressing themost abundant GABAA receptor subtype
of the human brain composed of two α1, two β2, and one γ2
subunit [8]. In our two-microelectrode assay [7] the petroleum
ether extract of A. pubescens enhanced the GABA-induced
chloride ion current (IGABA) through α1β2γ2S receptors by
197.0%±56.8%. The active extract was submitted to HPLC-
based activity profiling using a validated protocol [18]. The
chromatogram of a semipreparative separation of 10 mg
extract and the corresponding activity profile of the time-
based fractionation (28 microfractions of 90 s each) are shown
in Fig. 1. Moderate GABAA receptor modulating activity
was found in microfractions 8, 10, and 14 (75.3%±4.2%,
50.7%±8.1%, and 107.1%±19.1%, respectively), while high
activity could be detected in microfractions 11 and 12
(164.8%±13.9% and 320.3%±43.0%, respectively). The major
peak (eluting in microfraction 12) was then collected for
structure elucidation with semipreparative HPLC using the
same separation conditions as for microfractionation. The
molecular formula of the compound was extracted from an
HPLC-PDA-ESI-TOF-MS analysis of the extract, and the 1H NMR
of the collected peak yielded a spectrum reminiscent of
7,8-substituted coumarins, showing two pairs of doublets at
6.19 and 7.57 ppm, and 7.25 and 6.81 ppm with coupling
constants of 9.5 Hz and 8.5 Hz, respectively. The compound
could be identified as osthol (5) by comparing the data to
published values [26]. For determination of concentration-
dependent GABAA receptor modulation, the compounds of the
active time-windows were purified at preparative scale and
identified as columbianetin acetate (1), bisabolangelone (2),
imperatorin (3), cnidilin (4), and columbianedin (6) (Fig. 2) by
comparing 1H NMR shifts and 13C shifts deduced from hetero-
nuclear 2D NMR spectra, molecular formula derived from high
resolution mass spectra, and optical rotation (compounds 1, 2,
and6)withpublishedvalues [21–28]. Spectroscopicdata of1–6
are available as supporting information in the Appendix. All
compounds were tested at concentrations of 10, 100, and
300 μM in the oocyte assay (Fig. 3). At 300 and 100 μM
concentrations, osthol (5) potentiated IGABA by 273.6%±39.4%
and 108.3%±29.9%, respectively. Compound 6, in contrast, was
only marginally active (61.2%±20.2% at 300 μM and 42.2%±
4.9% at 100 μM). Cnidilin (4), which had been previously
reported from a different Angelica species [34], showed
comparable activity as 5 (204.5%±33.2% at 300 μM and
71.6%±8.7% at 100 μM). Compound 3 was responsible for the
moderate activity of microfraction 10, and potentiated IGABA at
100 μM by 50.5%±16.3% and at 300 μM by 109.8%±37.7%.
Compounds 1 and 2were weakly effective as pure compounds
(potentiation of IGABA of 33.0%±9.3% and 1.1%±4.7%, respec-
tively at 100 μM, and of 38.0%±21.3% and 25.8%±12.7%,
respectively at 300 μM). Compounds 1–6 modulated GABAA
receptors of the subunit combination α1β2γ2S with low
potency, since no significant potentiation of IGABA could be
detected at 10 μMconcentration (1: 3.4%±1.8%, 2: 3.4%±8.3%,
3: 9.8%±11.4%, 4: 5.7%±11.1%, 5: 19.4%±7.4%, 6: 6.3%±
5.6%). None of the compounds showed significant direct
activation on GABAA receptors when applied at a test
concentration of 300 μM (Fig. 3C).
There have been previous reports on coumarins as GABAA
receptor ligands. Li et al. isolated a new dihydroisocoumarin
Fig. 2. The chemical structures of compounds 1–6.
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Fig. 3. A: Concentration-dependent potentiation of the GABA-induced chloride current (IGABA) by compounds 1–6 on GABAA receptors composed ofα1, β2, and γ2S
subunits using a GABA EC5–10. Potencies (EC50) of compounds 3, 4, and 5 can be estimated to lie beyond 100 μM. B: Typical traces for modulation of chloride
currents throughα1β2γ2S GABAA receptors by compounds 1–6 at a concentration of 300 μM. C: Representative currents illustrate the absence of direct activation of
GABAA receptors (α1β2γ2S) by compounds 1–6.
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fromHaloxylon scoparium, which acts as a positivemodulator at
GABAA receptors of the subtype α1β2γ2S [31]. Dekermendjian
et al. tested imperatorin (3) and phellopterin, another linear
furanocoumarin, in a radioreceptor binding assay and found
that phellopterin and imperatorin inhibited [3H]diazepam
(2 nM) binding to rat cortical brain GABAA receptors with IC50
values of 12.3 μM and 0.4 μM, respectively [35]. From the
functional assay data shown in Fig. 3, it can be estimated that
the EC50 values of 3, 4 and 5 have to be N100 μM. However, the
binding affinity (determined as IC50) calculated from a binding
assay cannot be directly related to the potency (EC50) in a
functional assay due to fundamental differences of the test
systems (for a general review on this topic, see [36]).
To our knowledge, angular furanocoumarins such as
columbianetin acetate (1) and columbianedin (6), which
marginally modulated GABAA receptors (α1β2γ2S), have not
been reported previously for any GABAA receptor activity.
Given the structural diversity of a relatively small number of
coumarins isolated in this profiling, structural features critical
for activity could not be identified. A study on structure–
activity-relationship of (furano)coumarins at α1β2γ2S GABAA
receptors will be published elsewhere [37].
With estimated EC50 values of N100 μM, the potencies of
3, 4, and 5 were N500 fold lower than the potency of
benzodiazepines (e.g. such as clotiazepam, EC50: 0.184 μM±
0.088 μM) [32], indicating that the identified active coumar-
ins 3–5 represent low affinity GABAA receptor ligands in vitro.
There is limited data available on the bioavailability of these
coumarins and their CNS penetration. In a Caco-2 cell model,
Galkin et al. demonstrated that imperatorin rapidly perme-
ates across the membrane without being limited by efflux
[38]. In a Caco-2 model modified with a phase I reaction
system on the basolateral side, osthol passively permeated
the membrane but was immediately metabolized thereafter
[39]. This finding was consistent with a rather short half-life
(t1/2=41.13±5.73 min) of osthol found in rats after i.v.
application [40]. To our knowledge, a quantitative study on
blood–brain barrier penetration of naturally occurring cou-
marins and their metabolites is still lacking. Interestingly, an
earlier in vivo study using the maximal electroshock seizure
test and the chimney test with mice revealed some degree of
anticonvulsant1 but also neurotoxic activity of imperatorin
(3) and osthol (5) [41,42]. As possible mechanism of the
anticonvulsive action the authors discussed an inactivation of
the GABA-transaminase which would lead to a higher GABA
concentration in the synaptic cleft and, therefore, to an
elevated inhibitory neurotransmitter level in the brain [43].
Considering our results, an enhancement of the GABA-
induced chloride current by 3 and 5 (or their metabolites),
could have been partly responsible for their anticonvulsant
activity in vivo [41,42]. In summary, the investigated
coumarins act on several CNS targets in vitro [43–45], but
have limited potential for further development considering
the reported neurotoxicity of osthol and imperatorin [41],
and the known phototoxicity of linear furanocoumarins [46].
The investigation of compounds 1, and 3–6 provides
additional data on GABAA receptor activity of the coumarin
scaffold [31]. The example of A. pubescens corroborates the
usefulness of an HPLC-based activity profiling approach in the
search for bioactive molecules of natural origin [18,30,31].
Acknowledgments
Financial support from the Swiss National Science Foun-
dation (projects 31600-113109 and 205321-116157/1), the
Steinegg-Stiftung, Herisau, the Fonds zur Förderung von
Lehre und Forschung, Basel (M.H.), and the Mathieu-Stiftung
of the University of Basel, is gratefully acknowledged. D.C.R. is
recipient of a fellowship from the Swiss Government.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.fitote.2010.12.001.
References
[1] Zhongzhen Z. An illustrated Chinese Materia Medica in Hong Kong. First
ed. Hong Kong Baptist University, Hong Kong: School of Chinese
Medicine; 2004.
[2] Pan JX, Lam YK, Arison B, Smith J, Han GQ. Isolation and identification of
isoangelol, anpubesol and other coumarins from Angelica pubescens
Maxim. Yao Xue Xue Bao (Acta Pharm. Sin.) 1987;22:380–4.
[3] Li RZ, He YQ, Chiao M, Xu Y, Zhang QB, Meng JR, et al. Studies of the
active constituents of the Chinese drug duhuo Angelica pubescentis. Yao
Xue Xue Bao (Acta Pharm. Sin.) 1989;24:546–51.
[4] Tang W, Eisenbrand G. Chinese drugs of plant origin. Berlin Heidelberg
New York: Springer Verlag; 1992.
[5] Chang H-M, But PP-H. Pharmacology and applications of Chinese
Materia Medica, Vol. 2. Singapore: World Scientific Publishing Co. Pte.
Ltd; 1987.
[6] Huang KC. The pharmacology of Chinese herbs. Second ed. Boca Raton,
Florida: CRC Press; 1999.
[7] Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes
for drug screening. Pfluegers Arch Eur J Phys 2006;453:117–23.
[8] Simon J, Wakimoto H, Fujita N, Lalande M, Barnard EA. Analysis of the
set of GABA(A) receptor genes in the human genome. J Biol Chem
2004;279:41,422–35.
[9] Olsen RW, Sieghart W. International Union of Pharmacology. LXX.
Subtypes of gamma-aminobutyric acid(A) receptors: classification on
the basis of subunit composition, pharmacology, and function. Update.
Pharmacol Rev 2008;60:243–60.
[10] Barrera NP, Edwardson JM. The subunit arrangement and assembly of
ionotropic receptors. Trends Neurosci 2008;31:569–76.
[11] Olsen RW, Sieghart W. GABA(A) receptors: subtypes provide diversity
of function and pharmacology. Neuropharmacology 2009;56:141–8.
[12] D'Hulst C, Atack JR, Kooy RF. The complexity of the GABA(A) receptor
shapes unique pharmacological profiles. Drug Discovery Today
2009;14:866–75.
[13] Khom S, Strommer B, Ramharter J, Schwarz T, Schwarzer C, Erker T, et al.
Valerenic acid derivatives as novel subunit-selective GABA(A) receptor
ligands— in vitro and in vivo characterization. Br J Pharmacol 2010;161:
65–78.
[14] Potterat O, Hamburger M. Natural products in drug discovery —
concepts and approaches for tracking bioactivity. Curr Org Chem
2006;10:899–920.
[15] Potterat O, Wagner K, Gemmecker G, Mack J, Puder C, Vettermann R,
et al. BI-32169, a bicyclic 19-peptide with strong glucagon receptor
antagonist activity from Streptomyces sp. J Nat Prod 2004;67:1528–31.
[16] Danz H, Stoyanova S, Wippich P, Brattstroem A, Hamburger M.
Identification and isolation of the cyclooxygenase-2 inhibitory principle
in Isatis tinctoria. Planta Med 2001;67:411–6.
[17] Dittmann K, Gerhaeuser C, Klimo K, Hamburger M. HPLC-based activity
profiling of Salvia miltiorrhiza for MAO A and iNOS inhibitory activities.
Planta Med 2004;70:909–13.
[18] Kim HJ, Baburin I, Khom S, Hering S, Hamburger M. HPLC-based activity
profiling approach for the discovery of GABA(A) receptor ligands using
an automated two microelectrode voltage clamp assay on Xenopus
oocytes. Planta Med 2008;74:521–6.
1 Male Swiss albino mice, i.p. administration, 30 min pretreatment time.
ED50 per kg body weight of imperatorin, osthol, valproate [41], and
clonazepam [42]: 167 mg, 253 mg, 217 mg, 29.14 mg.
439J. Zaugg et al. / Fitoterapia 82 (2011) 434–440
77
[19] Adams M, Zimmermann S, Kaiser M, Brun R, Hamburger M. A protocol
for HPLC-based activity profiling for natural products with activities
against tropical parasites. Nat Prod Commun 2009;4:1377–81.
[20] Adams M, Christen M, Plitzko I, Zimmermann S, Brun R, Kaiser M, et al.
Antiplasmodial lanostanes from the Ganoderma lucidum mushroom. J
Nat Prod 2010;73:897–900.
[21] Hata K, Kozawa M, Baba K, Yen K-Y. Coumarins from the roots of
Angelica laxiflora. Chem Pharm Bull 1971;19:640–2.
[22] Liu R, Feng L, Sun A, Kong L. Preparative isolation and purification of
coumarins from Cnidium monnieri (L.) Cusson by high-speed counter-
current chromatography. J Chromatogr 2004;1055:71–6.
[23] Hata K, Kozawa M, Baba K, Chi H-J, Konoshima M. Coumarins and a
sesquiterpene from the crude drug Korean qianghuo the roots of
Angelica spp. Chem Pharm Bull 1971;19:1963–7.
[24] Bergendorff O, Dekermendjian K, Nielsen M, Shan R, Witt R, Ai J, et al.
Furanocoumarins with affinity to brain benzodiazepine receptors in
vitro. Phytochemistry 1997;44:1121–4.
[25] Franke K, Porzel A, Masaoud M, Adam G, Schmidt J. Furanocoumarins
from Dorstenia gigas. Phytochemistry 2001;56:611–21.
[26] Basile A, Sorbo S, Spadaro V, Bruno M, Maggio A, Faraone N, et al.
Antimicrobial and antioxidant activities of coumarins from the roots of
Ferulago campestris (Apiaceae). Molecules 2009;14:939–52.
[27] Khetwal KS, Pathak RP. Columbianadin: a novel coumarin from
Heracleum brunonis. Planta Med 1987;53:581.
[28] Vuorela H, Erdelmeier CA, Nyiredy S, Dallenbach-Tolke K, Anklin C,
Hiltunen R, et al. Isobyakangelicin angelate; a novel furanocoumarin
from Peucedanum palustre. Planta Med 1988;54:538–42.
[29] Fluegge J. Grundlagen der Polarimetrie. Berlin: De Gruyter-Verlag;
1970.
[30] Zaugg J, Baburin I, Strommer B, Kim HJ, Hering S, Hamburger M. HPLC-
based activity profiling: discovery of piperine as a positive GABA(A)
receptormodulator targeting a benzodiazepine-independent binding site.
J Nat Prod 2010;73:185–91.
[31] Li Y, Plitzko I, Zaugg J, Hering S, Hamburger M. HPLC-based activity
profiling for GABA(A) receptor modulators: a new dihydroisocoumarin
from Haloxylon scoparium. J Nat Prod 2010;73:768–70.
[32] Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S.
Pharmacological properties of GABA(A) receptors containing gamma1
subunits. Mol Pharmacol 2006;69:640–9.
[33] Methfessel C, Witzemann V, Takahashi T, Mishina M, Numa S, Sakmann
B. Patch clamp measurements on Xenopus laevis oocytes: currents
through endogenous channels and implanted acetylcholine receptor
and sodium channels. Pfluegers Arch Eur J Phys 1986;407:577–88.
[34] Baek NI, Ahn EM, Kim HY, Park YD. Furanocoumarins from the root of
Angelica dahurica. Arch Pharm Res 2000;23:467–70.
[35] Dekermendjian K, Ai J, Nielsen M, Sterner O, Shan R, Witt MR.
Characterisation of the furanocoumarin phellopterin as a rat brain
benzodiazepine receptor partial agonist in vitro. Neurosci Lett
1996;219:151–4.
[36] Kenakin T. Quantifying biological activity in chemical terms: a pharma-
cology primer to describe drug effect. ACS Chem Biol 2009;4:249–60.
[37] J. Singhuber, I. Baburin, M. Zehl, S. Hering, B. Kopp, in preparation.
[38] Galkin A, Fallarero A, Vuorela PM. Coumarins permeability in Caco-2 cell
model. J Pharm Pharmacol 2009;61:177–84.
[39] Yuan Z, Xu H, Wang K, Zhao Z, Hu M. Determination of osthol and its
metabolites in a phase I reaction system and the Caco-2 cell model by
HPLC-UV and LC-MS/MS. J Pharm Biomed Anal 2009;49:1226–32.
[40] Tsai TH, Tsai TR, Chen CC, Chen CF. Pharmacokinetics of osthole in rat
plasma using high-performance liquid chromatography. J Pharm
Biomed Anal 1996;14:749–53.
[41] Luszczki JJ, Wojda E, Andres-Mach M, Cisowski W, Glensk M, Glowniak
K, et al. Anticonvulsant and acute neurotoxic effects of imperatorin,
osthole and valproate in themaximal electroshock seizure and chimney
tests in mice: a comparative study. Epilepsy Res 2009;85:293–9.
[42] Luszczki JJ, Czuczwar SJ. Three-dimensional isobolographic analysis of
interactions between lamotrigine and clonazepam in maximal electro-
shock-induced seizures in mice. Naunyn-Schmiedeberg's Arch Pharma-
col 2004;370:369–80.
[43] Choi SY, Ahn EM, Song MC, Kim DW, Kang JH, Kwon OS, et al. In vitro
GABA-transaminase inhibitory compounds from the root of Angelica
dahurica. Phytother Res 2005;19:839–45.
[44] Wang SJ, Lin TY, Lu CW, Huang WJ. Osthole and imperatorin, the active
constituents of Cnidium monnieri (L.) Cusson, facilitate glutamate
release from rat hippocampal nerve terminals. Neurochem Int
2008;53:416–23.
[45] Lin TY, Lu CW, Huang WJ, Wang SJ. Osthole or imperatorin-mediated
facilitation of glutamate release is associated with a synaptic vesicle
mobilization in rat hippocampal glutamatergic nerve endings. Synapse
2010;64:390–6.
[46] Kitamura N, Kohtani S, Nakagaki R. Molecular aspects of furocoumarin
reactions: photophysics, photochemistry, photobiology, and structural
analysis. J Photochem Rev 2005;6:168–85.
440 J. Zaugg et al. / Fitoterapia 82 (2011) 434–440
78
SUPPORTING INFORMATION 
 
HPLC-based activity profiling of Angelica pubescens roots for new positive GABAA 
receptor modulators in Xenopus oocytes 
 
Janine Zaugga, Eva Eickmeiera, Diana Ruedaa, Steffen Heringb, Matthias Hamburgera,* 
 
a Institute of Pharmaceutical Biology, University of Basel, Klingelbergstrasse 50, 4056 Basel, 
Switzerland 
b Institute of Pharmacology and Toxicology, University of Vienna, Althanstrasse 14, 1090 
Vienna, Austria 
 
 
* Corresponding author. Tel.: +41 612671425; fax: +41 612671474.  
 E-mail addresses: steffen.hering@univie.ac.at (S. Hering) matthias.hamburger@unibas.ch (M. 
 Hamburger) 
 
 
79
Table S1. NMR spectroscopic data (500 MHz, CDCl3) for (1) 
(+)-Columbianetin acetate 
CAS Nr.: 23180-65-6 
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O
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O
 
 
m/z (ESITOFMS)  289.1065 [M+H+] (Calc.: 289.1071) 
   
[α]D  (20.2°C) +213° (c = 0.72, CHCl3)a 
   
position δC b δH (I, m, J in Hz)b 
2 160.8 - 
3 112.2 6.19 (CH, d, 9.4) 
4 143.8 7.60 (CH, d, 9.4) 
5 128.7 7.25 (CH, d, 8.5) 
6 106.5 6.72 (CH, d, 8.5) 
7 163.8 - 
8 113.0 - 
9 151.2 - 
10 113.0 - 
2’ 88.7 5.12 (CH, dd, 9.8, 7.9) 
3’ 27.6 3.26 (CH2, dd, 16.5, 7.9) 3.35 (CH2, dd, 16.5, 9.8) 
4’ 81.9 - 
4’-Mea 21.9 1.55 (CH3, s) 
4’-Meb 20.8 1.49 (CH3, s) 
1” 170.3 - 
2” 22.1 1.96 (CH3, s) 
aReference value can be found in K. Hata, Chem. Pharm. Bull. 1971, 19, 640-642 
b 13C-NMR shifts obtained from HSQC- and HMBC-NMR experiments. Spin 
systems evaluated by HSQC- NMR experiment 
cReference data can be found in H. Vuorela et al., Planta Med. 1988, 54, 538-542 
(except for 1” and 2”) 
dReference data can be found in K.S. Khetwal et al., Planta Med. 1987, 53, 581 
(except for 1” and 2”) 
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Table S2. NMR spectroscopic data (500 MHz, CDCl3) for (2) 
(+)-Bisabolangelone  
CAS Nr.: 30557-81-4 
 
 
 
m/z (ESITOFMS)  271.1298 [M+H+] (Calc.: 271.1305) 
  
[α]D  (20.5°C) +128° (c = 0.016, CHCl3)a 
   
position δC b,c δH (I, m, J in Hz)c 
2 160.2 - 
3 78.6 - 
4 196.8 - 
5 123.3 5.98 (CH, m) 
6 158.3 - 
7 34.9 2.66 (CH, dd, 18.6, 6.0) 
2.75 (CH, dd, 18.6, 6.0) 
8 75.9 4.84 (CH, ddd, 6.5, 6.0, 6.0) 
9 53.7 2.62 (CH, d, 6.5) 
1’ 94.6 5.34 (CH, d, 11.4) 
2’ 117.3 5.98 (CH, m, 11.4) 
3’ 132.6 - 
4’ 26.1 1.76 (CH3, s) 
5’ 18.2 1.69 (CH3, s) 
3-Me 27.4 1.59 (CH3, s) 
6-Me 24.6 1.98 (CH3, s) 
aReference data can be found in K. Hata, Chem. Pharm. Bull. 1971, 19, 1963-1967. 
b 13C-NMR shifts obtained from HSQC- and HMBC-NMR experiments. Spin 
systems evaluated by HSQC- NMR experiment 
cReference data can be found in J.-H. Liu, Phytochemistry 1998, 49, 211-213. 
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Table S3. NMR spectroscopic data (500 MHz, CDCl3) for (3) 
Imperatorin 
CAS Nr.: 482-44-0 
 
6
5
10
9
4
3
O O
O
O
3'
2'
2''
 
 
m/z (ESITOFMS)  293.0771 [M+Na+] (Calc.: 293.0784) 
   
position δCa, b δH (I, m, J in Hz)b
2 160.5 - 
3 114.3 6.34 (CH, d, 9.5) 
4 144.8 7.73 (CH, d, 9.5) 
5 113.0 7.33 (CH, s) 
6 125.8 - 
7 148.6 - 
8 131.4 - 
9 143.9 - 
10 116.3 - 
2’ 146.4 7.66 (CH, d, 2.5) 
3’ 106.7 6.78 (CH, d, 2.5) 
2” 70.3 4.98 (CH2, d, 7.4) 
3” 119.7 5.58 (CH, t, 7.4) 
4” 139.9 - 
5” 25.7 1.71 (CH3, s) 
6” 18.2 1.68 (CH3, s) 
a 13C-NMR shifts obtained from HSQC- and HMBC-NMR experiments. Spin 
systems evaluated by HSQC- NMR experiment 
bReference data can be found in O. Bergendorff et al. Phytochemistry, 1997, 44, 
1121-1124 
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Table S4. NMR spectroscopic data (500 MHz, CDCl3) for (4) 
Cnidilin 
CAS Nr.: 14348-22-2 
 
6 10
9
4
3
O O
O
2''
O
3'
2'
O
 
 
m/z (ESITOFMS)  301.1070 [M+H+] (Calc.: 301.1071) 
   
position δCa, b δH (I, m, J in Hz) 
2 161.0 - 
3 112.4 6.26 (CH, d, 9.7) 
4 139.7 8.09 (CH, d, 9.7) 
5 143.2 - 
6 116.9 - 
7 150.3 - 
8 127.8 - 
9 143.4 - 
10 108.9 - 
2’ 145.5 7.60 (CH, d, 2.5) 
3’ 104.9 6.92 (CH, d, 2.5) 
2” 70.8 4.77 (CH2, d, 7.2) 
3” 119.2 5.50 (CH, tm, 7.2) 
4” 139.9 - 
5” 26.0 1.76 (CH3, s) 
6” 18.4 1.63 (CH3, s) 
5-OMe 61.5 4.16 (CH3, s) 
a 13C-NMR shifts obtained from HSQC- and HMBC-NMR experiments. Spin 
systems evaluated by HSQC- NMR experiment 
bReference data can be found in K. Franke et al. Phytochemistry 2001, 56, 611-621 
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Table S5. NMR spectroscopic data (500 MHz, CDCl3) for (5) 
Osthole  
CAS Nr. 484-12-8 
 
6
5
10
9
4
3
O O
1'
O
 
 
m/z (ESITOFMS) 245.1180 [M+H+] (Calc.: 245.1172) 
   
position δCa, b δH (I, m, J in Hz)b 
2 161.0 - 
3 112.8 6.19 (CH, d, 9.5) 
4 143.7 7.57 (CH, d, 9.5) 
5 126.3 7.25 (CH, d, 8.5) 
6 107.5 6.81 (CH, d, 8.5) 
7 160.4 - 
8 118.3 - 
9 152.4 - 
10 112.9 - 
1’ 22.1 3.52 (CH2, d, 7.3) 
2’ 121.2 5.21 (CH, t, 7.3) 
3’ 132.5 - 
4’ 17.8 1.82 (CH3, s) 
5’ 25.8 1.65 (CH3, s) 
7 -OMe 56.3 3.89 (CH3, s) 
a 13C-NMR shifts obtained from HSQC- and HMBC-NMR experiments. Spin 
systems evaluated by HSQC- NMR experiment 
bReference data can be found in A. Basile et al., Molecules 2009, 14, 939-952 
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Table S6. NMR spectroscopic data (500 MHz, CDCl3) for (6) 
(+)-Columbianedin 
CAS Nr.: 5058-13-9 
 
6
5
10
9
4
3
O O
3'2'
O
4'O
1''
O
 
 
m/z (ESITOFMS) 329.1382  [M+H+] (Calc.: 329.1384) 
   
[α]D  (20.8°C) +249° (c = 1.42, CHCl3)a 
   
position δCb,c δH (I, m, J in Hz)d 
2 160.7 - 
3 112.0 6.16 (CH, d, 9.7) 
4 143.8 7.59 (CH, d, 9.7) 
5 128.7 7.22 (CH, d, 8.5) 
6 106.5 6.70 (CH, d, 8.5) 
7 163.3 - 
8 113.2 - 
9 150.6 - 
10 112.7 - 
2’ 88.9 5.13 (CH, dd, 7.8, 9.6) 
3’ 27.6 3.31 (CH2, dd 7.8, 16.3) 3.35 (CH2, dd, 9.6, 16.3) 
4’ 81.3 - 
4’-Mea 21.2 1.55 (CH3, s) 
4’-Meb 22.2 1.60 (CH3, s) 
1” 166.9 - 
2” 128.2 -
2”-Me 20.5 1.63 (CH3, m) 
3” 137.7 5.93 (CH, q, 7.1) 
4” 15.6 1.84 (CH3, d, 7.1) 
aReference value can be found in K. Hata, Chem. Pharm. Bull. 1971, 19, 640-642. 
b 13C-NMR shifts obtained from HSQC- and HMBC-NMR experiments. Spin 
systems evaluated by HSQC- NMR experiment 
cReference data can be found in H. Vuorela et al., Planta Med. 1988, 54, 538-542 
dReference data can be found in K.S. Khetwal et al., Planta Med. 1987, 53, 581.  
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3.3. POSITIVE GABAA RECEPTOR MODULATORS FROM ACORUS 
CALAMUS AND STRUCTURAL ANALYSIS OF (+)-
DIOXOSARCOGUAIACOL BY 1D AND 2D NMR AND MOLECULAR 
MODELING 
Zaugg J, Eickmeier E, Ebrahimi SN, Baburin I, Hering S, Hamburger M. 
J Nat Prod 2011; 74, 1437–1443. 
 
Five sesquiterpenes and β-asarone from Acorus calamus roots were identified as positive 
α1β2γ2S GABAA receptor modulating constituents using HPLC based activity profiling in 
combination with an in vitro functional assay using Xenopus oocytes. Structures were 
elucidated by high resolution mass spectrometry and microprobe NMR. The relative 
configuration of (+)-dioxosarcoguaiacol was determined by NOESY NMR and 
conformational analysis. 
 
 
Eva Eickmeier did upscaled extraction of plant material, isolation of compounds, 
recording and interpretation of analytical data for structure elucidation (HPLC-PDA-
ESI-TOF-MS, microprobe NMR, optical rotation) as part of her master’s thesis under my 
direct supervision. HPLC microfractionation, structure elucidation of (+)-
dioxosarcoguaiacol, Xenopus surgery, preparation of oocytes for electrophysiological 
measurements, two-microelectrode voltage clamp studies on fractions (except for open 
column fractions) and pure compounds, data analysis, writing of the manuscript, and 
preparation of figures were my contribution to this publication.        
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A corus calamus L. (Acoraceae), commonly known as “sweetflag”, is a polyploidic marsh plant indigenous to Asia and is
now distributed along trade routes all over the northern
hemisphere.1 The aromatic rhizome has been widely used as
an herbal remedy. It contains 1.79.3% of a volatile oil com-
posed of monoterpenes, sesquiterpenes, and phenylpropanoids.
The most characteristic constituent of the oil is β-asarone, even
though its concentration may vary considerably (96% in the
tetraploidic form found in eastern and tropical southern Asia, 5%
in the triploidic form found in Europe, Himalayan, and temperate
Indian regions, and 0% in the diploidic variety growing from
North America to Siberia).14 In European folk medicine,
A. calamus rhizomes have been mainly used as “Amarum aroma-
ticum” to alleviate gastrointestinal ailments such as acute and
chronic dyspepsia, gastritis and gastric ulcer, intestinal colic, and
anorexia.5,6 Ayurvedic medicine and traditional Chinese medi-
cine (TCM) use the drug preferably to treat central nervous
system (CNS) related diseases such as epilepsy, insanity, mental
weakness, or insomnia.79 Several in vivo studies support a
sedative and tranquillizing action of the essential oil and of
ethanolic and aqueous extracts of A. calamus.1012 Up to now,
the underlying mechanism of action has remained elusive despite
various investigations, even though the pharmacological effect
could be mainly attributed to R-asarone and β-asarone.11,1315
GABAA receptors are pentameric ligand-gated chloride ion
channels that are activated by GABA, the major inhibitory
neurotransmitter in the CNS. Most likely more than 11 different
receptor subtypes, assembled from five varying subunits, exist in
the human brain. These are involved in distinct neuronal circuits
and are targeted by numerous classes of drugs such as benzo-
diazepines, barbiturates, and some general anesthetics. The most
abundant GABAA receptor in the human brain consists of two
R1, two β2, and one γ2S subunit.1618
We recently screened a library of 982 extracts using an
automated functional two-microelectrode voltage clamp assay
with Xenopus oocytes19 that transiently expressed GABAA re-
ceptors of the R1β2γ2S subtype. A petroleum ether extract of
A. calamus rhizomes showed promising activity. As previously
shown, HPLC-based activity profiling is a miniaturized, effective
approach to discover new bioactive natural products,2024 and
we have successfully applied it to the discovery of new GABAA
receptor modulators of natural origin.2528 Herein, we describe
the identification of GABAA receptor modulating compounds in
A. calamus (16) and provide information suggesting the
complete relative configuration of (þ)-dioxosarcoguaiacol (2),
a sesquiterpene previously unknown in this plant.
’RESULTS AND DISCUSSION
Plant extracts were screened in an automated, fast perfusion
system during two-microelectrode voltage clamp measure-
ments with Xenopus oocytes that transiently expressed
GABAA receptors of the subunit combination R1β2γ2S.19 At a
Received: February 23, 2011
ABSTRACT: In a two-microelectrode voltage clamp with Xenopus laevis oocytes, a
petroleum ether extract of Acorus calamus rhizomes enhanced the GABA-induced chloride
current through GABAA receptors of the R1β2γ2S subtype by 277%( 9.7% (100 μg/mL).
β-Asarone (1), (þ)-dioxosarcoguaiacol (2), (þ)-shyobunone (3), and (þ)-preisocala-
menediol (4) were subsequently identified as main active principles through HPLC-based
activity profiling and targeted isolation. The compounds inducedmaximum potentiation of
the chloride current ranging from 588%( 126% (EC50: 65.3( 21.6 μM) (2) to 1200%(
163% (EC50: 171.5( 34.6 μM) (1), whereas ()-isoshyobunone (5) and ()-acorenone
(6) exhibited weak GABAA modulating properties (5: 164%( 42.9%; EC50: 109.4( 46.6
μM and 6: 241% ( 23.1%; EC50: 34.0 ( 6.7 μM). The relative configuration of 2 was
established as 4R*8S*10R* by NOESY experiments and conformational analysis.
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concentration of 100 μg/mL, the A. calamus petroleum ether
extract potentiated the GABA-induced chloride current
(IGABA) by 277% ( 9.7% (Figure 1C). To localize the activity
within the extract, it was submitted to HPLC-based activity
profiling using a previously validated protocol.29 The chroma-
togram (254 nm) of a semipreparative HPLC separation (10
mg of extract) and the corresponding activity profile of the
time-based microfractionation (28 microfractions of 90 s each)
are shown in Figure 1B and A, respectively. A major peak of
activity was found in fraction 14 (potentiation of IGABA by 237%
( 5.4%), which contained an unresolved complex of peaks
containing compounds 36. Minor activity was found in
fractions 1, 68, and 10. Fractions 6 and 7 contained a major
compound of the extract and enhanced IGABA by 54.7%( 9.3%
and 73.9% ( 17.7%, respectively. Fraction 8, consisting of a
minor compound, showed a potentiation of IGABA by 50.6% (
17.4%, whereas fraction 10 enhanced IGABA by 33.8%( 10.3%.
Fraction 1 showed marginal activity (38.3% ( 2.9%) but was
not further pursued.
Preparative isolation was focused on the purification of
compounds in the active time-based fractions and was started
by an open column separation of the extract. An HPLC-ESIMS
analysis of the resulting 21 fractions revealed that the extract was
significantly more complex than suggested by the semiprepara-
tive HPLC chromatogram at 254 nm (Figure 1B). Peaks with
retention times fitting to active microfractions were detected in
several fractions. Fractions AE and LU were submitted to
bioassay at a test concentration of 10 μg/mL (Figure 1C). The
most active fractions, A, C, L, and M (potentiation of IGABA by
132% ( 41.5%, 157% ( 20.7%, 235% ( 59.0%, and 158% (
72.9%, respectively), contained peaks that corresponded to the
active time windows in the HPLC-based activity profiling
(Figure 1D) and were further purified. Fraction D was not
further pursued since it was very similar to fraction C. Finally,
β-asarone (1), (þ)-dioxosarcoguaiacol (2), (þ)-shyobunone
(3), (þ)-preisocalamenediol (4), ()-isoshyobunone (5), and
()-acorenone (6) were isolated and unambiguously identified
by ESI-TOF-MS, 1D and 2Dmicroprobe NMR, optical rotation,
and comparison with published data.3037 Compounds 1 and
36 have been previously isolated from A. calamus.3841 Their
spectroscopic data are given as Supporting Information.
(þ)-Dioxosarcoguaiacol (2), a sesquiterpene new for
A. calamus, had been described from a Red Sea soft coral
(Sarcophyton glaucum). However, assignment of the relative
configuration was limited to stereocenters 4S* and 10R*, while
the configuration at the bridgehead C-8 was not established.35
Optical rotation and NMR data of 2 were identical to
published data. To confirm the relative configuration of the
stereocenters at C-4 and C-10, we submitted the four possible
stereoisomers of 2 (4R*8S*10R*, 4S*8S*10R*, 4R*8S*10S*,
4S*8S*10S*) to conformational analysis and compared 3JHH
coupling constants from 1H NMR and selective TOCSY
experiments, and NOESY correlations with the structures of
the calculated conformers (relevant NMR data are summar-
ized in Table 1; NMR spectra of 2 are given as Supporting
Information). For each stereoisomer, 13 conformers were
obtained within a 1 kcal/mol range from the corresponding
global energy minimum (Figure S1, Supporting Information).
However, only one conformer of each stereoisomer reason-
ably fit to the observed NMR data. These conformers were
then submitted to geometrical optimization using density
function theory (B3LYP/6-31G*), prior to comparison of
optimized dihedral angles and interatomic distances with
the experimental data.
Unambiguous assignment of themethylene protons at C-2 and
C-3 was established on the basis of 3JHH H-2b/H-3b of 0 Hz,
indicative of their perpendicular orientation. This was corrobo-
rated by a NOESY correlation between H-3b and H-2a. 3JHH
coupling constants H-9b/H-10 (5.2 Hz) and H-9a/H-10 (13.4
Hz) corresponded to dihedral angles of approximately 60 and
180, respectively. Geometrically optimized conformers matched
with the above-mentioned NMR data. However, two stereoi-
somers (4R*8S*10S*, 4S*8S*10S*) could be discarded since the
interatomic distances between H-2a and CH3-15, and between
H-6 and both methyl groups at C-11, were not in accord with the
observed NOESY correlations. Assignment of the relative con-
figuration at C-4 was supported by NOESY correlations between
H-3a and H-4, and H-3b and CH3-14. Hence, only the
4R*8S*10R* stereoisomer fully matched with the NMR data
of (þ)-dioxosarcoguaiacol (2) (Figure 2). A synoptical table
(Table S6) of the stereoisomers is given as Supporting Information.
(þ)-Dioxosarcoguaiacol35 was previously published with a
4S*10R* configuration, and with NMR shifts and optical rotation
identical to compound 2. 4R10R-Calamusenone, the 8-oxo,Δ7,11
analogue of 2, was previously reported from A. calamus essential
oil, and its absolute configuration determined by X-ray crystal-
lographic analysis.42 The formation of 2 can be plausibly
explained via photo-oxygenation of calamusenone by “ene-type”
addition of O2 at C-11 and subsequent ring closure to the
endoperoxide.43 1H NMR integrals of 2 showed an enantiomeric
excess of the 8S* epimer [8-OH: δ 3.08, 8S* and δ 2.94, 8R*
(95:5); H-6: δ 5.55, 8S* and δ 5.51, 8R* (95:5)]. The compar-
ison of computationally optimized conformers of 2 with struc-
tural information obtained by 1D and 2D NMR experiments
allowed us to unambiguously identify the relative configuration
of (þ)-dioxosarcoguaiacol (2) as 4R*8S*10R*, which contra-
dicted the previously reported structure.35 Our findings were
supported by the existence of a putative precursor, 4R10R-
calamusenone, with known absolute configuration.
Compounds 16 were tested in the oocyte assay at concen-
trations ranging from 0.1 to 1000 μM. To varying degrees, all
compounds enhanced IGABA at a GABA EC510 in a concentra-
tion-dependent manner (Figure 3). Compared to other natural
products,25,27,44 compounds 14 showed high efficiencies on
R1β2γ2S GABAA receptors. Potentiation of IGABA ranged from
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588%( 126% (2) to 1197%( 163% (1) (Table 2). Compounds
with higher efficiency usually displayed lower potencies (higher
concentrations for half-maximal stimulation of IGABA; EC50) and
vice versa. Compound 6 showed the highest potency (34.0 (
6.7 μM) but a maximum stimulation of IGABA of only 241% (
23.1%.
Even though the set of compounds tested was too small
for a study of structureactivity relationships, some interesting
observations were made: (þ)-shyobunone (3) and (þ)-preisoca-
lamenediol (4), which both derive from acoragermacrone,40,45
showed comparably high efficiencies. The potency of 4 was lower,
which could be due to the high conformational flexibility of the
germacrane-type scaffold. ()-Isoshyobunone (5) was much less
efficient than its presumed precursor 346 (Figure 3; Table 3), which
can only be explained by the varying C-2 substitution and the
consequential conformational difference. Interestingly, 5 showed a
weak (less than GABA EC510) direct activation of the R1β2γ2S
GABAA receptor, whereas 3 did not evoke any agonistic effect. Only
weak GABAA receptor modulation was found for ()-acorenone
(6). Compounds 26 broaden the spectrum of sesquiterpenes
acting at the GABAA receptors. Up to now only a few sequiterpenes
have been reported as GABAA receptor modulators. The most
prominent is picrotoxin, a strongGABAA receptor inhibitor
47 that is
widely used as an experimental compound for animal convulsion
models. Valerenic acid from Valeriana officinalis roots is a β2/3-
subunit-specific positive allosteric modulator44,48 with anxiolytic
effects in vivo.48,49 This compound has served as a new scaffold
for GABAA receptor ligands.
49,50
Among the compounds identified by the profiling of Acorus
extract, the simple phenylpropanoid β-asarone (1) induced the
highest potentiation of IGABA (1200% ( 163% with an EC50 of
171.5 ( 34.6 μM). Its efficiency at a GABA EC510 was
significantly higher than that of known GABAA receptor modula-
tors such as benzodiazepines (triazolam: 253% ( 12%, midazo-
lam: 342% ( 64%, clotiazepam: 260% ( 27%)51 or natural
products such as valerenic acid (400% ( 78%).44 The structure
of 1 is somewhat reminiscent of propofol, a general anesthetic
acting at the GABAA receptor. However, the pharmacologi-
cal potential of 1 is certainly limited due to its known toxicity.5254
There are many reports of sedative and tranquillizing properties
of Acorus extracts and essential oil in animal models, but the
mechanism of action was not established up to now.1015,55
Given that β-asarone (1) is a major compound of the essential
oil, its sedative and tranquillizing activities may be due to the
GABAA receptor modulating properties of 1. The quantity of
β-asarone in Acorus rhizome and essential oil, however, depends
on the chemotype and thus varies considerably.3,4 Medicinal
preparations made of the diploidic or triplodic form are free of
the toxic β-asarone and are, therefore, recommended for ther-
apeutic use.8 It is interesting to note that there seems to be a
correlation between β-asarone content in the three chemotypes
of A. calamus and their traditional uses. The tetraploidic,
β-asarone-rich types growing in Asia have been traditionally
used in Ayurvedic medicine and TCM as sedatives, whereas such
uses have not been reported from the β-asarone-poor European
and North American chemotypes. The reason for “Eastern” tradi-
tional usage as a sedative and “Western” traditional usage as an
aromatic bitter could possibly be explained by limited access in the
past to the geographically separated chemotypes of A. calamus.
The essential oil and extracts of A. calamus roots have multiple
pharmacological and biological effects,56 but there is not much
published data on bioactivity of sesquiterpenes 36 and (þ)-
dioxosarcoguaiacol (2). The compounds represent interest-
ing drug-like structures, since they all fulfill Lipinski’s “rule of
five”.57 From a pharmacological perspective, however, further
investigations may be limited to the highly efficient sesquiter-
penes 3 and 4 and to the minor compound 2. Further pharma-
cological and toxicological studies are needed to substantiate the
Figure 1. HPLC-based activity profiling of a petroleum ether extract of
Acorus calamus L. for GABAA modulating properties. The HPLC chro-
matogram (254 nm) of a semipreparative separation of 10mg of extract is
shown in B. Peak numbering corresponds to compounds 16. The 28
collected time-based fractions, 90 s each, are indicated with dashed lines.
Potentiation of the GABA-induced chloride current in Xenopus oocytes
(IGABA) of microfractions is shown in A. Potentiation of IGABA by the
extract (100 μg/mL) and by open column fractions AE and LU
(10 μg/mL) are shown in C. Fractions FKwere not tested due to limited
amounts (<100 μg). Part D shows analytical HPLC traces (254 nm) of
open column fractionsA,C,D, L, andM.The active time-windows from the
HPLC-based activity profiling (approximately corresponding to microfrac-
tions 68, 10, and 14) are indicated with dashed lines.
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sedative and tranquillizing properties of pure compounds and of
the essential oil.
’EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations of com-
pounds 26were measured on a Perkin-Elmer polarimeter (model 341)
equipped with a 10 cm microcell. The optical rotation for the Na-D-line
(589 nm) was extrapolated from the lines of a mercury lamp using the
Drude equation.58 NMR spectra were recorded at room temperature
with a Bruker Biospin Avance III spectrometer operating at 500.13MHz.
1H NMR, COSY, DEPT-edited HSQC, HMBC, 1D-TOCSY, and 2D-
NOESY spectra were measured with a 1 mm TXI probe. Spectra were
analyzed using Bruker TopSpin 2.1 software. ESI-TOF-MS spectra of
compounds 16 were recorded in positive mode on a Bruker Daltonics
microTOF ESIMS system. Nitrogen was used as a nebulizing gas at a
pressure of 2.0 bar and as a drying gas at a flow rate of 9.0 L/min (dry gas
temperature 240 C). Capillary voltage was set at 4500 V, hexapole at
230.0 Vpp. Instrument calibration was performed using a reference
solution of sodium formate 0.1% in 2-propanol/water (1:1) containing
5 mM NaOH.
HPLC-PDA-ESIMS spectra were obtained in positive mode on a
Bruker Daltonics Esquire 3000 Plus ion trap MS system connected via
T-splitter (1:5) to an Agilent HP 1100 series system consisting of a
binary pump, autosampler, column oven, and diode array detector
(G1315B). Data acquisition and processing of all mass spectra was
performed using Bruker HyStar 3.0 software.
Semipreparative HPLC separations were performed on a Waters
Alliance 2690 separation module connected to a 996 photodiode array
detector. Data acquisition and processing was performed using Waters
Empower Pro software. Preparative HPLC separation was performed
using a Shimadzu LC-8A preparative separation chromatograph equip-
ped with a SPD-M10A VP diode array detector. Medium-pressure liquid
chromatography (MPLC) was done on prepacked normal-phase car-
tridges (4063 μm, 40  150 mm) using a Buchi Sepacore system
consisting of a control unit C-620, a fraction collector C-660, and two
pump modules C-605. The MPLC unit was controlled with the Buchi
SepacoreControl software (version 1.0.3000.1). Deuterated chloroform
(100 atom % D, stabilized with Ag) for NMR experiments was
purchased from Armar Chemicals. HPLC-grade MeOH (Scharlau
Chemie S.A.) and water were used for HPLC separations. Solvents
used for extraction, open column chromatography, and MPLC were of
technical grade and purified by distillation. Silica gel (63200 μm,
Merck) was used for open column chromatography.
Plant Material. Dried and cut rhizomes of A. calamus Ph. Helv.
were purchased from Haenseler AG (Herisau, Switzerland) (batch
2009.12.0224). The identity of the plant material was confirmed at
Table 1. NMR Spectroscopic Data (500 MHz, CDCl3) for (þ)-Dioxosarcoguaiacol (2)
position δC
a mult. δH (J in Hz) HMBC
b NOESYc
1 145.8 C
2 35.6 CH2 H-2a: 2.58, ddd (16.7, 8.5, 7.2)
H-2b: 2.21, ddd (16.7, 10.9, 0)
H-2aT H-3b, 15
3 29.9 CH2 H-3a: 1.95, m
H-3b: 1.40, dddd (16.6, 8.5, 3.5, 0)
H-3aT 4
H-3bT H-2a, 14
4 44.3 CH 2.63, m
5 132.5 C
6 114.6 CH 5.55, s C-11, 4, 8, 7, 5 H-13, 12, 14, 4
7 153.2 C
8 103.4 C
8-OH 3.08, br s
9 38.0 CH2 H-9a: 1.63, dd (13.4, 13.4) C-14, 10, 8, 7, 1 H-9aT H-15
H-9b: 2.03, dd (13.4, 5.2) H-9bT H-15
10 31.5 CH 2.71, m
11 85.3 C
12 28.0 CH3 1.37, s C-15, 11, 7 H-6
13 24.8 CH3 1.43, s C-12, 11, 7 H-6
14 20.1 CH3 1.04, d (7.1) C-3, 4, 5
15 19.6 CH3 1.12, d (7.1) C-10, 9, 8, 1 H-9a, 9b, 2a
a 13C shifts are deduced from HSQC and HMBC experiments. bHMBC correlations from hmbcgp experiment (NS: 128, DS: 16), optimized for 10 Hz,
are from proton(s) stated to the indicated carbon. cCritical NOESY correlations from noesygpphpp experiment (mixing time 0.75 s, NS: 32, DS: 16)
Figure 2. Geometrically optimized structure of 4R*8S*10R*-(þ)-diox-
osarcoguaiacol (2). Critical NOESY correlations for assigning the
relative configuration are indicated with arrows. The geometrical
optimization was performed using density function theory at the
B3LYP/6-31G* level.
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the Division of Pharmaceutical Biology, University of Basel, where a
voucher specimen (00 380) is deposited.
Microfractionation forActivityProfiling.Analiquot (approximately
20 g) of ground roots was macerated at room temperature with petroleum
ether (3 0.5 L, 1 h each). Microfractionation for GABAA receptor activity
profiling was performed as previously described,25,2729 with minor modifica-
tions; separation was carried out on aWaters SunFire Prep C18 (5 μm, 10
150 mm) column with MeOH (solvent A) and H2O (solvent B) using the
following gradient: 60%A to 100%A in30min, hold for 10min.The flow rate
was 4 mL/min, and 100 μL of the extract (100 mg/mL in DMSO) was
injected. A total of 28 time-based microfractions of 90 s each were collected.
Microfractions were evaporated in parallel with a Genevac EZ-2 Plus vacuum
centrifuge. The dry films were redissolved in 1 mL of MeOH; aliquots of
0.5 mL were dispensed in two vials, dried under N2 gas, and submitted to
bioassay.
Preparative Extraction and Isolation. The plant material was
ground with a Retsch ZM1 ultracentrifugal mill. Ground roots (630 g)
were extracted by maceration at room temperature with petroleum ether
(4  2.5 L, 1 h each). The solvent was evaporated at reduced pressure to
yield 20.7 g of petroleumether extract. A portion of the extract (18.8 g) was
separated by open column chromatography (9 80 cm, 1.2 kg silica gel)
using a step gradient of petroleum ether and ethyl acetate (95:5, 10 L;
90:10, 4 L; 80:20, 2 L; 70:30, 2 L; 60:40, 2 L; 50:50, 4 L; 25:75, 1.8 L; 100:0,
2 L). The flow rate was approximately 15 mL/min. The effluents were
combined to 21 fractions (AU) based on TLC patterns (detection at
254 nm and at daylight after staining with anisaldehydesulfuric acid
reagent). Fractions AU were analyzed by HPLC-PDA-ESIMS on a
Waters SunFire C18 (3.5 μm, 3.0  150 mm) column with MeOH
(solvent A) and H2O (solvent B), both containing 0.1% formic acid. A
gradient of 60% A to 100% A in 30 min, hold for 10 min, and a flow rate of
0.4 mL/min were used. The sample concentration was 10 mg/mL in
DMSO, and the injection volume was 5 μL. The fractions were then
submitted to bioassay. A portion (700 mg) of fraction A (1.32 g) was
separated into 21 fractions (A1A21) by MPLC using toluene, hexane,
Figure 3. Part A shows the concentrationresponse curves for compounds 16 on GABAA receptors (R1, β2, and γ2S subunit composition) using a
GABA EC510. Typical traces for modulation of chloride currents through R1β2γ2S GABAA receptors for compounds 16 are given in B.
Table 2. Potencies (EC50) and Efficiencies (Maximum Stimulation of the GABA-Induced Chloride Current) of Compounds 16
for GABAA Receptors of the Subunit Composition R1β2γ2S
compd EC50 [μM] ( SE maximum stimulation of IGABA (EC510) ( SE [%] Hill coefficienta (nH) ( SE no. of experiments (n)
1 171.5( 34.6 1200( 163 1.8( 0.2 6
2 65.3( 21.6 588( 126 1.6( 0.3 5
3 64.8( 19.8 669( 112 1.7( 0.3 6
4 135.1( 34.4 886( 105 1.6( 0.2 5
5 109.4( 46.6 164( 42.9 2.1( 0.8 6
6 34.0( 6.7 241( 23.1 1.6( 0.3 5
a Indicates the slope of the concentrationresponse curve at the EC50. Hill coefficients > 1 indicate positive cooperativity during receptor binding.62
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and CH2Cl2 in the following gradient: 10:90:0 to 100:0:0 in 3 h, 0:0:100
for 1 h at a flow rate of 30 mL/min. Fractions A10 (60.9 mg), A14
(140.8 mg), and A18 (19.2 mg) consisted of (þ)-shyobunone (3), (þ)-
preisocalamenediol (4), and ()-isoshyobunone (5), respectively. A
portion (750 mg) of fraction C (920 mg) was separated into five fractions
(C1C5) byMPLCusing a gradient of hexane and ethyl acetate (100:0 to
95:5 in 1.5 h, flow rate 30 mL/min) to yield 376 mg (fraction C3) of ()-
acorenone (6). Fraction L (385 mg) was separated by MPLC using a
gradient of a CHCl3/EtOAc [9:1]mixture and hexane (20:80 to 50:50 in 2
h, flow rate 30 mL/min), which yielded 15 fractions (L1L15). Fraction
L13 (29.5 mg) was dissolved in 400 μL of DMSO and separated by
preparative HPLC on a Waters SunFire Prep C18 OBD (5 μm, 30 
150 mm) column using a gradient of MeOH/H2O (50:50 to 100:0 in 30
min, flow rate 20 mL/min) to obtain 3.8 mg of (þ)-dioxosarcoguaiacol
(2). A portion (790 mg) of fractionM (952 mg) was separated by MPLC
using a gradient of a CH2Cl2/EtOAc [9:1] mixture and hexane (20:80 to
50:50 in 2 h, flow rate 30 mL/min), which yielded 12 fractions
(M1M12). Fraction M2 (290.9 mg) was identified as β-asarone (1).
A portion (30 mg) of fraction M5 (83.4 mg) was dissolved in hexane
(300 μL) and submitted repeatedly to semipreparative HPLC on a Merck
LiChroSorb 100 Diol (10 μm, 10  250 mm) column (hexane/
2-propanol (97:3) isocratic, flow rate 5 mL/min) to isolate another
18.5 mg of (þ)-dioxosarcoguaiacol (2).
(þ)-Dioxosarcoguaiacol (2): yellow oil; [R]22D þ36 (c 0.16,
CHCl3); UV (MeOH) λmax 260 (sh), 267 nm; NMR data see Table 1
and Supporting Information; ESI-TOF-MS m/z 273.1447 [M þ Na]þ
(calcd for C15H22O3Na, 273.1463).
Compounds 1 and 36 were unambiguously identified by means of
1D and 2DNMR experiments, ESI-TOF-MS, and optical rotation in the
case of chiral compounds. The data were compared with published
values3037 and are available as Supporting Information.
Conformational Analysis and Geometrical Optimization.
Conformational analysis of the stereoisomers of 2 was performed with
Schr€odinger 9.1 software at theOPLS_2005 level in CHCl3. Selection of
the conformers was done within a 1 kcal/mol energy window. Con-
formers not fitting to NMR data were discarded (exclusion criteria: (i)
dihedral angles clearly mismatching the 3JHH coupling constants be-
tween H-10/H-9a and H-10/H-9b or (ii) dihedral angles mismatching
J2b,3b 0 Hz and interatomic distances between H-6/H-12 and H-6/H-13
mismatching the corresponding NOESY correlations). The Gaussian 03
package59 was used for optimizing the remaining starting geometries by
means of the density function theory with the B3LYP functional and the
6-31G* basis set in the gas phase.60 Dihedral angles and interatomic
distances were taken from minimized conformers and compared with
NMR data.
Expression of GABAA Receptors. Stage VVI oocytes from
Xenopus laevis were prepared and cRNA was injected as previously
described by Khom et al. (2006).51 Female X. laevis (NASCO, Fort
Atkinson, WI) were anesthetized by exposing them for 15 min to a 0.2%
MS-222 (3-aminobenzoic acid ethyl ester methanesulfonate, Sigma-
Aldrich, Munich, Germany) solution before surgically removing parts of
the ovaries. Follicle membranes from isolated oocytes were enzymati-
cally digested with 2 mg/mL collagenase from Clostridium histolyticum
(Type 1A, Sigma-Aldrich). Synthesis of capped runoff poly(Aþ) cRNA
transcripts was obtained from linearized cDNA templates (pCMV
vector). One day after enzymatic isolation, the oocytes were injected
with 50 nL of DEPC-treated H2O (Sigma-Aldrich) containing different
cRNAs at a concentration of approximately 3003000 pg/nL per
subunit. The amount of injected cRNA mixture was determined
by means of a NanoDrop ND-1000 (Kisker Biotech, Steinfurt,
Germany). Rat cRNAs were mixed in a 1:1:10 ratio to ensure expression
of the gamma subunit in R1β2γ2S receptors. Oocytes were then stored
at 18 C in an aqueous solution of 90 mM NaCl, 1 mM KCl, 1 mM
MgCl2, 1 mM CaCl2, and 5 mM HEPES (pH 7.4), containing 1% of
penicillinstreptomycin solution (Sigma-Aldrich).61 Voltage clamp
measurements were performed between days 1 and 5 after cRNA
injection.
Two-Microelectrode Voltage Clamp Studies. Electrophysio-
logical experiments were performed by the two-microelectrode voltage
clamp method at a holding potential of 70 mV making use of a
TURBO TEC 03X amplifier (npi Electronic GmbH, Tamm, Germany)
and an Axon Digidata 1322A interface (Molecular Devices, Sunnyvale,
CA). Data were recorded by using pCLAMP v10.2 data acquisition
software (Molecular Devices). Currents were low-pass-filtered at 1 kHz
and sampled at 3 kHz. The bath solution contained 90 mMNaCl, 1 mM
KCl, 1 mMMgCl2, 1 mMCaCl2, and 5mMHEPES (pH 7.4). Electrode
filling solution contained 2 M KCl.
Fast Solution Exchange during IGABA Recordings. Test
solutions (100 μL) of extracts, fractions, and pure compounds were
applied to the oocytes at a speed of 300 μL/s by means of the
ScreeningTool automated fast perfusion system (npi Electronic
GmbH).19 In order to determine GABA EC510 (typically between 3
and 10 μM for receptors of the subunit combination R1β2γ2S), a
concentrationresponse experiment with GABA concentrations ran-
ging from 0.1 μM to 1 mM was performed. Stock solutions (10 mg/mL
in DMSO) of A. calamus extract and open column fractions (121)
were diluted to concentrations of 100 and 10 μg/mL, respectively, with
bath solution containing GABA EC510. As previously described in a
validated protocol, microfractions collected from the semipreparative
HPLC separations were dissolved in 30 μL of DMSO and subsequently
mixed with 2.97 mL of bath solution containing GABA EC510.
29 For
concentrationresponse experiments, bath solution containing com-
pounds 16 in concentrations ranging from 0.1 to 1000 μMwas applied
to the oocyte. After a 20 s incubation period, a second application
immediately followed containing the corresponding compound solution
combined with GABA EC510.
Data Analysis. Enhancement of the GABA-induced chloride current
(IGABA) was defined as I(GABAþComp)/IGABA 1, where I(GABAþComp) is
the current response in the presence of a given compound, and IGABA is
the control GABA-induced chloride current. Data were analyzed using the
ORIGIN 7.0 SR0 software (OriginLab Corporation) and are given as
mean ( SE of at least 2 oocytes and g2 oocyte batches.
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Table S1. Spectral characterization data for (1) (NMR spectra recorded in CDCl3) 
β-Asarone 
CAS Nr.: 5273-86-9 
 
1
3
5
OO
O  
 
m/z (ESITOFMS) 231. 0998 [M+Na+] (Calc.: 231.0992) 
   
position δC a,b δH (I, m, J in Hz)a 
1 142.6 - 
1-OCH3 56.5 3.57 (CH3, s) 
2 148.9 - 
2-OCH3 55.8 3.6 (CH3, s) 
3 98.4 6.30 (CH, s) 
4 151.8 - 
4-OCH3 56.0 3.52 (CH3, s) 
5 118.0 - 
5-CH=CHCH3 124.9 6.28 (CH, dq, 11.5, 2.0) 
5-CH=CHCH3 124.8 5.49 (CH, dq, 11.5, 7.0) 
5-CH=CHCH3 14.3 1.61 (CH3, dd, 7.0, 2.0) 
6 115.0 6.64 (CH, s) 
aReference data can be found in A. Patra et al., J. Nat. Prod. 1981, 44, 668-669 
bCalculated 13C shift of HSQC- and HMBC-NMR experiments. Spin systems evaluated by HSQC- 
NMR experiment 
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Table S2. Spectral characterization data for (3) (NMR spectra recorded in CDCl3) 
(+)-Shyobunone 
CAS Nr.: 21698-44-2 
O
H H
H H
3
1
6
O
 
 
 
Relative configuration detected 
by 1D NOE NMR. Critical 
correlations highlighted by red 
and blue arrows. 
 
m/z (ESITOFMS)  243.1722 [M+Na+] (Calc.: 243.1719) 
   
[α]D (21.4°C) +100° (c = 0.19, CHCl3)a 
   
position δC b,c δH (I, m, J in Hz)c 
1 209.6 - 
2 66.9 2.99 (CH, s) 
2-CCH2CH3 139.7 - 
2-CCH2CH3 
116.5 4.70 (CH2, s)  
4.93 (CH2, s)  
2-CCH2CH3 24.1 1.70 (CH3, s) 
3 46.2 - 
3-CH3 18.9 0.98 (CH3, s) 
3-CHCH2 146.6 5.76 (CH, dd, 11.0, 17.8) 
3-CHCH2 
110.7 4.89 (CH2, dd, 11.0, 1.0) 
4.91 (CH2, dd, 17.8, 1.0) 
4 39.3 Hα: 1.56, CH2, m  
Hβ: 1.86, CH2, ddd (5.2, 13.2, 13.2)  
5 24.8 1.59 (CH2, m) 1.96 (CH2, m) 
6 56.4 2.09 (CH, m) 
6-CH(CH3)2 26.3 2.09 (CH, m) 
6-CH(CH3)2 18.3 0.82 (CH3, d, 6.4) 
6-CH(CH3)2 21.0 0.86 (CH3, d, 6.4) 
aNo reference value could be found in literature. Relative configuration detected by 1D NOE NMR 
experiments. Important correlations highlighted by red (plain) and blue (dashed) arrows. 
bCalculated 13C shift of HSQC-NMR and HMBC-NMR experiments. Spin systems evaluated by 
HSQC- NMR experiment 
cReference data can be found in P. Weyerstahl et al. Liebigs Ann. Chem. 1987, 2, 89-101
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Table S3. Spectral characterization data for (4) (NMR spectra recorded in CDCl3) 
(+)-Preisocalamenediol 
CAS Nr.: 25645-19-6  
 
 
 
m/z (ESITOFMS) 243.1731 [M+Na+] (Calc.: 243.1719) 
   
[α]D (20.3°C) +61.6° (c = 0.71, CHCl3)a 
   
position δC b,c δH (I, m, J in Hz)a 
1 207.2 - 
2 60.0 2.20 (CH, ddd, 1.0, 4.9, 10.9) 
2-CH(CH3)2 30.5 1.61 (CH, m) 
2-CH(CH3)2 19.5 0.82 (CH3, d, 6.9) 
 20.5 0.77 (CH3, d, 6.9) 
3 28.2 1.43 (CH2, dm, 13.5) 
2.03 (CH2, m) 
4 40.6 1.75 (CH2, dt, 3.4, 12.8) 
1.98 (CH2, m) 
5 137.9 - 
6 125.6 5.15 (CH, dd, 3.0, 10.7) 
7 29.2 1.96 (CH2, m) 
2.11 (CH2, m) 
8 36.7 1.94 (CH2, m) 
2.27 (CH2, m) 
9 142.6 - 
10 53.4 2.85 (CH2, d, 14.8) 
3.21 (CH2, d, 14.8) 
5-CH3 15.2 1.30 (CH3, s) 
9=CH2 116.5 4.77 (CH2, s) 
4.90 (CH2, s) 
aReference value can be found in C. Zdero et al. Phytochemistry 1989, 28, 531-542 
bCalculated 13C shift of HSQC- and HMBC-NMR experiments. Spin systems evaluated by HSQC- 
NMR experiment 
cReference data can be found in D.M. Delvalle et al. Planta Med. 1987, 87, 230.
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Table S4. Spectral characterization data for (5) (NMR spectra recorded in CDCl3) 
(-)-Isoshyobunone 
CAS Nr.: 21698-46-4  
 
3
1 6
O  
 
m/z (ESITOFMS) 243.1730 [M+Na+] (Calc.: 243.1719) 
   
[α]D (21.5°C) -156° (c = 0.61, CHCl3)a 
   
position δC b, c δH (I, m, J in Hz)b,c 
1 209.4 - 
2 140.1 - 
3 44.4 - 
4 39.3 1.33 (CH2, ddd, 14.0, 6.8, 3.6) 
1.44 (CH2, ddd, 14.0, 10.7, 3.3) 
5 21.4 1.79 (CH2, m) 
1.60 (CH2, m) 
6 55.2 2.11 (CH, ddd, 9.0, 9.0, 6.3) 
2-C(CH3) 146.6 - 
2-C(CH3)2 23.5 1.69 (CH3, s) 
 24.2 1.74 (CH3, s) 
3-CH3 24.5 1.29 (CH3, s) 
3-CHCH2 146.4 5.83 (CH, dd, 10.4, 17.9) 
3-CHCH2 110.7 
4.91 (CH2, dd, 10.4, 1.2) 
4.90 (CH2, dd, 17.9, 1.2) 
6-CH(CH3)2 29.4 2.00 (CH, m) 
6-CH(CH3)2 18.4 0.79 (CH3, d, 6.8) 
 20.6 0.84 (CH3, d, 6.8) 
aReference value can be found in M. Niwa et al. Chem. Lett. 1977, 12, 1415-1418 
bCalculated 13C shift of HSQC- and HMBC-NMR experiments. Spin systems evaluated by HSQC- 
NMR experiment 
cReference data can be found in P. Weyerstahl et al. Liebigs Ann. Chem. 1987, 2, 89-101
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Table S5. Spectral characterization data for (6) (NMR spectra recorded in CDCl3) 
(-)-Acorenone 
CAS Nr.: 5956-05-8 
 
4
51
7
O  
 
m/z (ESITOFMS) 243.1730 [M+Na+] (Calc.: 243.1719) 
   
[α]D (21.5°C) -27° (c = 0.37, CHCl3)a 
   
position δC a, b δH (I, m, J in Hz)a, c 
1 56.9 1.24 (CH, m) 
1-CH(CH3)2 28.9 1.49 (CH, o, 6.5) 
1-CH(CH3)2 21.5 0.73 (CH3, d, 6.8) 
 24.0 0.84 (CH3, d, 6.8) 
2 25.4 1.24 (CH2, m) 1.60 (CH2, m) 
3 29.9 1.14 (CH2, m) 1.57 (CH2, m) 
4 47.0 1.57 (CH, m) 
4-CH3 16.1 0.70 (CH3, d, 6.8) 
5 47.9 - 
6 38.8 2.16 (CH2, d, 16.6) 2.21 (CH2, d, 16.6) 
7 200.3 - 
8 134.6 - 
8-CH3 15.6 1.63 (CH3, s) 
9 144.4 6.54 (CH, s) 
10 37.4 2.01 (CH2, dm, 19.9) 2.53 (CH2, dm, 19.9) 
aReference value can be found in S.W. Baldwin et al., Tetrahedron Lett. 1982, 23, 1235-1238 
bCalculated 13C shift of HSQC- and HMBC-NMR experiments. Spin systems evaluated by HSQC- 
NMR experiment 
cReference data can be found in W. Rascher et al., Tetrahedron, 33, 575-577 
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 Figure S1: Predominant conformers of the four possible stereoisomers of (+)-
dioxosarcoguaiacol (2) within a 1 kcal/mol energy window from the particular global minimum. 
Conformational analysis was performed at the OPLS_2005 level in chloroform. A: 4R*8S*10R*, 
B: 4S*8S*10S*, C: 4R*8S*10S*, D: 4S*8S*10R* 
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Table S6. Comparison of NMR Data (3JHH-Coupling Constants and NOESY Correlations) with 
Geometrically Optimized Conformers of the Four Stereoisomers of (+)-Dioxosarcoguaiacol (2) 
NMR observations  Matching geometrically optimized conformersa  
  4R*8S*10R* 4S*8S*10R* 4R*8S*10S* 4S*8S*10S*  
J2b,3b = 0 Hz ,  
NOESY: H-3b ↔ H-2a 
 
yes yes yes yes 
 
J9b,10 = 5.2 Hz,  
J9a,10 = 13.4 Hz 
 
yes yes yes yes 
 
NOESY: H-6 ↔ H-12,13  yes yes no no  
NOESY:  H-2a ↔ H-15   yes yes no no  
NOESY: H-3a ↔ H-4,  
H-3b ↔ H-14 
 
yes no no yes 
 
aConformers were found by conformational analysis in CHCl3 and further geometrically optimized based on 
Density function theory (DFT) on the B3LYP/6-31G* level in gas-phase. 
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3.4. IDENTIFICATION AND CHARACTERIZATION OF GABAA RECEPTOR 
MODULATORY DITERPENES FROM BIOTA ORIENTALIS THAT 
DECREASE LOCOMOTOR ACTIVITY IN MICE 
Zaugg J, Khom S, Eigenmann D, Baburin I, Hamburger M, Hering S.  
J Nat Prod 2011; 74, 1764-1772. 
 
 
Apart from identification of a new natural product, sandaracopimaric acid and isopimaric 
acid were identified as main positive GABAA receptor modulating constituents of B. 
orientalis twigs and leaves. The diterpenes were characterized at six different GABAA 
receptor subtypes in a functional assay using Xenopus oocytes. Sandaracopimaric acid 
was tested in the Open Field Test in mice for measuring in vivo pharmacological effects. 
 
 
 
 
 
 
Daniela Eigenmann did upscaled extraction of plant material, isolation of compounds, 
recording and interpretation of analytical data for structure elucidation (HPLC-PDA-
ESI-TOF-MS, microprobe NMR) as part of her master’s thesis under my direct 
supervision. HPLC microfractionation, Xenopus surgery, preparation of oocytes for 
electrophysiological measurements, two-microelectrode voltage clamp studies with 
sandaracopimaric acid and isopimaric acid, data analysis, writing of the manuscript, and 
preparation of figures (except for Fig. 5) were my contribution to this publication. 
      
Janine Zaugg 
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Gamma-aminobutyric acid (GABA) is the major inhibitoryneurotransmitter in the central nervous system (CNS).
GABA binding to the GABAA receptor leads to opening of the
intrinsic chloride ion channel. This causes a hyperpolarization of
the neuronal membrane and thus to an inhibition of further action
potential triggering.1,2 The quaternary structure of the GABAA
receptor is an assembly of five varying subunits. The human genome
encodes for 19 subunits, namely,R16,β13,γ13,F13,δ, ε,π, and
θ, which may combine into numerous heteropentamers.3 So far, 11
GABAA receptor subtypes with distinct pharmacological properties
are known to be expressed in human neurons.4,5 CNS-related
diseases such as insomnia, anxiety, and epilepsy are often treated
withGABAA receptormodulating drugs, such as benzodiazepines or
barbiturates, which, however, suffer from various side-effects.6
We screened a library consisting of 982 plant and fungal
extracts for GABAA receptor modulatory activity with the objec-
tive of identifying new scaffolds for the target. For this purpose, we
used an automated, functional, two-microelectrode voltage clamp
assay with Xenopus oocytes7 that transiently expressed rat GABAA
receptors of the subunit composition R1β2γ2S. An ethyl acetate
extract of Biota orientalis (L.) Endl. (Cupressaceae) leaves and
twigs showed promising activity.
B. orientalis originates from Eastern Asia,8 but nowadays is also
widely cultivated in Europe. In addition to various flavonoids,
phenylpropanoids, and some lignans, over 100 different terpenoids
have been identified from B. orientalis (a synoptical table with
secondary metabolites identified in B. orientalis is provided as
Supporting Information).828 The crude drug consisting of leaves
and twigs is known as Cebaye in China and is one of the
50 fundamental herbs of traditional Chinese medicine (TCM).
It is used to treat disorders such as diarrhea, respiratory mal-
function,2931 gout, rheumatism, leukotrichia, and alopecia.32 The
TCM drug Baiziren consists of seeds of B. orientalis and is
prescribed, among other indications, to treat anxiety.31
HPLC-based activity profiling is a miniaturized and highly
effective approach for rapid dereplication and characterization of
bioactive natural products in extracts33 and can be combinedwith
various cell-based and biochemical assays.3440 We recently
developed and validated a profiling protocol for the discovery
of newGABAA receptor ligands,
41 which was successfully applied
in the investigation of several active plant extracts.4246 Here we
report the structural elucidation of a new diterpene, sandaraco-
pimaradienolal (3), and the identification of isopimaric acid (4)
and sandaracopimaric acid (5) as GABAA receptor modulatory
constituents via HPLC-based activity profiling of the active B.
orientalis extract. The GABAA receptor subtype specificity of 4
and 5was characterized at receptors of the compositionR1β1γ2S,
Received: April 13, 2011
ABSTRACT: An ethyl acetate extract of Biota orientalis leaves potentiated
GABA-induced control current by 92.6%( 22.5%when tested at 100μg/mL
in Xenopus laevis oocytes expressing GABAA receptors (R1β2γ2S subtype) in
two-microelectrode voltage clamp measurements. HPLC-based activity
profiling was used to identify isopimaric acid (4) and sandaracopimaric acid
(5) as the compounds largely responsible for the activity. Sandaracopimar-
adienolal (3) was characterized as a new natural product. Compounds 4 and 5
were investigated for GABAA receptor subtype selectivity at the subtypes
R1β1γ2S, R1β2γ2S, R1β3γ2S, R2β2γ2S, R3β2γ2S, and R5β2γ2S. Sandaracopi-
maric acid (5) was significantly more potent than isopimaric acid (4) at the
GABAA receptor subtypes R1β1γ2S,R2β2γ2S, andR5β2γ2S (EC50 4: 289.5(
82.0, 364.8( 85.0, and 317.0( 83.7 μM vs EC50 5: 48.1( 13.4, 31.2( 4.8,
and 40.7 ( 14.7 μM). The highest efficiency was reached by 4 and 5 on
R2- and R3-containing receptor subtypes. In the open field test, ip administration of 5 induced a dose-dependent decrease of
locomotor activity in a range of 3 to 30 mg/kg body weight in mice. No significant anxiolytic-like activity was observed in doses
between 1 and 30 mg/kg body weight in mice.
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R1β2γ2S,R1β3γ2S,R2β2γ2S,R3β2γ2S, andR5β2γ2S, and themost
potent compound, sandaracopimaric acid (5), was examined in a
mouse model by means of the open field test.
’RESULTS AND DISCUSSION
Extracts were screened by means of an automated, fast
perfusion system used for two-microelectrode voltage clamp
measurements in Xenopus oocytes that expressed functional
GABAA receptors with the subunit compositionR1β2γ2S.
7When
tested at 100 μg/mL, an ethyl acetate extract of B. orientalis leaves
and twigs enhanced the GABA-induced chloride ion current
(IGABA) by 92.6% ( 22.5%. To localize the activity within the
extract, we performed an HPLC-based activity profiling after a
validated protocol.41 The relevant time window of the chroma-
togram (210 nm) from a semipreparative HPLC separation
(10 mg of extract, 28 microfractions of 90 s each) is shown in
Figure 1A. GABAA receptor modulatory activity was concen-
trated in fractions 15 to 18 (Figure 1A, dark gray bar). Fraction 18
induced the strongest potentiation of IGABA (414.5% ( 95.3%),
and fractions 15, 16, and 17 enhanced GABA-induced chloride
currents by 67.6% ( 21.0%, 131.5% ( 47.3%, and 39.2% (
25.8%, respectively (Figure 1B). The active region of the
chromatogram was rather complex, and the time-based fractio-
nation did not provide the necessary resolution to track the active
peaks. This was achieved by a peak-based fractionation. Peak-based
fractions au are shown in Figure 1A by a light gray bar, and the
corresponding activity profile is given in Figure 1C.The high activity
of time-based fraction 18 could thus be assigned to peak o
(potentiation of IGABA by956.9%( 0.0%). Fraction 16was resolved
into peaks e, f, and g. However, only e showed an appreciable
potentiation of IGABA (146.45% ( 33.3%). Fraction 15 corre-
sponded to part of peak e, to d, and to part of c. Moderate
activity was found in c and d (potentiation of IGABA by 100.0%
( 3.0% and 76.1%( 8.9%, respectively). Although time-based
fractions 14 and 19 did not show any activity, the corresponding
peak-based microfractions were collected and tested. Moderate
activity was found in peak-based fraction t (enhancement of
IGABA by 76.6% ( 18.8%).
For structure elucidation and for further pharmacological
testing, compounds corresponding to the active peaks were
purified at preparative scale. Liquidliquid extraction of the
EtOAc extract, separation on a silica gel MPLC column, and
semipreparativeRP-HPLCafforded four pure compounds (13,6)
and an inseparable mixture of 4 and 5. Structures were estab-
lished by 1D NMR and 2D NMR experiments as pinusolide (1),
sandaracopimaradienediol (2), totarol (6), and a mixture of
isopimaric acid (4) and sandaracopimaric acid (5) in a ratio of
77:23 (1HNMR). Analytical data of 1, 2, 4, 5, and 6 are provided
as Supporting Information. Structural analysis of minor com-
pound 3 revealed a pimaradiene-type diterpene that differed
from 2 only by the oxidation state of C-18. Due to its close
relationship to 2 and the aldehyde function at C-18, compound 3
was named sandaracopimaradienolal.
Figure 1. HPLC-based activity profiling of Biota orientalis ethyl acetate
extract. Part A shows critical time window of a semipreparative HPLC
separation (10mg of extract, detection at 210 nm). Time windows of the
time-based microfractionation (90 s each) are highlighted in dark gray,
and corresponding potentiation of GABA-induced control current by
fractions 1419 is shown in B. Subsequent peak-based fractionation is
shown in light gray bars in A, and potentiation of GABA-induced control
current by peak-based microfractions au is displayed in C.
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Pure compounds and the isomer mixture were tested at
concentrations of 10 and 100 μM in the oocyte assay for a
preliminary activity profile at R1β2γ2S receptors. The isomer
mixture 4/5 potentiated IGABA by 43.9% ( 1.1% and 318.9% (
101.1% at 10 and 100 μM, respectively (n = 2). Rather
unexpectedly, none of the other compounds induced a significant
potentiation of IGABA at the tested concentrations (10 μM:
13.4% ( 2.0% (1), 13.8% ( 1.3% (2), 3.8% ( 3.8% (3),
10.6%( 4.8% (6); 100 μM:13.1%( 2.6% (1), 7.7%( 7.7%
(2), 3.0%( 3.0% (3),15.1%( 15.1% (6) (n = 2)). Therefore,
further concentrationresponse experiments were performed
only with 4 and 5, which were commercially obtained as pure
substances. Modulation of IGABA through R1β2γ2S receptors was
studied with concentrations ranging from 0.1 to 500 μM.
Maximum IGABA potentiation by 4 (425.2% ( 96.5%, n = 5)
was observed at ∼500 μM, with an EC50 of 141.6 ( 68.0 μM.
Sandaracopimaric acid (5) was more potent (EC50: 33.3 (
8.7 μM) and more efficient than 4 (max. potentiation of IGABA:
855.7% ( 114.9%, n = 4) (Figure 2; Table 1).
Next, the concentration-dependent IGABA modulation of
compounds 4 and 5 was tested on distinct GABAA receptor
subtypes (R1β1γ2S,R1β3γ2S,R2β2γ2S,R3β2γ2S, andR5β2γ2S) to
elucidate potential subunit specificity. As displayed in Figure 3
and summarized in Table 1, sandaracopimaric acid (5) showed
higher potencies (EC50) than isopimaric acid (4) on all receptor
subtypes, reflected by potency ratios [EC50(4)/EC50(5)] of 4.25
(R1β2γ2S receptors) and upward (Table 2). However, only on
receptor subtypes R1β1γ2S, R2β2γ2S, and R5β2γ2S was this
difference statistically significant. Moreover, on R1β2γ2S recep-
tors, 5 was twice as efficient in stimulating IGABA compared to 4,
as reflected by the efficiency ratio [Imax(4)/Imax(5)] (Table 2).
Overall, 5 seemed slightly more efficient, except at subtype
R1β1γ2S (differences not statistically significant). The huge
discrepancies between potency and efficiency of 4 and 5 are of
particular interest in light of the small structural differences
between these compounds. The two diterpenes differ only in
the position of a double bond (Δ7,8 in 4 vs Δ8,14 in 5).
However, neither of the compounds exerted significant parti-
cular subtype specificity, as reflected by their comparable EC50
values at the subtypes of investigation (p > 0.05) (Table 1). The
order of efficiency of isopimaric acid (4) on GABAA receptors
comprising different R-subunits was R1β2γ2S ≈ R5β2γ2S <
R2β2γ2S (p < 0.05). The apparently higher efficiency of 4 on
R3β2γ2S receptors compared to R1/R5-containing subtypes,
however, was not statistically significant. A different order of
efficiency was observed for 5withR5β2γ2S <R1β2γ2S≈R2β2γ2S
≈ R3β2γ2S (p-values see Table 1). On GABAA receptors
comprising varying β-subunits, only 5 showed a significant
difference in efficiency (R1β1γ2S < R1β2γ2S; p < 0.05)
(Table 1). When tested at the R1β2γ2S subtype, benzodiazepines
(triazolam, midazolam, and clotiazepam) were clearly more
potent than 4 and 5 (Table 1). Efficiencies, however, ranged from
253% ( 12% (triazolam) to 342 ( 64% (midazolam) potentia-
tion of IGABA
47 and are thus comparable with efficiencies of 4 and
5 (Table 1). To determine a possible dependency on the γ-
subunit, which is involved in the benzodiazepine binding site, 4
and 5 were tested on GABAA receptors comprising R1 and β2
subunits only. No significant difference in activity was found
between R1β2 and R1β2γ2S subtypes at 30 and 100 μM, which
suggested a γ-subunit-independent binding site (Figure 4). Pre-
incubation experiments revealed that neither 4 nor 5 showed
direct activation on any of the expressedGABAA receptor subtypes
(Figure 3, parts B, D, F, and H; Figure 4, parts B and D).
Therefore, isopimaric acid (4) and sandaracopimaric acid (5)
can be described as positive allosteric GABAA receptormodulators
devoid of direct agonistic activity and particular subtype specificity.
Modulation of GABAA receptors comprising R1, R2, and R3
subunits by 4 and 5 (Figure 3, Table 1) suggests sedative-like and
anxiolytic-like action in vivo (see Mohler et al. 2010 for a recent
review).48 We, therefore, studied the in vivo effects of the more
potent compound (5) in mice in the open field (OF) test. The
OF test is based on the natural behavior of rodents such as an
innate fear of open spaces and represents a standard behavior-
al paradigm for evaluation of anxiolytic-like properties of
drugs and for the measurement of locomotor activity.49 We
analyzed the explorative behavior of male c57Bl/6N mice 30
min after intraperitoneal injection of either vehicle (= control)
or 5 in the OF test. As illustrated in Figure 5A, ambulation of
control mice and mice treated with 1 mg/kg BW 5 did not
significantly differ (control: 31.8 ( 1.7 m, n = 10 vs 1 mg/kg
BW: 31.8 ( 2.3 m, n = 10; p > 0.05). Administration of 5 at a
dose of 3 mg/kg BW, however, resulted in significantly reduced
ambulation (25.1 ( 2.0 m, n = 19; p < 0.05), which reached its
Figure 2. Part A shows concentrationresponse curves of isopimaric
acid (4) and sandaracopimaric acid (5) at GABAA receptors of the
subunit composition R1β2γ2S, using a GABA EC510. Typical traces for
modulation of chloride currents through R1β2γ2S GABAA receptors
without direct activation by 4 and 5 are given in B and C, respectively.
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maximum at a dose of 30 mg/kg BW (22.3 ( 1.2 m; n = 17; p <
0.05). Control mice and mice treated with 130 mg/kg BW of 5
spent the same amount of time in the center of the OF (no
statistically significant difference observed). Hence no anxiolytic-
like effect was observed under influence of 5 (Figure 5B).
With the example of B. orientalis, HPLC-based activity profil-
ing led to the identification of two positive GABAA receptor
modulators with a diterpene scaffold that is new for the target.
In addition, a new natural product, sandaracopimaradienolal (3),
was identified. The GABAA receptor modulation observed with
the time-based fractions 1518 could be located at higher
resolution in the peak-based fractions. However, only the com-
pounds responsible for the activity of 18/owere finally identified.
Further work is required to identify the active compounds
located in peak-based microfractions ce, o, and t. A thorough
characterization of isopimaric acid (4) and sandaracopimaric acid
(5) at several GABAA receptor subtypes revealed two novel
positive GABAA receptor modulators with virtually the same
efficiencies but varying potencies at the investigated subtypes.
The two diterpenes differ only in the position of a double bond
(Δ7,8 in 4 vs Δ8,14 in 5), which seems to affect potency rather
than efficiency. Future investigation of structurally related diter-
penes could, therefore, provide deeper insights on how potency
and efficiency relate to structural features of pimarane diterpe-
noids. Interestingly, activity of 4 and 5 was independent of the
γ-subunit, which clearly indicated that both compounds interact
with a non-benzodiazepine binding site (Figure 4).
The reduced locomotor activity observed with intraperitoneal
administration of 5 may result from an enhancement of the
GABAergic system—in particular a positive allosteric modulation
of GABA-induced currents and thus an enhanced inhibitory
neurotransmission—but might be also due to interaction with
completely different molecular targets. Analysis of the EEG or
measurement of body temperature upon administration of the
compound would substantiate whether the observed decrease of
locomotor activity was due to sedation.50,51 Interestingly, the
observed effects of 5 occurred at doses comparable to those of
known GABAA receptor modulators and sedatives such as mid-
azolam or zolpidem.52,53
The absence of an anxiolytic-like effect was inconsistent with
the in vitro data (high efficiency at R2- and R3-containing
subtypes) (Figure 3, Table 1). Other behavioral paradigms for
anxiolysis might reveal whether the observed decrease in loco-
motor activity negatively interfered with an anxiolytic-like effect
in the OF. Sandaracopimaric acid (5) is a molecule with suitable
physicochemical properties for oral bioavailability (H-acceptors/
donors 2:1, MW 302, cLogP 4.16, rotatable bonds 2).54 In
addition, a relatively small polar surface area of 37.3 Å2 is
favorable for blood-brain-barrier (BBB) penetration.54,55 How-
ever, further studies on metabolism and BBB penetration of 5 are
needed. This first preliminary in vivo evaluation was performed
with intraperitoneal administration, which circumvents the liver
first-pass. Oral administration and comparison with clinically
used GABAA receptor ligands will be needed to determine the
therapeutic potential of 5.
’EXPERIMENTAL SECTION
General Experimental Procedures. NMR spectra were re-
corded at target temperature 18 C on a Bruker Avance III 500 MHz
Table 1. Potencies and Efficiencies of Compounds 4 and 5 for GABAA Receptors of Different Subtype Compositions and of
Reference Compounds (Benzodiazepines) at the R1β2γ2S Subtype
Isopimaric Acid (4)
subtype EC50 [μM] max. potentiation of IGABA (EC510) [%](Imax) Hill coeff (nH)
a nb
R1β1γ2S 289.5( 82.0 715.9( 143.3 1.6( 0.2 6
R1β2γ2S 141.6( 68.0 425.2( 96.5chc 1.6( 0.4 5
R1β3γ2S 257.0( 121.2 475.7( 150.9 1.5( 0.3 4
R2β2γ2S 364.8 ( 85.0 1031.5( 173.9chc,d 1.9( 0.3 5
R3β2γ2S 724.1( 340.7 1074.0( 370.5 1.2( 0.1 6
R5β2γ2S 317.0 ( 83.7 472.2( 93.7chd 2.0( 0.3 5
Sandaracopimaric Acid (5)
subtype EC50 [μM] max. potentiation of IGABA (EC510) [%] Hill coeff (nH)
a nb
R1β1γ2S 48.1( 13.4 501.6( 55.7che 1.8( 0.3 4
R1β2γ2S 33.3( 8.7 855.7( 114.9che,f 1.6( 0.4 4
R1β3γ2S 24.9( 6.3 519.7( 83.8 2.1( 0.5 4
R2β2γ2S 31.2( 4.8 1093.7( 60.1chg 2.1( 0.3 4
R3β2γ2S 56.6( 10.6 1101.1( 97.8chh 1.7( 0.3 5
R5β2γ2S 40.7( 14.7 512.7( 98.3chfh 1.6( 0.3 6
Benzodiazepines at R1β2γ2S (Data by Khom et al., 2006)47
compound EC50 [nM] max. potentiation of IGABA (EC510) [%]
triazolam 22( 3 253( 12
midazolam 143( 88 342( 64
clotiazepam 184( 88 260( 27
a Indicates the slope of the concentrationresponse curve at the EC50. Hill coefficients > 1 indicate positive cooperativity during ligand binding.69
bNumber of experiments. ch Each letter separately shows significantly different efficiencies (cep < 0.05, fp = 0.06, g,hp < 0.01).
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spectrometer (Bruker BioSpin, Faellanden, Switzerland) operating at
500.13 MHz for 1H and 125.77 MHz for 13C. A 1 mm TXI-microprobe
with a z-gradient was used for 1H-detected experiments; 13C NMR
spectra were recorded with a 5 mm BBO-probe head with z-gradient.
Spectra were analyzed using Bruker TopSpin 2.1 software. High-
resolution mass spectra (HPLC-PDA-ESITOFMS) in positive mode
Figure 3. Parts A and E display the R-subunit dependency of isopimaric acid (4) and sandaracopimaric acid (5), respectively, reflected by
concentrationresponse curves with GABAA receptors of subunit compositions R1β2γ2S, R2β2γ2S, R3β2γ2S, and R5β2γ2S. Parts C and G show the β-
subunit dependency of 4 and 5, respectively, reflected by concentrationresponse curves at GABAA receptors of the subunit compositions R1β1γ2S,
R1β2γ2S, and R1β3γ2S. Typical traces reflecting modulation of chloride currents without direct activation were recorded with compounds 4 and 5 at all
expressed GABAA receptor subtypes (typical currents of 4 and 5 are displayed in B andD, and F and H, respectively). All measurements were performed
with a GABA EC510.
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were obtained on a Bruker micrOTOF ESIMS system (Bruker Dal-
tonics, Bremen, Germany) connected via a T-splitter (1:10) to an
Agilent HP 1100 Series system consisting of a binary pump, autosam-
pler, column oven, and diode array detector (G1315B) (Agilent
Technologies, Waldbronn, Germany). Nitrogen was used as a nebulizing
gas at a pressure of 2.0 bar and as a drying gas at a flow rate of 9.0 L/min
(dry gas temperature 240 C). Capillary voltage was set at 4500 V;
hexapole at 230.0 Vpp. Instrument calibration was done with a reference
solution of sodium formate 0.1% in 2-propanol/water (1:1) containing
5 mM NaOH. Data acquisition and processing were performed using
Bruker HyStar 3.0 software. Semipreparative HPLC separations for
activity profiling were carried out with an Agilent HP 1100 Series system
consisting of a quaternary pump, autosampler, column oven, and diode
array detector (G1315B). HPLC fractions were evaporated with a
Genevac EZ-2 Plus vacuum centrifuge (Genevac Ltd., Ipswich, United
Kingdom). Waters SunFire C18 (3.5 μm, 3.0  150 mm) and SunFire
Prep C18 (5 μm, 10  150 mm) columns (Waters, Wexford, Ireland)
were used for HPLC-PDA-ESITOFMS and semipreparative HPLC,
respectively. Medium-pressure liquid chromatography (MPLC) was
performed with a glass column (49  460 mm) packed with silica gel
(0.0150.040 μm;Merck) on a Buchi Sepacore system consisting of two
C605 pumps, a C635 detector, a C620 control unit, and a C660 fraction
collector (Buchi Labortechnik AG, Flawil, Switzerland). Sample intro-
duction was carried out with a precolumn packed with the sample
absorbed onto silica gel. The separation was monitored with Buchi
Sepacore Control 1.0 software.
Plant Material. Cebaye (dried twigs and leaves of B. orientalis) was
purchased from a local market in Shanxi Province, China. Identity of the
sample was confirmed with the aid of the corresponding monograph of
the Chinese Pharmacopoeia IX and other literature56 at the Division of
Pharmaceutical Biology, University of Basel, where a voucher specimen
(00 305) is deposited.
Figure 4. Parts A and C display the γ-subunit dependency of isopimaric acid (4) and sandaracopimaric acid (5), respectively. The bar graphs indicate
the potentiation of GABA-induced control currents by 30 and 100 μM of compound, at GABAA receptors of the subunit compositions R1β2 and
R1β2γ2S. Traces show typical modulation of chloride currents in GABAA receptor subtypes by compounds 4 and 5 (parts B and D, respectively).
Table 2. Potency Ratio and Efficiency Ratio for Isopimaric Acid (4) and Sandaracopimaric Acid (5)
subtype R1β1γ2S R1β2γ2S R1β3γ2S R2β2γ2S R3β2γ2S R5β2γ2S
potency ratio [EC50(4)/EC50(5)] 6.02
a 4.25 10.32 11.69b 12.79 7.79a
efficiency ratio [Imax(4)/Imax(5)] 1.43 0.50
a 0.92 0.94 0.98 0.92
a Statistically significant (p < 0.05). b Statistically significant (p < 0.01).
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Extraction. The plant material was frozen with liquid nitrogen and
groundwith a ZM1 ultracentrifugal mill (Retsch). The EtOAc extract for
screening and HPLC-based activity profiling was prepared with an ASE
200 extraction system with solvent module (Dionex, Sunnyvale, CA).
Extraction pressure was 120 bar, temperature was set at 70 C, and three
extraction cycles of 5 min each were performed. For preparative
isolation, 430 g of ground plant material was macerated overnight with
1.25 L of EtOAc, followed by percolation with EtOAc (2  1 L). The
solvent was evaporated at reduced pressure to yield 22.8 g of extract. The
extracts were stored at 20 C until use.
Microfractionation for Activity Profiling. Time-based micro-
fractionation for GABAA receptor activity profiling was performed as
previously described,41 with minor modifications. Separation for both
time-based and peak-based microfractionation was carried out on a
semipreparative HPLC column with acetonitrile containing 0.1% formic
acid (solvent A) andwater containing 0.1% formic acid (solvent B) using
the following gradient: 10% A to 100% A for 30 min, hold for 10 min. In
the time-based fractionation, 28 microfractions of 90 s each were
collected from an injection of 10 mg of extract (in 500 μL of DMSO).
The flow rate was 7 mL/min. In peak-based fractionation (10 mg of
extract in 100 μL of DMSO), 21microfractions were collected. The flow
rate was 4 mL/min. All microfractions were dried, evenly distributed to
two vials, and submitted to activity testing.
Isolation. The EtOAc extract (22.8 g) was dissolved in MeOH and
extracted with n-hexane to remove essential oils. Themethanolic portion
was then redissolved in CHCl3 and extracted with H2O to remove polar
constituents. The residue (11.1 g) was coated onto silica gel (44.9 g) and
packed into a precolumn prior to elution onto the MPLC column.
Elution was done with an n-hexane (solvent A) and EtOAc (solvent B)
gradient: 0% B to 30% B in 4 h, followed by 30% A to 100% B in 4 h. The
flow rate was set at 15 mL/min. Fractions of 15 mL were collected and
were later combined to 20 fractions (120) on the basis of a TLC
analysis. Selected fractions were submitted to semipreparative gradient
HPLC with acetonitrile (solvent C) and H2O containing 0.1% formic
acid (solvent D) as eluents. The flow rate was 4 mL/min. Methanolic
stock solutions (100 mg/mL) were prepared and repeatedly injected in
portions of 30 to 100 μL. A portion (140 mg) of fraction 2 (322.4 mg)
afforded compound 6 (12.0 mg). The gradient profile was 30% C
to 100% C in 20 min. An aliquot (56 mg) of fraction 7 (265.7 mg)
gave amixture of 4 and 5 (30.5 mg). A gradient of 70%C to 100%C over
20minwas used. The same gradient was used for separation of an aliquot
(120mg) of fraction 13 (281.6 mg). Compounds 1 (24.4 mg) and 3 (2.6
mg) were obtained. Compound 2 (5.2 mg) was isolated from 80 mg of
fraction 16 (2.035 g). A gradient of 65% C to 73% C over 16 min was
used. Several attempts to separate the mixture of 4 and 5 failed.
Compounds 16 were identified by comparison of physicochemical
data (NMR, ESI-TOF-MS, and UVvis spectroscopy) with published
values.11,5766 The purity (except for the mixture of 4 and 5) was >95%
(purity check by 1H NMR).
Sandaracopimaradienolal (3): 1H NMR (CDCl3, 500.13 MHz) δ
9.38 (1H, s, H-18), 5.73 (1H, dd, J = 17.7, 10.7Hz, H-15), 5.24 (1H, br s,
H-14), 4.87 (1H, dd, J = 17.7, 2.0 Hz, H-16a), 4.85 (1H, dd, J = 10.7, 2.0
Hz, H-16b), 3.77 (1H, dd, J = 11.6, 4.5 Hz, H-3), 2.21 (1H, ddd, 14.2,
4.3, 2.3 Hz, H-7a), 2.04 (1H, ddm, J = 14.2, 12.9 Hz, H-7b), 1.80 (1H,
ddd, J = 13.7, 3.0, 3.0 Hz, H-1a), 1.74 (1H, m, H-9), 1.74 (1H, m, H-2a),
1.63 (1H, m, H-2b), 1.60 (1H, m, H-11a), 1.53 (1H, dd, J = 12.7, 1.7 Hz,
H-5), 1.52 (1H, m, H-11b), 1.47 (1H, m, H-6a), 1.45 (1H, m, H-12a),
1.36 (1H, m, H-12b), 1.22 (1H, ddd, J = 13.7, 13.7, 4.5 Hz, H-1b), 1.08
(3H, s, H-19), 1.07 (1H, m, H-6b), 1.02 (3H, s, H-17), 0.84 (3H, s,
H-20); 13C shifts (CDCl3, 125.77 MHz) δ 206.86 (CH, C-18), 148.57
(CH, C-15), 135.66 (C, C-8), 129.80 (CH, C-14), 110.41 (CH2, C-16),
72.12 (CH, C-3), 55.30 (C, C-4), 50.06 (CH, C-9), 46.87 (CH, C-5),
37.45 (C, C-13), 37.12 (C, C-10), 36.75(CH2, C-1), 35.21 (CH2, C-7),
34.25 (CH2, C-12), 26.56 (CH2, C-2), 26.02 (CH3, C-17), 24.08 (CH2,
C-6), 18.74 (CH2, C-11), 15.36 (CH3, C-20), 9.22 (CH3, C-19);
relevant NOESY correlations, H-3 T H-17, H-3 T H-5, H-5 T
H-17, H-5 T H-9, H-20 T H-19, H-20 T H-17; HR-ESIMS m/z
325.2153 [M + Na]+ (calcd for C20H30O2Na, 325.2143). NMR spectra
of 3 are available as Supporting Information.
Expression and Functional Characterization of GABAA
Receptors. The preparation of stage VVI oocytes from Xenopus
laevis, the synthesis of capped-off runoff poly(A+) cRNA transcripts
from linearized cDNA templates (pCMV vector), and cRNA injection
into oocytes were performed as previously described.47 In summary,
female X. laevis (Nasco, Fort Atkinson, WI) were anesthetized by a
15 min exposure to a 0.2% MS-222 (methanesulfonate salt of 3-amino-
benzoic acid ethyl, Sigma-Aldrich, Munich, Germany) solution before
surgically removing parts of the ovaries. Follicle membranes from
isolated oocytes were enzymatically digested with 2 mg/mL collagenase
(Type 1 A, Sigma-Aldrich). One day after enzymatic isolation, the
Figure 5. Ambulation and explorative behavior in the open field test assessed over 10 min for control and sandaracopimaric acid (5)-treated mice at the
indicated doses (doses represent mg/kg BW). Bars indicate the total distance traveled (A) and the time spent in the center (B). Bars represent mean(
SEM from g10 mice. The asterisks indicate statistically significant differences (p < 0.05).
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oocytes were injected with approximately 1050 nL of DEPC-treated
water (diethyl pyrocarbonate, Sigma-Aldrich) containing different cRNAs
at a concentration of approximately 3003000 pg/nL per subunit. The
amount of injected cRNA mixture was determined by means of a
NanoDrop ND-1000 (Kisker Biotech, Steinfurt, Germany). To ensure
expression of the γ2S subunits in R1β2γ2S, R2β2γ2S, R3β2γ2S, R5β2γ2S,
and R1β3γ2S receptors, cRNAs were mixed in a 1:1:10 ratio, except
R1β1γ2S (ratio 3:1:10). For R1β2 receptors, the cRNAs were mixed in a
1:1 ratio. Oocytes were then stored at 18 C in an aqueous solution of
90mMNaCl, 1 mMKCl, 1 mMMgCl2, 1 mMCaCl2, and 5 mMHEPES
(pH 7.4), containing 1% penicillinstreptomycin solution (Sigma-
Aldrich).67 Voltage clamp measurements were performed between days
1 and 5 after cRNA injection. Electrophysiological experiments on a two-
microelectrode voltage clamp setup were performed at a holding potential
of70 mVmaking use of a TURBO TEC 01C amplifier (npi electronic,
Tamm, Germany) and an Axon Digidata 1322A interface (Molecular
Devices, Sunnyvale, CA). Data were recorded by using pCLAMP v10.2.
Currents were low-pass-filtered at 1 kHz and sampled at 3 kHz. The bath
solution contained 90mMNaCl, 1 mMKCl, 1 mMMgCl2, 1 mMCaCl2,
and 5 mM HEPES (pH 7.4). Electrodes with resistances between 1 and
3 MΩ were used and filled with 2 M KCl.
Sample Application during Current Recordings. Of each
sample, 100μLwas applied to the oocytes at a perfusion speedof 300μL/s
by the ScreeningTool automated fast perfusion system (npi electronic).7
Before application of test solutions, concentrationresponse experiments
with GABA concentrations ranging from 0.01 μM to 1 mM were per-
formed to determine the GABA concentration eliciting 510% of the
maximal current amplitude at 1 mM (GABA EC510), which typically
ranged from3 to 10μMfor receptors comprising aγ2S subunit and 0.3 to 1
μM for R1β2 receptors. The stock solution (10 mg/mL in DMSO) of
B. orientalis extract was diluted to a concentration of 100 μg/mL with bath
solution containing GABA EC510. As previously described in a validated
protocol, time-based and peak-based microfractions collected from the
semipreparative HPLC separations were dissolved in 30 μL of DMSO
andmixed with 2.97 mL of bath solution containing GABA EC510.
41 For
concentrationresponse experiments, bath solution containing com-
pounds 4 and 5 in concentrations ranging from 0.1 to 1000 μM was
applied to the oocyte. After a preincubation period of 20 s, a second
application immediately followed containing the corresponding com-
pound solution combined with GABA EC510. Pure isopimaric acid (4)
(g98%) and GABA were purchased from Sigma-Aldrich, and sandar-
acopimaric acid (g95%) (5) was purchased from Orchid Cellmark
(Princeton, NJ).
Data Analysis. Enhancement of the GABA-induced chloride current
(IGABA) was defined as I(GABA+Comp)/IGABA  1, where I(GABA+Comp) is
the current response in the presence of a given compound, and IGABA is the
control GABA-induced chloride current. Concentrationresponse curves
were generated, and the data were fitted by nonlinear regression analysis
using ORIGIN software (OriginLab Corporation, Northampton, MA).
Data were fitted to the equation 1/[1 + (EC50/[Comp])
nH], where EC50 is
the concentration of the compound that increases the amplitude of the
GABA-evoked current by 50%, and nH is the Hill coefficient. The
maximum potentiation of IGABA by a given compound was derived from
the fit. Data are given as mean ( SE of at least 2 oocytes and g2 oocyte
batches. Statistical significance was calculated using the paired Student
t-test with confidence intervals of p < 0.05 unless otherwise stated.
In Vivo Experiments.Male mice (C57Bl/6N) were obtained from
Charles River Laboratories (Wilmington, MA). For breeding and main-
tenance mice were group housed with free access to food and water.
Temperature was fixed to 23 ( 1 C and 60% humidity with a 12 h
lightdark cycle (lights on 07001900 h). Male mice at 36 months of
age were tested in all experiments. All procedures involving animals were
approved by the Austrian Animal Experimentation Ethics Board in
compliancewith the European convention for the protection of vertebrate
animals used for experimental and other scientific purposes ETS no.: 123.
Every effort was taken to minimize the number of animals used.
Chemicals. A stock solution of sandaracopimaric acid was prepared
in 100%DMSO (50mg/mL).Working concentrations were adjusted by
dilution with 0.9% NaCl. NaOH was used to adjust the pH to 7.27.4.
For ip administration the compound was solubilized with 3% Poly-
sorbate 80 and with DMSO, whereby the final DMSO concentrations
did not exceed 10% (see Broadwell et al. 1982 for DMSO effects on the
permeability of the blood brain barrier).68 All solutions were freshly
prepared every day prior to experiments.
Open Field Test. Ambulation 30 min after ip injection of either
control (vehicle without compound) or test solution (vehicle containing
compound at the indicated doses) was tested over 10 min in 50 50 cm
Flexfield boxes equipped with infrared rearing detection. Animals
were video monitored, and their explorative behavior was analyzed using
ActiMot 2 equipment and software (TSE Systems, Bad Homburg,
Germany). Arenas were subdivided into border (up to 8 cm from wall),
center (20 20 cm, i.e. 16%of total area), and intermediate area according
to the recommendations of EMPRESS (European Mouse Phenotyping
Resource of Standardised Screens; http://empress.har.mrc.ac.uk).
For comparison of control groups and compound-treated groups the
unpaired Student’s t test was used. Comparison of more than two groups
was done by one-way ANOVA. p-values of <0.05 were accepted as
statistically significant.
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 S5. Analytical data of pinusolide (1) (CAS = 31685-80-0) 
Experimental data  
m/z (ESI-ion trap, positive mode)1 [M+H]+ 347.2; [2M+Na]+ 715.3 
m/z (ESI-TOF-MS, positive mode)1 [M+Na]+ 369.2152; [2M+Na]+ 715.4238 
Sum formula C21H30O4 
UV λmax [nm] 210 
 
 
 
 δC (CDCl3)a 2 δH (I, m, J in Hz) (CDCl3) 2 
1 39.7 1.81 (1H, m); 1.06 (1H, m) 
2 20.2 1.83 (1H, m); 1.50 (1H, m) 
3 38.6 2.16 (1H, m); 1.01 (1H, m) 
4 45.3 - 
5 56.9 1.59  (1H, dd, 12.6, 3.1) 
6 26.5 1.97 (1H, m); 1.77 (1H, m) 
7 39.1 2.40 (1H, m); 1.88 (1H, m) 
8 148.0 - 
9 56.3 1.60 (1H, br d, 10.8) 
10 40.4 - 
11 22.4 1.57 (1H, m); 1.76 (1H, m) 
12 25.1 2.45 (1H, m); 2.10 (1H, m) 
13 135.3 - 
14 144.0 7.06 (1H, dd, 1.8) 
15 70.2 4.73 (2H, dd, 4.3, 1.8) 
16 175.2 - 
17 107.3 4.87 (1H, br s); 4.56 (1H, br s) 
18 178.7 - 
19 29.1 1.16 (3H, s) 
20 13.1 0.50 (3H, s) 
21 51.4 3.58 (3H, s) 
a13C-Shifts from HSQC- and HMBC-NMR-experiments  
125
 S6. Analytical data of sandaracopimaradienediol (2) (CAS = 59219-64-6) 
Experimental data  
m/z (ESI-ion trap, positive mode) [2M+H] + 609.3
m/z (ESI-TOF-MS, positive mode)3 [M+Na]+ 327.2313
Sum formula C20H32O2
UV λmax [nm] 210
 
3
10
1
6
7
9
14
13
11
20
H
18
19
H
17
15
16
HO
HO
 
 
 δC (CDCl3)a3 δH (I, m, J in Hz) (CDCl3)3 
1 37.31 1.74 (1H, m); 1.15 (1H, m) 
2 27.57 1.57 – 1.65 (2H, m) 
3 77.03 3.66 (1H, m) 
4 42.62 - 
5 48.88 1.16 (1H, m) 
6 22.75 1.38 – 1.45 (2H, m) 
7 35.87 2.24 (1H, m); 2.02 (1H, m) 
8 136.56 - 
9 50.71 1.66 (1H, m) 
10 38.34 - 
11 19.12 1.58 (1H, m); 1.49 (1H, m) 
12 34.93 1.45 (1H, m); 1.34 (1H, m) 
13 37.68 - 
14 129.45 5.21 (1H, s) 
15 149.17 5.74 (1H, dd, 17.6, 10.6) 
16 110.38 4.88 (1H, dd, 17.6, 1.22); 4.85 (1H, dd, 10.6, 1.22) 
17 26.34 1.02 (3H, s) 
18 71.88 3.66 (1H, d, 10.5); 3.40 (1H, d, 10.5) 
19 11.74 0.90 (3H, s) 
20 15.74 0.84 (3H, s) 
a13C-shifts measured at 125.77 MHz. 
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 S7. Analytical data of isopimaric acid (4) (CAS = 5835-26-7) 
Experimental data  
m/z (ESI-ion trap, negative mode)4 [M-H]- 301.2 ; [2M-H]- 603.1  
m/z (ESI-TOF-MS, negative mode) [M-H]- 301.2174 
Sum formula C20H30O2 
UV λmax [nm] 210 
 
3 5
10
1
6
7
8
9
11
20
H19 18
H
OHO
16
17
 
 
 δC (CDCl3)a 5, 6 δH (I, m, J in Hz) (CDCl3)7 
1 38.9 1.87 (1H, m); 1.14 (1H, m) 
2 18.0 1.58 (2H, m) 
3 37.0 1.81 (1H, m); 1.69 (1H, m) 
4 46.2 - 
5 45.3 1.98  (1H, m) 
6 25.1 2.03 (1H, m); 1.73 (1H, m) 
7 120.7 5.34 (1H, dd, 5.53, 1.30) 
8 n.d. - 
9 52.0 1.78 
10 35.1 - 
11 20.0 1.59 (1H, m); 1.40 (1H, m) 
12 36.0 1.51 (1H, m); 1.39 (1H, m) 
13 n.d. - 
14 46.3 1.99 (1H, m); 1.94 (1H, m) 
15 150.7 5.82 (1H, dd, 17.4, 10.8) 
16 109.9 4.94 (1H, dd, 17.4, 0.8); 4.88 (1H, dd, 10.8, 0.8) 
17 21.6 0.89 (3H, s) 
18 185.9 - 
19 17.2 1.30 (3H, s) 
20 15.1 0.94 (3H, s) 
a13C-Shifts from HSQC- and HMBC-NMR-experiments  
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 S8. Analytical data of sandaracopimaric acid (5) (CAS = 471-74-9) 
Experimental data  
m/z (ESI-ion trap, negative mode) [M-H]- 301.2 ; [2M-H]- 603.1 4 
m/z (ESI-TOF-MS, negative mode) [M-H]- 301.2174 
Sum formula C20H30O2 
UV λmax [nm] 210 
 
3 5
10
1
6
7
8
9
11
20
H19 18
H
OHO
16
17
 
 
 δC (CDCl3)a 5, 6 δH (I, m, J in Hz) (CDCl3)7, 8 
1 38.3 1.78 (1H, m); 1.15 (1H, m) 
2 18.0 1.58 (2H, m) 
3 37.0 1.81 (1H, m); 1.69 (1H, m) 
4 47.9 - 
5 48.8 1.94  (1H, m) 
6 24.9 1.48 (1H, m); 1.31 (1H, m) 
7 35.4 2.25 (1H, m); 2.15 (1H, m) 
8 n.d. - 
9 50.7 1.83 (1H, m) 
10 38.4 - 
11 18.4 1.63 (1H, m); 1.49 (1H, m) 
12 34.5 1.49 (1H, m); 1.40 (1H, m) 
13 37.5 - 
14 129.5 5.25 (1H, br s) 
15 148.7 5.79 (1H, dd, 17.2, 10.7) 
16 110.0 4.92 (1H, dd, 17.2, 1.2); 4.89 (1H, dd, 10.7, 1.2) 
17 26.1 1.06 (3H, s) 
18 185.9 - 
19 16.7 1.23 (3H, s) 
20 15.1 0.86 (3H, s) 
a13C-Shifts from HSQC- and HMBC-NMR-experiments  
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 S9. Analytical data of totarol (6) (CAS = 511-15-9) 
Experimental data  
m/z (ESI-ion trap, negative mode) [M-H]- 285.3 
m/z (ESI-TOF-MS, negative mode)9 [M-H]- 285.2248  
Sum formula C20H30O 
UV λmax [nm] 10 210; 280  
 
11
8
14
10
5
6
7
1
3
OH
15
17
16
20
H
1819  
 
 δC (CDCl3)a 9, 11 δH (I, m, J in Hz) (CDCl3)11 
1 39.6 2.25 (1H, br d, 12.7); 1.37 (1H, m) 
2 19.5 1.75 (1H, m); 1.61 (1H, m) 
3 41.7 1.49 (1H, br d, 13.3); 1.23 (1H, ddd, 13.3, 13.3, 3.1) 
4 33.2 - 
5 49.7 1.29 (1H, dd, 12.6, 2.0) 
6 19.3 1.94 (1H, br dd, 12.6, 7.7); 1.69 (1H, m) 
7 28.6 2.96 (1H, dd, 17.2, 6.7); 2.78 (1H, ddd, 17.2, 10.1, 7.7) 
8 133.7 - 
9 143.2 - 
10 37.6 - 
11 122.9 7.00 (1H, d, 8.5) 
12 114.3 6.51 (1H, d, 8.4) 
13 151.8 - 
14 131.1 - 
15 27.1 3.32 (1H, sept, 7.2) 
16/17 20.5 1.38 (3H, d, 7.2) and 1.36 (3H, d, 7.2) 
18 33.2 0.98 (3H, s) 
19 21.6 0.95 (3H, s) 
20 25.1 1.20 (3H, s) 
a13C-Shifts from HSQC- and HMBC-NMR-experiments  
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 S10. Monoterpenes isolated from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
Borneol 507-70-0 C10H18O 154.25 
HO
 
12 
Bornyl acetate 76-49-3 C12H20O2 196.29 
O
O  
13 
Camphene hydrate 465-31-6 C10H18O 154.25 OH
 
12 
Camphor 76-22-2 C10H16O 152.23 O
 
12 
Δ3-Carene 13466-78-9 C10H16 136.23 
 
12 
cis-Carveol 1197-06-4 C10H16O 152.23 
 
12 
Carvone 99-49-0 C10H14O 150.22 
O  
12 
cis-Carvyl acetate 1205-42-1 C12H18O2 194.27 
 
12 
α-Fenchene 471-84-1 C10H16 136.23 
 
14 
Geraniol 106-24-1 C10H18O 154.25 
 
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
Isoborneol 124-76-5 C10H18O 154.25 
HO
 
12 
Isobornyl acetate 125-12-2 
C12H20O2 
 
196.29 
 
12 
α-Limonene 138-86-3 C10H16 136.23 
 
12 
Linalool oxide 5989-33-3 C10H18O2 170.25 
 
12 
Linalyl propionate 144-39-8 C13H22O2 210.31 12 
trans-p-Menth-2-en-1-
ol 29803-82-5 C10H18O 154.25 
 
12 
p-Methyl-cumene 
(p-Cymene) 
99-87-6 C10H14O 134.22 
 
12 
Methyleugenol 93-15-2 C11H14O2 178.23 
 
12 
Myrtenol 515-00-4 C10H16O 152.23 
 
12 
β-Nerol 
(cis-Geraniol) 
106-25-2 C10H18O 154.25 
 
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
cis-β-Ocimene 3338-55-4 C10H16 136.23 
 
12 
trans-β-Ocimene 3779-61-1 C10H16 136.23 
 
12 
Perilla ketone 553-84-4 C10H14O2 166.22 
 
12 
α-Phellandrene 99-83-2 C10H16 136.23 
 
12 
β-Phellandrene 555-10-2 C10H16 136.23 
 
13 
α-Pinene 80-56-8 C10H16 136.23 
 
12 
Platydiol 70630-07-8 C10H18O2 170.25 
 
4 
cis-Sabinene hydrate 
(cis-4-Thujanol) 15537-55-0 C10H18O 154.25 
 
12 
trans-Sabinene hydrate 
(trans-4-Thujanol) 17699-16-0 C10H18O 154.25 
 
12 
Sabinyl acetate 53833-85-5 C12H18O2 194.27 O
O
 
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
γ-Terpinene 99-85-4 C10H16 136.23 
 
12 
4-Terpineol 562-74-3 C10H18O 154.25 OH
 
12 
α-Terpineol 98-55-5 C10H18O 154.25 
 
12 
α-Terpinyl acetate 80-26-2 C12H20O2 196.29 O
O
 
12 
α-Thujene 2867-05-2 C10H16 136.23 
 
13 
α-Thujone 546-80-5 C10H16O 152.23 
 
14 
β-Thujone 471-15-8 C10H16O 152.23 
 
14 
Thymol acetate 528-79-0 C12H16O2 192.25 
 
12 
Verbenone 80-57-9 C10H14O 150.22 
O
 
12 
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 S11. Sesquiterpenes isolated from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
Acetylcedrene 32388-55-9 C17H26O 246.39 
 
12 
trans-α-Atlantone 32207-08-2 C15H22O 218.33 
 
12 
α-Biotol 19902-30-8 C15H24O 220.35 
OH
 
15 
β-Biotol 19902-26-2 C15H24O 220.35 
 
15 
α-Bisabolol 515-69-5 C15H26O 222.37 
 
12 
epi-α-Bisabolol 78148-59-1 C15H26O 222.37 
 
12 
β-Bisabolol 15352-77-9 C15H26O 222.37 
 
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
β-Cadinene 523-47-7 C15H24 204.35 
 
12 
γ-Cadinene 39029-41-9 C15H24 204.35 
 
12 
α-Cadinol 481-34-5 C15H26O 222.37 
H
H OH  
12 
β-Cadinol 481-33-4 C15H26O 222.37 
HO  
12 
τ-Cadinol 5937-11-1 C15H26O 222.37 
OH
H
H  
12 
β-Caryophyllene 87-44-5 C15H24 204.35 
 
12 
β-Caryophyllene oxide 
(Caryophyllene oxide) 
1139-30-6 C15H24O 220.35 H
H
O  
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
α -Cedrene 469-61-4 C15H24 204.35 
 
12 
β-Cedrene 546-28-1 C15H24 204.35 
 
12 
α-Cedrol 77-53-2 C15H26O 222.37 
 
4, 12 
Cedryl acetate 77-54-3 C17H28O2 264.40 
HH
O
O  
12 
α-Cubebene 17699-14-8 C15H24 204.35 
HH
 
12 
β -Cubebene 13744-15-5 C15H24 204.35 
HH
 
12 
(-)-Cuparene 56324-31-3 C15H22 202.34 
 
12 
(+)-Cuparene 16982-00-6 C15H22 202.34 
 
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
α-Cuparenol 21730-88-1 C15H22O 218.33 
OH
 
15 
β-Cuparenol 24887-33-0 C15H22O 218.33 
 
15 
γ-Cuparenol 4584-25-2 C15H22O 218.33 
 
15 
Curcumene 644-30-4 C15H22 202.34 
 
12 
Curcumene ether 24048-43-9 C15H22O 218.33 
 
16 
Dehydro-α-curcumene 4999-58-0 C15H20 200.32 
 
17 
δ-Elemene 20307-84-0 C15H24 204.35 
 
12 
α-Elemol 639-99-6 C15H26O 222.37 
 
12 
α-Eudesmol 473-16-5 C15H26O 222.37 
 
12 
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 Trivial name CAS number Sum formula MW Structure Ref. 
β -Eudesmol 473-15-4 C15H26O 222.37 
 
12 
γ-Eudesmol 1209-71-8 C15H26O 222.37 
 
12 
Farnesene 502-61-4 C15H24 204.35 18 
cis,trans-Farnesol 3790-71-4 C15H26O 222.37 12 
trans-Farnesol/ E,E-
Farnesol 106-28-5 C15H26O 222.37 
12 
Furanodienone 24268-41-5 C15H18O2 230.30 
O
O
 
12 
Germacrene D 23986-74-5 C15H24 204.35 
 
12 
Globulol 489-41-8 C15H26O 222.37 
H
HOH  
12 
β-Isobiotol 24048-41-7 C15H24O 220.35 
 
16 
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 Trivial name CAS number Sum formula MW Structure Ref. 
α -Isocuparenol 21730-87-0 C15H22O 218.33 OH
 
15 
α-Muurolene 10208-80-7 C15H24 204.35 
 
12 
Nerolidol 7212-44-4 C15H26O 222.37  
12 
α-Selinene 473-13-2 C15H24 204.35 
 
12 
Spathulenol 6750-60-3 C15H24O 220.35 
H
HHO
 
12 
Thujopsene 470-40-6 C15H24 204.35 
 
12 
Zingiberene 495-60-3 C15H24 204.35 
 
12 
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 S12. Diterpenes isolated from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
14,15-bisnor-13-oxo-
8(17),11(E)-
labdadiene-19-oic acid 
98531-41-0 C18H26O3 290.40 
 
4 
cis-Communic acid 1231-35-2 C20H30O2 302.45 
CO2H
H
 
4 
trans-Communic acid 10178-32-2 C20H30O2 302.45 
CO2H
H
 
4 
15-Hydroxy-
pinusolidic acid 131737-65-0 C20H28O5 348.43 
CO2H
H
O
HO
O
 
4 
3-Hydroxy-sandaraco-
pimaric acid methyl 
ester 
151384-98-4 C21H32O3 332.48 
 
19 
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 Trivial name CAS number Sum formula MW Structure Ref. 
Isocupressic acid 1909-91-7 C20H32O3 320.47 
HO
CO2H
H
 
19 
Ent-isopimara-15-en-
3α,8α-diol 462122-56-1 C20H34O2 306.48 
 
20 
Isopimaric acid 5835-26-7 C20H30O2 302.45 
 
4 
Lambertianic acid 
(Daniellic acid) 4966-13-6 C20H28O3 316.43 
CO2H
H
O
 
20 
16-Methoxy labda-
8(17),13-dien-15,19-
dioic acid butenolide 
303176-48-9 C21H30O5 362.46 
CO2H
H
O
O
O
 
19 
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 Trivial name CAS number Sum formula MW Structure Ref. 
15-Methoxypinu-
solidic acid 769928-72-5 C21H30O5 362.46 
CO2H
H
O
O
O
 
20 
Methyl 8(17),13(16)-
labdadiene-16,15-olide-
18-oate 
443965-67-1 C21H30O4 346.46 
H
O
O
O O
 
21 
Methyl 8(17),13-
labdadiene-16,15-olide-
18-oate 
130464-01-6 C21H30O4 346.46 
H
O
O O
O
 
21 
15-norlabda-
8(17),12(E)-diene-14-
carboxyaldehyde-19-
oic-acid 
144125-18-8 C19H28O3 304.42 
O
H
H CO2H  
4 
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 Trivial name CAS number Sum formula MW Structure Ref. 
8,15-Pimaradien-18-oic 
acid 7715-76-6 C20H30O2 302.45 
 
4 
Pinusolide 31685-80-0 C21H30O4 346.46 
H
O
O O
O
 
4 
Pinusolidic acid 40433-82-7 C20H28O4 332.43 
H
O
O
CO2H  
4 
Sandaraco-
pimaradienediol 59219-64-6 C20H32O2 304.47 
H
H
HO
HO
 
22 
Sandaracopimaric acid 471-74-9 C20H30O2 302.45 
 
4 
Totarol 511-15-9 C20H30O 286.45 
OH
H  
23 
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 S13. Steroles isolated from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
β-Sitosterol 83-46-5 C29H50O 414.71 
 
4 
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 S14. Flavonoids isolated from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
Acacetin 480-44-4 C16H12O5 284.26
O
O
HO
OH
O
 
19 
Amentoflavone 1617-53-4 C30H18O10 538.46
 
24 
Apigenin 520-36-5 C15H10O5 270.24
 
19, 25 
Chamecyparin 20931-35-5 C32H22O10 566.51
 
19 
(+)-Catechin 154-23-4 C15H14O6 290.27
 
26 
Cupressuflavone 3952-18-9 C30H18O10 538.46 O
OH
HO
O
OH
O
HO
O OH
OH
 
27, 28 
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 Trivial name CAS number Sum formula MW Structure Ref. 
5,4'-dimethyl 3'-acetyl 
eriodicytol 70.β   
rutinoside 
752259-33-9 C31H38O16 666.62
O
O
O
O
O
O
O
O
OH
HO
HO
O
O
HO
HO
OH  
29 
4',7-Dimethyl-
apigenin 5128-44-9 C17H14O5 298.29
 
4 
(-)-Epicatechin 490-46-0 C15H14O6 290.27 O
OH
OH
HO
OH
OH
 
26 
Heveaflavone 23132-13-0 C33H24O10 580.54 19 
Hinokiflavone 19202-36-9 C30H18O10 538.46 28 
Isocryptomerin 20931-58-2 C31H20O10 552.48 19 
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 Trivial name CAS number Sum formula MW Structure Ref. 
Isorhamnetin 480-19-3 C16H12O7 316.26 25 
Kaempferol 7-O-
glucoside 16290-07-6 C21H20O11 448.38
27 
Myricetin 529-44-2 C15H10O8 318.24 25 
Myricitrine 17912-87-7 C21H20O12 464.38
 
27 
Podocarpusflavone 22136-74-9 C31H20O10 552.48
 
28 
Procyanidin B1 20315-25-7 C30H26O12 578.52
 
26 
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 Trivial name CAS number Sum formula MW Structure Ref. 
Procyanidin B3 23567-23-9 C30H26O12 578.52
O
OH
OH
HO
OH
OH
O
OH
OH
OH
OH
HO
 
26 
Putraflavone 23624-21-7 C32H22O10 566.51
 
19 
Quercetin 117-39-5 C15H10O7 302.24
24, 25, 27, 
30 
Quercetin 7-O-
rhamnoside 22007-72-3 C21H20O11 448.38
27 
Quercitrin 522-12-3 C21H20O11 448.38 24 
Rutin 153-18-4 C27H30O16 610.52
O
OH O
OH
O
OH
HO
O
OH
OH
OH
OO
OH
OH
HO
 
24, 30 
 
148
 S15. Fatty acids isolated from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
Decyl 11-
hydroxytritriacontan-
oate 
444311-96-0 C43H86O3 651.14  
21 
Dodecane 112-40-3 C12H26 170.33  
12 
5,11,14,17-
Eicosatetraenoic acid, 
(5Z,11Z,14Z,17Z)- 
18016-45-0 C20H32O2 304.47 31 
11,14,17-Eicosatrienoic 
acid, (11Z,14Z,17Z)- 17046-59-2 C20H34O2 306.48
31 
Ethyl tetradecanoate 124-06-1 C16H32O2 256.42
 
12 
Ginnol 2606-50-0 C29H60O 424.79
(CH2)18 (CH2)8
OH  
4 
Heptadecane 629-78-7 C17H36 240.47  
12 
1-Hexacosanol 506-52-5 C26H54O 382.71  
4 
Hexadecanal 629-80-1 C16H32O 240.42
 
12 
Hexadecane 544-76-3 C16H34 226.44  
12 
8-Hexyltricosane 137280-60-5 C29H60O2 408.79
 
21 
Linoleic acid 60-33-3 C18H32O2 280.45 31 
Linolenic acid 463-40-1 C18H30O2 278.43 31 
Nonacosane 630-03-5 C29H60 408.79  
30 
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 Trivial name CAS number Sum formula MW Structure Ref. 
Octacosane-10-ol-21-
ene 444311-95-9 C28H56O 408.74  
21 
Octadecane 593-45-3 C18H38 254.49  
12 
Oleic acid 112-80-1 C18H34O2 282.46
 
31 
Palmitic acid 57-10-3 C16H32O2 256.42
(CH2)14
O
HO
 
4, 31 
Stearic acid 57-11-4 C18H36O2 284.48
 
31 
Tetradecane 629-59-4 C14H30 198.39  
12 
Triacontanoic acid 116044-06-5 C35H70O2 522.93
 
21 
Tridecane 629-50-5 C13H28 184.36  
12 
Tridecanoic acid 638-53-9 C13H26O2 214.34
 
12 
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 S16. Miscellaneous compounds from Biota orientalis 
Trivial name CAS number Sum formula MW Structure Ref. 
Coumarins      
Coumarin 
(Umbelliferon) 93-35-6 C9H6O3 162.14  
19 
Phenylpropanoids      
Cinnamyl valerate 10482-65-2 C14H18O2 218.29
 
12 
Docosyl cis-ferulate 133882-81-2 C32H54O4 502.77
 
4 
Docosyl trans-ferulate 101927-24-6 C32H56O4 502.77
 
4 
Docosyl trans-3-
hydroxy-ferulate 252366-72-6 C32H54O5 518.77
4 
Elemicin 487-11-6 C12H16O3 208.25
 
12 
8-Hydroxy-labda-
13(16),14-dien-19-yl-
E-coumarate 
117254-98-5 C29H40O4 452.63 19 
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 Trivial name CAS number Sum formula MW Structure Ref. 
Lignans      
Dehydrohelio-
buphthalmin 66547-92-0 C22H20O8 412.39
 
32 
Hinokinin 26543-89-5 C20H18O6 354.35
 
32 
Savinin 493-95-8 C20H16O6 352.34
O
O
O
O
O
O
 
32 
Phenolic compounds      
Methyleugenol 93-15-2 C11H14O2 178.23
 
12 
Benzylbenzoate 120-51-4 C14H12O2 212.24
 
12 
Heptylsalicylate 6259-77-4 C14H20O3 236.31
 
12 
Miscellaneous      
Bornesitol 484-71-9 C7H14O6 194.18
 
4 
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3.5. IDENTIFICATION OF GABAA RECEPTOR MODULATORS IN 
KADSURA LONGIPEDUNCULATA AND ASSIGNMENT OF ABSOLUTE 
CONFIGURATIONS BY QUANTUM-CHEMICAL ECD CALCULATIONS  
Zaugg J, Ebrahimi SN, Smiesko M, Baburin I, Hering S, Hamburger M.  
Phytochemistry 2011, in press (doi: 10.1016/j.phytochem.2011.08.014) 
 
 
HPLC-based activity profiling enabled the identification of 10 lignans and 3 terpenoids 
(two of them were new natural products) of K. longipedunculata fruits to be tested in the 
functional Xenopus oocyte assay for positive α1β2γ2S GABAA receptor modulating 
activity. Concentration-response experiments on 12 compounds revealed interesting new 
scaffolds at the target. Structures were elucidated by mass spectrometry and microprobe 
NMR. The absolute configuration of the terpenoids was determined by ECD supported by 
in silico simulation of ECD spectra. 
 
 
 
Extraction of plant material for isolation, isolation of compounds, recording and 
interpretation of analytical data for structure elucidation (mass spectrometry, microprobe 
NMR, optical rotation, ECD), few quantum-chemical calculations (major contribution by 
Samad N. Ebrahimi and Martin Smiesko), HPLC microfractionation, Xenopus surgery, 
preparation of oocytes for electrophysiological measurements, two-microelectrode 
voltage clamp studies (except for crude extracts), data analysis, writing of the manuscript, 
and preparation of figures were my contribution to this publication. 
Janine Zaugg 
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a b s t r a c t
A petroleum ether extract of Kadsura longipedunculata enhanced the GABA-induced chloride current
(IGABA) by 122.5 ± 0.3% (n = 2) when tested at 100 lg/ml in Xenopus laevis oocytes expressing GABA A
receptors (a1b2c2S subtype) in two-microelectrode voltage clamp measurements. Thirteen compounds
were subsequently identified by HPLC-based activity profiling as responsible for GABA A receptor activity
and purified in preparative scale. 6-Cinnamoyl-6,7-dihydro-7-myrceneol and 5,6-dihydrocuparenic acid
were thereby isolated for the first time. The determination of the absolute stereochemistry of these com-
pounds was achieved by comparison of experimental and calculated ECD spectra. All but one of the 13
isolated compounds from K. longipedunculata potentiated IGABA through GABA A receptors composed of
a1b2c2S subunits in a concentration-dependent manner. Potencies ranged from 12.8 ± 3.1 to 135.6 ±
85.7 lM, and efficiencies ranged from 129.7 ± 36.8% to 885.8 ± 291.2%. The phytochemical profiles of
petroleum ether extracts of Kadsura japonica fruits (114.1 ± 2.6% potentiation of IGABA at 100 lg/ml,
n = 2), and Schisandra chinensis fruits (inactive at 100 lg/ml) were compared by HPLC-PDA-ESIMS with
that of K. longipedunculata.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Gamma-aminobutyric acid typeA (GABAA) receptors arehetero-
pentameric chloride ion channels and are targets for the major
inhibitory neurotransmitter of the central nervous system, gam-
ma-aminobutyric acid (GABA). Chloride channel opening of the
GABA A receptor leads to a hyperpolarization of the neuronal mem-
brane and inhibition of further action potentials. To date, 11 GABA A
receptor subtypes known to exist in the human brain differ in func-
tion and tissue localization, the most prominent being the a1b2c2S
subtype (Olsen and Sieghart, 2008). Numerous sedative-anxiolytics
and sedative-hypnotics, such as benzodiazepines and z-compounds
(zolpidem, zaleplon etc.), and some general anesthetics and antiepi-
leptics, bind to GABA A receptors. However, side-effects of these
drugs due to lack of GABA A receptor subtype selectivity limit their
clinical use. Thus, there is a continued medical need for GABA A
receptor modulators with new structural scaffolds and potential
subtype selectivity (Mohler, 2011).
We recently screened a library of fungal and plant extracts in an
automated functional two-microelectrode voltage clamp assay on
Xenopus oocytes (Baburin et al., 2006) which transiently expressed
GABA A receptors of the a1b2c2S subtype. Among the 982 extracts
of the library were nine extracts originating from three different
species of the Schisandraceae family (Kadsura longipedunculata,
Kadsura japonica and Schisandra chinensis). Among these, petro-
leum ether extracts of K. longipedunculata and K. japonica showed
promising activity.
Kadsura and Schisandra species are scandent, woody vines
growing throughout Eastern and Southeastern Asia, with the high-
est diversity lying in Southern China (Saunders, 1998, 2000). Both
genera share highly similar morphologic and anatomic characteris-
tics (Saunders, 1998). In Russia, S. chinensis fruits have been used as
an adaptogen and stimulant (limonnika kitajskogo nastojka) (Pan-
ossian and Wikman, 2008), whereas in traditional Chinese medi-
cine dried fruits of S. chinensis (Bei-Wuweizi) and S. sphenanthera
(Nan-Wuweizi) are officinal drugs to treat respiratory malfunction,
spermatorrhoea, enuresis, diarrhea, night sweating, insomnia and
hepatitis (Haensel et al., 1993; Hou and Youyu, 2005; Lu and Chen,
2009; Stoeger, 2009). K. japonica fruits have more or less the same
indications as Schisandra fruits and are used as an unofficial com-
mercial grade of these (Haensel et al., 1993). K. longipedunculata is
0031-9422/$ - see front matter  2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.phytochem.2011.08.014
⇑ Corresponding author. Tel.: +41 612671425; fax: +41 612671474.
E-mail addresses: martin.smiesko@unibas.ch (M. Smiesko), steffen.hering@
univie.ac.at (S. Hering), matthias.hamburger@unibas.ch (M. Hamburger).
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one of the most common species of Kadsura in China. Traditionally
the stems and roots are used for medicinal purposes, while the
fruits are eaten locally or serve as a source of fragrant oils (Saun-
ders, 1998). Up to now, only roots and stems of K. longipedunculata
have been investigated phytochemically, but not the fruits. Due to
morphological similarity, Schisandra fruits may easily be confused
with the dried fruits from Kadsura species (Fujita, 1929; Haensel
et al., 1993; Xiao et al., 2010).
In this study, 13 natural products from a petroleum ether ex-
tract of K. longipedunculata fruits were identified as positive GABA
A receptor modulators with the aid of HPLC-based activity profil-
ing. This miniaturized approach enables rapid identification of bio-
active constituents in extracts (Potterat and Hamburger, 2006) and
has been successfully used in combination with various cell-based
and biochemical assays (Adams et al., 2009; Danz et al., 2001; Ditt-
mann et al., 2004; Potterat et al., 2004), including the discovery of
new GABA A receptor modulators (Kim et al., 2008; Li et al., 2010;
Pei et al., 1980; Yang et al., 2011; Zaugg et al., 2010, 2011a, 2011b,
submitted for publication).
2. Results and discussion
2.1. Isolation and structure elucidation
A preformatted library of 982 extracts was tested in an auto-
mated, fast perfusion system during two-microelectrode voltage
clamp measurements with Xenopus oocytes which transiently ex-
pressed GABA A receptors of the subunit combination a1b2c2S
(Baburin et al., 2006). At a concentration of 100 lg/ml petroleum
ether extracts of K. longipedunculata and K. japonica fruits enhanced
the GABA induced chloride current (IGABA) by 122.5 ± 0.3% (n = 2)
and 114.1 ± 2.6% (n = 2), respectively, while ethyl acetate and
MeOH extracts of both drugs were not active (data not shown).
Interestingly, the petroleum ether, ethyl acetate and MeOH ex-
tracts from the taxonomically related S. chinensis fruits showed
no activity. Next, we performed HPLC-based activity profiling with
the active extract of K. longipedunculata using a validated protocol
(Kim et al., 2008) to identify the constituents responsible for the
activity. The chromatogram (266 nm) of a semipreparative HPLC
separation (10 mg of extract) and the corresponding activity profile
of the time-based microfractionation (28 microfractions of 90 s
each) are shown in Fig. 1B and A, respectively. The highest activity
was found in fraction 12 which potentiated IGABA by 498.0 ± 150.4%
(n = 3). Fractions 4 and 13 also were active, albeit to a lesser degree
(potentiation of IGABA by 103.2 ± 8.2% (n = 2) and 160.5 ± 19.9%
(n = 3), respectively). Fractions 8 and 14 showed minor activity
(potentiation of IGABA by 80.4 ± 7.2% (n = 3) and 70.3 ± 11.1%
(n = 3), respectively). Preparative isolation of active compounds
was achieved by liquid–liquid partitioning, normal phase open col-
umn chromatography and preparative RP-HPLC. Some structurally
related but inactive compounds were also purified in view of pre-
liminary structure–activity considerations. Nine known lignans,
Fig. 1. HPLC-based activity profiling of a petroleum ether extract of K. longipedunculata fruits. The chromatogram (266 nm) of a semipreparative separation of 10 mg
extract is displayed in part (B). The numbers correspond to the isolated compounds. The 28 collected microfractions (90 s each) are indicated with dashed lines. The
corresponding GABA A receptor modulatory activity of each microfraction is shown in part (A) (in percent potentiation of the GABA-induced chloride current, error bars
correspond to S.E.).
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arisantetralones A–D (1–4), dihydroguaiaretic acid (5), mono-
methyl dihydroguaiaretic acid (8), deoxyschizandrin (9), zuihonin
A (10), anwulignan (11), and saururenin (13), and a known sesqui-
terpene, (+)-c-cuparenol (6), were identified by ESI-MS, 1D and 2D
NMR spectroscopy, optical rotation, CD, and by comparison with
published data (Cheng et al., 2009; da Silva and Lopes, 2004; Ikeya
et al., 1980, 1979; Lee, 1981; Miyazawa et al., 1997; Nakatani et al.,
1988; Sadhu et al., 2003; Schrecker, 1957; Urzua et al., 1987; Wang
et al., 2000, 2006) (Chart 1). Analytical data of the known
compounds are given as Supplementary data. In addition, a sesqui-
terpene structurally closely related to 6 [()-5,6-dihydrocuparenic
acid (12)] and a monoterpene cinnamic acid ester [(+)-6-cinnam-
oyl-6,7-dihydro-7-myrceneol (7)] (Chart 1) were identified as pre-
viously unreported natural products. Their structures, including
absolute configurations, were established with the aid of HR-ESI-
MS, 1 and 2 D NMR spectroscopic experiments, optical rotation,
and ECD. Multiplicity-edited HSQC NMR and HMBC NMR
unambiguously revealed the covalent structures of compounds 7
and 12 (Chart 1, Tables 1 and 2, for complete NMR spectral datasets
see Figures S8–S14 of the Supplementary data). In both cases,
Fig. 2. (A) Minimized conformers of R-e6 in the gas phase using DFT at the B3LYP/6-
31G⁄⁄ level. Two major core conformations occurred within a 2 kcal/mol range from
the global minimum. According to Boltzmann weights, core conformation A (8
species) accounted for 66%, and core conformation B (4 species) accounted for 34%
of the total population. (B) Experimental ECD spectrum of (+)-c-cuparenol (6) in
MeOH and calculated ECD spectra of R-e6 in gas-phase and MeOH using density
function theory at the B3LYP/6-31G⁄⁄ level.
Chart 1. Isolated compounds from K. longipedunculata fruits.
Table 1
1H NMR and 13C NMR spectroscopic data of compounds 6 and 12a.
C 6b 12 H 6b 12
C1 138.0 124.4 1 – –
C2 126.6 137.3 2 7.26 d (8.7) 7.14 d (6.1)
C3 127.4 118.7 3 7.35 d (8.7) 5.93 d (6.1)
C4 147.4 156.1 4 – –
C5 127.4 26.0 5 7.35 d (8.7) 2.27 m
C6 126.6 24.7 6 7.26 d (8.7) 2.39 m
C7 65.4 173.3 7 4.63 s –
C10 50. 7 52.5 10 – –
C20 44.5 44.1 20 – –
C30 39.9 40.5 30a 1.70 m b 1.61–1.69 m b
30b 1.57 m a 1.50–1.56 m a
C40 20.0 19.6 40 1.81 m 1.66 m
C50 37.0 36.5 50a 2.51 m a 2.20 m a
50b 1.72 m b 1.44–1.50 m b
C10–CH3 24.6 22.1 10-CH3 1.28 s 1.06 s
C20–CH3 24.5 b 25.1 b 20-CH3a 1.09 s b 1.03 s b
C20–CH3 26.6 a 26.9 a 20-CH3b 0.57 s a 0.82 s a
a Recorded in CDCl3 at 500 MHz (1H) and 125 MHz (13C), with chemical shift
(ppm) of solvent used as internal standard.
b Shift differences between 6 and 12 are due to the anisotropic effect of the
aromatic ring.
Table 2
1H NMR and 13C NMR spectroscopic data of compound 7a.
Cb H
C1 24.5 1 1.21 s
C2 71.3 2 -
C2-CH3 24.5 2-CH3 1.21 s
C3 79.6 3 4.98 dd (2.3, 10.3)
C4 27.9 4a
4b
1.98 dddd (14.4, 9.7, 6.4, 2.3)
1.81 dddd (14.4, 10.3, 9.7, 5.4)
C5 28.2 5a
5b
2.29 ddd (14.6, 5.4, 9.7)
2.21 ddd (14.6, 9.7, 6.4)
C6 146.0 6 -
C6–CH2 115.1 6-CH2 5.01 s
C7 138.9 7 6.36 dd (17.6, 12.0)
C8 112.3 8a
8b
5.22 d (17.6)
5.04 d (12.0)
C10 167.5 10 –
C20 117.7 20 6.57 d (16.0)
C30 145.0 30 7.75 d (16.0)
C40 134.4 40 –
C50 127.7 50 7.59 m
C60 128.7 60 7.39 m
C70 130.2 70 7.39 m
C80 128.7 80 7.39 m
C90 127.7 90 7.59 m
a Recorded in MeOD at 500 MHz (1H) with chemical shift (ppm) of solvent used
as internal standard.
b 13C shifts from HSQC and HMBC NMR experiment.
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NOESY NMR allowed the determination of the conformations of
the predominant conformers in DMSO. A transoid diene
conformation of the myrceneyl moiety of 7 was confirmed by cor-
relations between H-7 and C6–CH2 and between H-8a and H-5.
Furthermore, the presence of an E-cinnamoyl residue was indi-
cated by the NOESY correlation between H-20 and H-50/H-90. In
the case of 12, NMR shifts of the cyclopentane moiety closely
matched with the data of 6 (Table 1). The mutual orientation of
the cyclopentane and the cyclohexadiene units was established
by a NOESY correlation between H-50a (a-orientated) and H-3.
The absolute configurations of 6, 7 and 12 were determined and
that of 6 confirmed by comparison of their CD spectra with ECD
spectra calculated in the gas phase and in MeOH using time depen-
dent density functional theory (DFT). For this purpose, 3D struc-
tures of R-6 (e6), S-7 (e7), and R-12 (e12) were submitted to a
systematic conformational search in H2O (OPLS 2005), within an
energy window of 5 kcal/mol. A total of 275 conformational spe-
cies were found for e7, and 24 each were found for e6 and e12.
Conformers which were within an energy range of 1 kcal/mol
(e7: 20) and 2 kcal/mol (e6: 16 and e12: 7) from the global minima
were subject to geometrical optimization (DFT/B3LYP/6-31G⁄⁄) in
the gas-phase combined with calculation of vibrational modes to
confirm these minima. No imaginary frequencies were found. For
e6, e7, and e12, a total of 12, 7, and 17 species, respectively,
could be confirmed (Figs. 2A, Fig. 3A, and Fig. 4A). For these
conformations, ECD spectra were calculated (TDDFT/B3LYP/6-
31G⁄⁄) in the gas phase and in MeOH (SCRF/CPCM). Each calculated
ECD spectrum was assigned a Boltzmann weight according to the
energy of the minimized conformers at 298.15 K and overlaid prior
to comparison with the particular experimental ECD spectrum
(Figs. 2B, Figs. 3B, and Figs. 4B). The positive and negative CE of
S-e7 at around 300 nm and 250 nm, respectively, appeared in-
verted in comparison with the experimental ECD spectrum of 7.
Mirror-images of the computed ECD spectra in the gas-phase and
MeOH were in agreement with the experimental data. The mir-
ror-image of the ECD calculation in MeOH closely matched the
experimental spectrum, especially with respect to Cotton effects
(CE) at lower wavelengths. In 7, differences between calculated
and experimental spectra presumably resulted from an overesti-
mation of the UV absorbance in the calculations (Tayone et al.,
2011), or may be due to minor differences between calculated
and solution conformers (Kamel et al., 2009) of this flexible mole-
cule. The predominant conformers of e7 (7 species, 83%) had a ci-
soid enone conformation, while the remaining ones (10 species,
17%) showed a transoid enone conformation. Among these two
major conformational groups, individual conformers further varied
by bond rotations around C5-C6 and C2-C3 (Fig. 3). Boltzmann-
weighted calculated ECD spectra of each conformer in the gas
phase and in MeOH are given as Supplementary data (Fig. S3 and
S4). Thus, compound 7 was identified as R-(+)-6-cinnamoyl-6,7-
dihydro-7-myrceneol.
In a conformational search, compound e6 occurred in two major
core conformations A (66% contribution) and B (34% contribution)
differing in the orientation of the substituted cyclopentane ring.
Fig. 3. (A) Minimized conformers of S-e7 in the gas-phase using DFT at the B3LYP/6-31G⁄⁄ level. Two major core conformations occurred within a 1 kcal/mol range from the
global minimum. According to Boltzmann weights, a transoid enone core (10 species) accounted for 17%, and a cisoid enone core (7 species) accounted for 83% of the total
population. (B) Experimental ECD spectrum of (+)-6-cinnamoyl-6,7-dihydro-7-myrceneol (7) in MeOH and calculated ECD spectra of S-e7 in gas-phase and MeOH using
density function theory at the B3LYP/6-31G⁄⁄ level. Mirror images reflecting R-configuration are displayed with dashed lines.
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Further variations arose by bond rotation around C1–C7 and rota-
tion of the hydroxy group itself (Fig. 2A). The calculations of the e6-
ECD spectra closely matched the experimental spectrum of 6. The
positive CE at around 220 nm was likely due to a p? p⁄ transition
of the aromatic ring system. In agreement with the calculated ECD
spectra it indicated an R-configuration of the stereocenter at C-10
(Fig. 2B), and compound 6was thus identified as R-(+)-c-cuparenol
(Ito et al., 1965; Nayek et al., 2003). Conformational analysis and
geometrical optimization of e12 provided twomajor cores with po-
sitive helicity (P) (2 species; 42% contribution) and negative helic-
ity (M) of the cyclic diene (5 species; 58% contribution),
respectively. The latter further differed in the orientation of the
cyclopentane residue (Fig. 4A; dihedral angles of the cyclic diene
are listed in Table S2 of the Supplementary data). Inspection of
the calculated ECD spectra of each conformer revealed that the
change in helicity of the cyclic diene inverted the sign of the CE.
P-helicity and M-helicity corresponded to a negative and a positive
CE at 302 nm, respectively. Other conformational differences had
no pronounced influence on the spectra (Fig. S5). Despite the
apparent biosynthetic relation to 6, calculation of ECD with R-
e12 did not match the negative CE at 302 nm observed in the
experimental spectrum. The close match with the mirror-inverted
calculated curve pointed towards an S-configuration of 12. How-
ever, small conformational changes in e12 strongly affected the
sign of the calculated ECD spectra. Hence we feel that independent
evidence is needed to unambiguously identify the absolute config-
uration of 12.
2.2. Modulation of GABA A receptors
Modulation of GABA A receptors by compounds 1–13 (0.1-
500 lM)was assessed in an automated two-microelectrode voltage
clamp assay on Xenopus oocytes transiently expressing a1b2c2S
receptors. All compounds except the dibenzocyclooctadiene lignan
(9) enhanced IGABA at a GABA EC5-10 in a concentration-dependent
manner (see Fig. 5 and Table 3 for details). The potencies (EC50 val-
ues) of the four arisantetralone lignans (1–4) did not significantly
differ from each other (p > 0.05). In contrast, the structural differ-
ences between 2, and 3 and 4 significantly affected efficiencies in
stimulation of IGABA at a GABA EC5-10 (p < 0.05). Compound 2 had
the highest efficiency of IGABA modulation (885.8 ± 291.2%, n = 4,
Table 3). Interchange of substituents at C-7 and C-6, as in 1, did
not significantly alter the efficiencies of IGABA modulation (2  1,
p > 0.05). Replacing the hydroxy group at C-40 of the benzylic
moiety by a methoxy group, as in 3, significantly lowered the activ-
ity (p < 0.05). Stereochemistry at C-2 had no influence on the effi-
ciencies (2 > 3  4, p < 0.05). However, the inversion of absolute
configuration at C-2 apparently affected agonistic and antagonistic
potential at a1b2c2S GABA A receptors: similar to 5,7,8, and 12, com-
pounds 1–3 produced small chloride currents in the absence of
GABA, as observed in preincubation experiments (Fig. 5 D–F). This
partial agonistic activity did not exceed 10% of the maximal current
induced by a saturating GABA concentration (1 mM).
The conformationally more flexible acyclic lignans 5, 8, 11, and
13 showed equal to slightly higher potencies than the arisantetral-
ones 1–4 at GABA A receptors of a1b2c2S subunit composition.
Whereas the EC50 values of the investigated lignans were not much
affected by replacement of the free hydroxy moiety by a methoxy
group at C-4’ (EC50: 1  3; 5  8; 11  13, p > 0.05), this structural
change decreased efficiency of acyclic lignans (8 < 5; 13 < 11,
p < 0.05; 3  1, p > 0.05, see Table 3). A dioxomethylene moiety
at C–3 and C-4 significantly decreased potency and efficiency in
the cases of 5 and 11, but not of 8 and 13 (EC50: 5 > 11, p = 0.06;
efficiency 5 > 11, p < 0.05; EC50, efficiency: 8  13) (Table 3).
Fig. 4. (A) Minimized conformers of R-e12 in the gas-phase using DFT at the B3LYP/6-31G⁄⁄ level. Two major core conformations occurred within a 2 kcal/mol range from the
global minimum. According to Boltzmann weights, two species accounting for nearly half of the total population (42%) showed P-helicity of the cyclic diene. They only
differed in the orientation of the carboxylic group. Conformers with an M-helicity (58% in total) showed further conformational variations in the orientation of the
cyclopentane residue. (B) Experimental ECD spectrum of ()-5,6-dihydrocuparenic acid (12) in MeOH and calculated ECD spectra of R-e12 in gas-phase and MeOH using
density function theory at the B3LYP/6-31G⁄⁄ level. Mirror images reflecting S-configuration are displayed with dashed lines.
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However, it visibly influenced the mode of action at the GABA A
receptor. Interestingly, compounds 5 and 8 exerted partial agonis-
tic activity, but not the dioxomethylene derivatives 11 and 13 (evi-
dent from the absence of chloride currents during the
preincubation period in absence of GABA). Different kinetics of
the IGABA may be related structural differences among the studied
compounds. Furthermore, near plateau-like currents induced by
11 and 13 are in contrast to the fast decaying IGABA induced by 5
and 8 (similar to 4, 6, and 7), reflecting either pronounced desensi-
tization of GABA A receptors or an open channel block. Zuihonin A
(10) and deoxyschizandrin (9) are structurally too different from
the other lignans for structure–activity considerations. Compound
Fig. 5. (A–C) Concentration-dependent potentiation of the GABA-induced chloride current (IGABA) through a1b2c2S GABA A receptors by compounds 1–8 and 10–13. (D–F)
Typical currents elicited by GABA control samples (GABA EC5–10), and different concentrations of compounds 1–8 and 10–13 in absence and presence of GABA EC510
(preincubation experiments). Note that compounds 1–3, 5, 7, 8, and 12 induce small chloride currents in the absence of GABA suggesting partial agonist activity.
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10, however, can be grouped with anwulignan (11) and saururenin
(13) considering potency, efficiency, and also with respect to the
slowly decaying IGABA induced by this compound. The cuparene
sesquiterpenes 6 and 12 showed little to no agonistic activity at
GABA A receptors of a1b2c2S subunit composition, but reasonably
potent modulation of IGABA with comparable potency and effi-
ciency. The monoterpene cinnamic acid ester (7) showed partial
agonistic activity as lignans 1–3, and potent maximal IGABA stimu-
lation (834.6 ± 77.5%) (Fig. 5, Table 3; Chart 1).
2.3. Phytochemical differences between the genera Kadsura and
Schisandra
Kadsura and Schisandra are closely related genera which share a
similar phytochemical profile (Haensel et al., 1993; Saunders,
1998). Therefore, Kadsura fruits were often used as a substitute
for Schisandra (Haensel et al., 1993; Ookawa et al., 1981; Saunders,
1998). In the initial extract screening only the Kadsura species ex-
erted GABA A receptor modulatory activity. We compared the phy-
tochemical profiles of the petroleum ether extracts of S. chinensis
and both Kadsura species by HPLC-PDA-ESIMS. The HPLC-based
activity profiling of K. longipedunculata led to the identification of
constituents (1–8 and 10–13) which were responsible, to varying
degrees, for the GABA A receptor modulatory activity of the crude
extract. Most of these compounds could also be detected in the K.
japonica extract, which had previously shown comparable activity
in the oocyte assay as K. longipedunculata (Fig. 6). In contrast, the
HPLC profile of the inactive petroleum ether extract of S. chinensis
strongly differed from those of the Kadsura extracts. Only traces of
some of the active compounds could be detected by comparison of
UV and mass spectra (Fig. 6).
The lignan content of Schisandra sp. fruits varies depending on
geographical origin and time of harvest (Lu and Chen, 2009; Tang
and Eisenbrand, 2011; Zhu et al., 2007), and constituents such as
(+)-anwulignan (11) or meso-dihydroguaiaretic acid (5), which
we identified as GABA A receptor active, have already been isolated
from this source, however not as major compounds (Lu and Chen,
2009; Wei et al., 2010). Nonetheless, our results suggest that, de-
spite a rather similar phytochemical profile of Kadsura and Schisan-
dra species, their specific lignan patterns are decisive for the GABA
A receptor activities of the extracts. More samples should be tested
to draw a more general conclusion on this issue. Interestingly,
deoxyschisandrin (9), one of the extensively studied pharmacolog-
ically-active dibenzocyclooctadiene lignans (Hancke et al., 1999;
Opletal et al., 2004) and a major compound of S. sphenanthera
(Lu and Chen, 2009), does not affect GABA A receptors of the
a1b2c2S composition. It is possible that a sedative action of S. sphe-
nanthera in rodents is not due to GABA A receptor activity, but due
to other mechanisms as Huang et al. conjectured (Huang et al.,
2007). In contrast, the GABA A receptor modulating lignans of Kad-
sura species indeed reach a concentration sufficient for GABA A
receptor activity of the crude extract. Animal behavioral experi-
ments and pharmacokinetic studies with extracts and pure
compounds are needed to assess the GABA A receptor related activ-
ity in vivo.
2.4. Conclusions
Compared to other natural products previously isolated and
tested for GABA A receptor activity (Li et al., 2010; Yang et al.,
2011; Zaugg et al., 2010, 2011a), the lignans of K. longipedunculata
showed medium to high potencies and moderate efficiencies (ex-
cept for 2,4, and 5). Apart from neolignans honokiol and magnolol
(Ai et al., 2001), this is the first time that lignans are described as
GABA A receptor modulators. With exception of 11 and 131, all
lignans possessed physico-chemical properties favorable for oral
bioavailability and blood–brain-barrier penetration (H-acceptors
67, H-donors 63, MW 6450, cLogP: 65, number of rotatable bonds
68, polar surface area (PSA) 660–70 (90) Å2) (Pajouhesh and Lenz,
2005). Arisantetralones A–C (1–3) showed an interesting mode of ac-
tion, combining partial agonistic activity, positive modulation, and
possibly an open channel block at high concentrations, which war-
rants a more detailed investigation of their binding site(s), and po-
tential GABA A receptor subtype selectivity of this compound class.
Interestingly, two different compound classes, lignans and iso-
prenoids, contribute to the GABA A receptor modulating activity
of the K. longipedunculata extract. Among the 3 active terpenoids
6, 7 and 12, two were newly-described natural products. Their
absolute configurations were determined by comparison of
experimental and calculated ECD. ECD calculations have been
Table 3
Potencies and Efficiencies of Compounds 1–13 at the GABA A receptor (a1b2c2S).
Compounds EC50 lM Max. stimulation of IGABA at EC510% Hill-Coeff. nH Nr of exp. (n)
Arisantetralone lignans (Fig. 5A and D)
1 52.2 ± 24.8 245.0 ± 59.6 1.4 ± 0.5 6
2 135.6 ± 85.7 885.8 ± 291.2a,b 1.1 ± 0.3 4
3 36.6 ± 16.4 168.7 ± 41.5a 1.7 ± 0.8 5
4 118.7 ± 54.4 129.7 ± 36.8b 1.3 ± 0.5 4
Acyclic lignans (Fig. 5B and E)
5 79.2 ± 19.4cd 793.4 ± 107.4egh 1.5 ± 0.2 4
8 54.6 ± 28.8 362.5 ± 87.1e 1.4 ± 0.6 4
11 31.5 ± 7.1d 395.6 ± 27.2f,g 1.9 ± 0.7 4
13 12.8 ± 3.1c 288.8 ± 23.7f,h 1.2 ± 0.2 4
Other lignans (Fig. 5B and E)
9 n.d. n.d. n.d. 0
10 21.8 ± 7.5 218.1 ± 20.8 1.2 ± 0.5 4
Sesquiterpenes (Fig. 5C and F)
6 57.3 ± 19.7 383.5 ± 89.3 2.6 ± 1.0 4
12 118.4 ± 29.9 413.4 ± 66.3 1.7 ± 0.3 4
Monoterpene derivatives (Fig. 5C and G)
7 70.6 ± 12.2 834.6 ± 77.5 1.9 ± 0.3 4
a–h Statistically significant differences between the measured values in the columns are indicated by letters.
d p = 0.06; p < 0.05.
g p < 0.01.
1 Compounds 11 and 13 have a cLogP of 5.59. The other criteria are fulfilled.
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increasingly used for the interpretation of CD spectra (Bringmann
et al., 2009), However, the example of 12 shows the current limita-
tions of this approach and highlights the sensitivity of circular
dichroism to conformational changes. Therefore, proper conforma-
tional analysis and geometrical optimizations of the conformers
prior to calculations of energy transitions is essential.
3. Experimental
3.1. General experimental procedures
Optical rotation was measured on a Perkin Elmer polarimeter
(model 341) equipped with a 10 cm microcell. The optical rotation
for the sodium D line (589 nm) was extrapolated from the lines of
a mercury lamp using the Drude equation (Fluegge, 1970). CD
spectra of compounds 1–4were recorded in MeOH (50 lg/ml) on a
Chirascan CD spectrometer and analyzed with the Pro-Data V2.4
software. CD spectra of other compoundsweremeasuredonanAVIV
CD Spectrometer Model 62ADS and analyzed with the AVIV 60DS
V4.1 software. NMR spectra were recorded at target temperature
of 18 C on a Bruker Avance III 500 MHz spectrometer operating at
500.13 MHz for 1H and 125.77 MHz for 13C. A 1 mmTXI-microprobe
with a z-gradient was used for 1H-detected experiments; 13C-NMR
spectra were recorded with a 5 mm BBO-probe head with z-gradi-
ent. Spectra were analyzed using Bruker TopSpin 2.1 software. High
resolution mass spectra (HPLC-PDA-ESI-TOF-MS) in positive mode
were obtained on a Bruker micrOTOF ESI-MS system connected via
T-splitter (1:10) to an Agilent HP 1100 series system consisting of
a binary pump, autosampler, column oven and diode array detector
(G1315B) with settings as previously reported (Zaugg et al., 2010).
Data acquisition and processingwas performedusing Bruker HyStar
3.0 software. Semi-preparativeHPLCseparation for activity profiling
and compound isolationwas performed on anAlliance 2690 Separa-
tion module connected to a 996 photodiode array detector. Data
acquisition and processing was performed using Waters Empower
Pro Software. Waters SunFire C18 (3.5 lm, 3.0  150 mm) and
SunFire Prep C18 (5 lm, 10  150 mm) columns were used for ana-
lytical HPLC and semipreparative RP-HPLC, respectively. Semipre-
parative NP-HPLC was performed on a Merck LiChroSorb 100 Diol
(10 lm, 10  250 mm) column. Medium pressure liquid chroma-
tography (MPLC) was done on a pre-packed normal phase cartridge
(40-63 lm, 40  150 mm)using a Buchi Sepacore system consisting
of a control unit C-620, twopumpmodules C-605, and a fraction col-
lector C-660. The MPLC unit was controlled with the SepacoreCon-
trol software (version 1.0.3000.1). Preparative HPLC separation
was performed with a Waters SunFire Prep C18 OBD (5 lm,
30  150 mm) column on a Shimadzu LC-8A preparative separation
Fig. 6. HPLC-PDA-ESIMS analysis of K. longipedunculata, Kadsura japonica and Schisandra chinensis fruits (gradient 65% to 100% MeOH + HCO2H 0.1% in 30 min). Numbers
correspond to isolated compounds from K. longipedunculata with (black) and without (grey) GABA A receptor modulatory activity. The potentiation of the GABA induced
chloride current by the crude extract (100 lg/ml) is indicated on the upper right side of each chromatogram. UV traces recorded at 266 nm are shown. (For interpretation of
the references to colour in this figure legend, the reader is referred to the web version of this article.)
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chromatograph equippedwith a SPD-M10AVPdiode array detector.
HPLC-grade MeOH (Scharlau Chemie S.A.) and H2O were used for
HPLC separations. HPLC solvents contained 0.1% HCO2H for analyti-
cal separations. CDCl3 (100 Atom% D, stab. with Ag) and DMSO-d6
(100 Atom%) for NMR was purchased from Armar Chemicals. Sol-
vents used for extraction, open column chromatography, and MPLC
were of technical grade and purified by distillation. Silica gel (63–
200 lm, Merck) was used for open column chromatography.
3.2. Plant material
Dried fruits of K. longipedunculata Finet & Gagnep., K. japonica
(L.) Dunal, and S. chinensis (Turczaninow) Baillon were purchased
by Mr. Jinfu Wan, Yunnan Baiyao group Co. Ltd., Kunming, China,
at the Juhuayan herbal market in Kunming, Yunnan, China, and
identified at the labs of Yunnan Baiyao group. Voucher specimens
(00 450, 00 440, and 00 451, respectively) are deposited at the
Institute of Pharmaceutical Biology, University of Basel. The orga-
noleptic, macroscopic, and microscopic characteristics of apocarps
and seeds were confirmed by Janine Zaugg by comparison with lit.
(Fujita, 1929; Saunders, 1998, 2000). A detailed description of the
plant material is provided as Supplementary data.
3.3. Extraction
The plant material was frozen with liquid N2 and ground with a
Retsch ZM1 ultracentrifugal mill. The extract for the screening and
HPLC-based activity profiling was prepared with a Dionex ASE 200
extraction system with solvent module by extraction with
pet-ether, b.p. 40–60, redistilled. In total, 3 extraction cycles were
performed at an extraction pressure of 120 bar and a temperature
of 70 C. For compound isolation 1.08 kg of ground fruits were
macerated at room temperature with n-hexane (4  3.2 l, 1 h
each). The solvent was evaporated at reduced pressure to yield
109.7 g of extract. The extracts were stored at 20 C until use.
3.4. HPLC microfractionation
Microfractionation for GABA A receptor activity profiling was
performed as previously described (Kim et al., 2008), with minor
modifications: separation was carried out on a semipreparative
RP-HPLC column with MeOH (solvent A) and H2O (solvent B) using
the following gradient: 65% A–100% A in 30 min, hold for 10 min.
The flow rate was 4 ml/min, and 100 ll of the extract (100 mg/
ml in DMSO) were injected. A total of 28 time-based microfractions
of each 90 s each were collected. Microfractions were evaporated
in parallel with a Genevac EZ-2 plus vacuum centrifuge. The dry
films were redissolved in 1 ml of MeOH; aliquots of 0.5 ml were
dispensed in two vials, dried under N2 gas, and submitted to
bioassay.
3.5. Isolation
A portion of the extract (51.4 g) was partitioned by liquid–liquid
extraction with n-hexane and MeOH:H2O [9:1] to yield a lipophilic
fraction (36.0 g) and a polar fraction (14.8 g). The latter was sepa-
rated by open column chromatography (9  42 cm, 1.0 kg silica
gel) using a step gradient of n-hexane–EtOAc–MeOH (100:0:0, 2 l;
95:5:0, 2 l, 90:10:0, 2 l; 80:20:0, 2 l; 70:30:0, 2 l; 60:40:0, 2 l;
50:50:0, 1 l; 40:60:0, 1 l; 30:70:0, 1 l; 20:80:0, 1 l; 10:90:0, 1 l;
0:100:0, 2 l, 0:50:50, 1 l; 0:0:100, 1 l). The flow rate was ca. 50 ml/
min. The effluent was combined to 23 fractions (1–23) according
to TLC patterns (detection at 254 nm, 366 nm and at daylight after
staining with anisaldehyde–sulphuric acid reagent). Crystallization
of fraction 9 (1.68 g) yielded 692 mg of the major compound anwu-
lignan (11). Themother liquor of fraction 9 aswell as other fractions
used for compound isolation were diluted in MeOH (125-500 mg/
ml) and separated by preparative HPLC with different gradients of
MeOH and H2O and a flow rate of 20 ml/min as follows: 50 mg of
fraction 7 (102 mg), gradient of 70:30 to 85:15 in 14 min, yielded
(+)-Zuihonin A (10) (10 mg); 200 mg of themother liquor of fraction
9, gradient of 80:20 to 100:0 in 17 min yielded more anwulignan
(11) (111 mg) and saururenin (13) (19.5 mg), 100 mg of fraction
11 (474 mg), gradient of 73:27–90:10 in 22 min, yielded 8 mg of a
cinnamic acid ester of 6,7-dihydro-6,7-myrcenediol (Bohlmann
et al., 1983), 6-cinnamoyl-6,7-dihydro-7-myrceneol (7) and the dib-
enzocyclooctadiene lignan deoxyschizandrin (9) (1.3 mg); 60 mg of
fraction 12 (322 mg), gradient of 73:27–90:10 in 22 min, yielded
meso-dihydroguaiaretic acid (5) (17 mg) and meso-mono-
methyldihydroguaiaretic acid (8) (1 mg); 100 mg of fraction 14
(770 mg), gradient of 65:35–70:30 in 5 min, yielded arisantetralone
A (1) (2 mg), B (2) (1 mg), C (3) (29 mg), and D (4) (1 mg) (Cheng
et al., 2009; da Silva and Lopes, 2004; Liu et al., 1988).
An aliquot (980 mg) of fraction 10 (5.95 g) was separated by
MPLC using a CH2Cl2:THFmixture [97:3] and n-hexane in a gradient
ranging from 10:90 to 90:10 in 2 h, followed by 90:10–100:0 in
10 min, hold for 30 min. The flow rate was set at 15 ml/min and 12
fractions (A–L) were collected based on TLC analysis. Fractions 10B
(76 mg), 10C (28 mg), and 10G (61 mg) were dissolved in n-hexane
containing 64% iso-PrOH (100 mg/ml) and separated by semipre-
parative NP-HPLC using n-hexane and iso-PrOH (0.01% HCO2H) as
mobile phase. Isocratic conditions (10B, 10C: [98:2]; 10G:
[99.8:0.2]) were used; the flow ratewas 5 ml/min.Manual peak col-
lection yielded anwulignan (12) (21 mg of fraction 10B and 10 mgof
fraction 10C) and c-cuparenol (7) (4.5 mg) of fraction 10G. A part
(960 mg) of fraction 15 (1.52 g) was separated byMPLC using a gra-
dient of dichloromethane and MeOH (100:0–90:10 in 2 h, followed
by 90:10–0:100 in 30 min, flow rate 15 ml/min). Five fractions
(A–E) were collected based on TLC pattern. Repeated injections of
fraction15B (55 mg) onto semipreparativeNP-HPLCusingn-hexane
and iso-PrOH (0.01% HCO2H) in an isocratic mode [99.5:0.5] and a
flowrateof 5 ml/minyielded the5,6-dihydroderivativeof cuparenic
acid (Enzell and Erdtman, 1958) (13) (4 mg).
3.6. Spectroscopic data of new compounds
3.6.1. R-(+)-c-cuparenol (Ito et al., 1965; Nayek et al., 2003) (6)
White amorphic substance; ½a20D :+20.7 (MeOH; c 0.38); UV:
kmax (nm) 222, 263 sh; CD (MeOH, c = 1.8  103 M, 0.1 cm path-
length): [h]200 + 2 667, [h]209 + 1 009, [h]220 + 2 127; ESIMS m/z
219 [M + H]+. For 1H and 13C NMR data see Table 1.
3.6.2. R-(+)-6-cinnamoyl-6,7-dihydro-7-myrceneol (7)
Colorless oil; ½a20D :+15.2 (CHCl3; c 0.66); UV: kmax (nm) 218, 222,
230 sh; 278.5, 230 sh; CD (MeOH, c = 6.6  104 M, 0.1 cm path-
length): [h]205 + 13 380, [h]216 + 2 207, [h]229 + 6 677, [h]239 0,
[h]253-3 025, [h]282 0, [h]294 + 1 059; HRESIMS m/z 323.1649 (calcd.
for C19H24NaO3: 323.1618). For 1H and 13C NMR data see Table 2.
3.6.3. S-()-5,6-Dihydrocuparenic acid (12)
White amorphic substance; ½a20D : 31.3 (CHCl3; c 0.47); UV:
kmax (nm) 215, 302; CD (MeOH, c = 1.7  103 M, 0.1 cm path-
length): [h]205 + 1 938, [h]233 0, [h]302  1 905; HRESIMS m/z
257.1519 (calcd. for C15H22NaO2: 257.1512). For 1H and 13C NMR
data see Table 1.
3.7. Conformational analysis, geometrical optimization, and CD
calculation
Conformational analyses of compounds e6, e7 and e12 were
performed with Schrödinger MacroModel 9.1 software using the
OPLS 2005 (Optimized Potential for Liquid Simulations) force field
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in H2O. Conformers of e7 and e6/e12 occurring within a 1 and
2 kcal/mol energy window from the particular global minimum,
respectively, were chosen for geometrical optimization and energy
calculation using density functional theory (DFT) with the B3LYP
functional and the 6-31G⁄⁄ basis-set in the gas-phase with the
Gaussian 03 program package (Frisch et al., 2004). Vibrational
analysis was done at the same level to confirmminima (Bringmann
et al., 2009). TD-DFT/B3LYP/6-31G⁄⁄ (in the gas phase and in MeOH
using the ‘‘self-consistent reaction field‘‘ method (SCRF) with the
CPCM polarizable conductor calculation model) was employed to
calculate excitation energy (denoted by wavelength in nm) and
rotatory strength R in dipole velocity (Rvel) and dipole length (Rlen)
forms. ECD curves were calculated based on rotatory strengths
using half bandwidth of 0.2 eV with conformers of e6, e7 and
e12. The spectra were combined after Boltzmann-weighting
according to their population contribution.
3.8. Expression of GABA A receptors
Stage V–VI oocytes from Xenopus laevis were prepared and
cRNA was injected as previously described (Khom et al., 2006). Fe-
male X. laevis (Nasco) were anesthetized by exposing them for
15 min to a 0.2% MS-222 (3-aminobenzoic acid ethyl ester meth-
anesulfonate, Sigma–Aldrich) solution before surgically removing
parts of the ovaries. Follicle membranes from isolated oocytes were
enzymatically digested with 2 mg/ml collagenase from Clostridium
histolyticum (Type 1A, Sigma–Aldrich). Synthesis of capped run-off
poly(A+) cRNA transcripts was obtained from linearized cDNA
templates (pCMV vector). One day after enzymatic isolation, the
oocytes were injected with 50 nL of DEPC-treated H2O (Sigma–
Aldrich) containing different cRNAs at a concentration of ca. 300-
3000 pg/nL per subunit. The amount of injected cRNA mixture
was determined by means of a NanoDrop ND-1000 (Kisker Bio-
tech). Rat cRNAs were mixed in a 1:1:10 ratio to ensure expression
of the c-subunit in a1b2c2S receptors. Oocytes were then stored at
18 C in an aqueous solution of 90 mM NaCl, 1 mM KCl, 1 mM
MgCl2, 1 mM CaCl2 and 5 mM HEPES (pH 7.4), containing 1% of
Penicillin–Streptomycin solution (Sigma–Aldrich) (Methfessel
et al., 1986). Voltage clamp measurements were performed be-
tween days one and five after cRNA injection.
3.9. Two-microelectrode voltage clamp studies
Electrophysiological experiments were performed by the two-
microelectrode voltage clamp method making use of a TURBO
TEC 03X amplifier (npi electronic) at a holding potential of
70 mV and pCLAMP 10 data acquisition software (Molecular De-
vices). Currents were low-pass-filtered at 1 kHz and sampled at
3 kHz. The bath solution contained 90 mM NaCl, 1 mM KCl, 1 mM
MgCl2, 1 mM CaCl2 and 5 mM HEPES (pH 7.4). Electrode filling
solution contained 2 M KCl.
3.10. Fast solution exchange during IGABA recordings
Test solutions (100 lL) of extracts, fractions and pure
compounds were applied to the oocytes at a speed of 300 lL/s by
means of the ScreeningTool automated fast perfusion system (npi
electronics) (Baburin et al., 2006). In order to determine GABA
EC510 (typically between 3 and 10 lM for receptors of the subunit
combination a1b2c2S), a concentration-response experiment with
GABA concentrations ranging from 0.1 lM to 1 mM was per-
formed. Stock solution of plant extracts (10 mg/ml in DMSO) were
diluted to a concentration of 100 lg/ml with bath solution contain-
ing GABA EC510 according to a validated protocol (Kim et al.,
2008). As previously described, microfractions of the K. longipe-
dunculata extract collected from the semi-preparative HPLC sepa-
ration were dissolved in 30 ll DMSO and subsequently mixed
with 2.97 ml of bath solution containing GABA EC510 (Kim et al.,
2008). For concentration–response experiments, stock solutions
of compounds 1–13 (100 mM in DMSO) were diluted to concentra-
tions ranging from 0.1 to 500 lMwith bath solution and applied to
the oocyte for measuring agonistic activity. After a preincubation
period of 20 s, a second application immediately followed contain-
ing the corresponding compound solution combined with GABA
EC510 to measure GABA A receptor modulation.
3.11. Analyzing concentration–response curves
Enhancement of the GABA-induced chloride current (IGABA) was
defined as I(GABA + Comp)/IGABA–1, where I(GABA + Comp) is the current
response in the presence of a given compound, and IGABA is the con-
trol GABA-induced chloride current.
Concentration–response curves were generated, and the data
were fitted by nonlinear regression analysis using ORIGIN software
(OriginLab Corporation, Northampton, MA, USA). Data were fitted
to the equation 1
1þ EC50½Comp
 nH , where EC50 is the concentration of the
compound that increases the amplitude of the GABA-evoked
current by 50%, and nH is the Hill coefficient. The maximum poten-
tiation of IGABA by a given compound was derived from the fit.
Data are given as mean ± S.E. of at least 2 oocytes and P2
oocyte batches. Statistical significance was calculated using t-test
by ANOVA with confidence intervals of p < 0.05 and p < 0.01.
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S1. Plant material 
Kadsura longipedunculata (Syn.: K. peltigera 
Rehder & Wilson; K. Discigera Finet & Gagnep. ; 
K. omeiensis S.F. Lan). Material: dried apocarps 
purple to dark brown, 5-7 mm long, 3-5 mm wide; 
1-2 reniform seeds found per apocarp, 3-4 mm 
long and wide. Seed testa smooth, dark brown (in 
accordance to lit. (Saunders, 1998). Tastes 
aromatic, slightly sour.  
Kadsura japonica (L.) Dunal (Syn.: K. matsudai 
Hayata). Material : dried apocarps purple to dark 
brown, 5-7 mm long, 3-4 mm wide; 1-2 reniform 
seeds found per apocarp, approx. 4 mm long, 3-4 
mm wide. Seed testa smooth, redish brown to dark 
brown. (in accordance to literature (Saunders, 
1998). Tastes aromatic, slightly sour. Microscopic 
characteristics were in agreement with lit. (Fujita, 
1929) 
Schisandra chinensis (Turczaninow) Baillon 
(Syn.: Maximowiczia amurensis Ruprecht; 
Sphaerostema japonicum A. Gray) Material: dried 
apocarps dark puple, with hoarfrost like coating, 5-
7 mm long, 4-5 mm wide; 2 reniform seeds found 
per apocarp; approx. 4 mm long, 3-4 mm wide. 
Seed testa smooth, orange-brown (in accordance to 
literature (Saunders, 2000). Tastes aromatic and 
very sour. Microscopic characteristics were in 
agreement with lit. (Fujita, 1929) 
S2. Analytical Data of Isolated Compounds 
 
 
S2.1 (2S,3S,4R)-Arisantetralone A (1) (Cheng et 
al., 2009; da Silva and Lopes, 2004) 
[α]20D: -32.3° (CHCl3; c 0.15); CD (MeOH, c = 
1.46 × 10-4 M, 1 cm pathlength): [θ]213 +23 796, 
[θ]226 +6 370, [θ]240 +24 118, [θ]252 0, [θ]256 
-1 330, [θ]261 0, [θ]273 +7 013, [θ]281 0, [θ]290 
-10 031, [θ]302 -4 020, [θ]324 -5 820; 13C NMR 
(shifts from HSQC and HMBC experiment; 
MeOD): δ 10.6 (CH3-2), 14.5 (CH3-3), 42.2 (C-3), 
42.8 (C-2), 49.9 (C-4), 54.9 (OCH3-6), 55.1 
(OCH3-3’), 111.8 (C-8), 111.9 (C-5), 112.2 (C-2’), 
114.6 (C-5’), 121.1 (C-6’), 125.5 (C-9), 135.3 (C-
1’), 138.2 (C-10), 145.0 (C-4’), 145.5 (C-7), 148.0 
(3’), 153.1 (C-6), 201.6 (C-1); 1H NMR (500.13 
MHz, MeOD): δ 0.97 (3H, d, J = 7.0 Hz, C3-CH3), 
1.09 (3H, d, J = 7.2 Hz, C2-CH3), 2.42 (1H, ddq, 
J3,2 = 4.0 Hz, J3,4 = 5.9, J = 7.0 Hz, C3-H), 2.73 
(1H, dq, J = 4.0 Hz, J = 7.2 Hz, C2-H), 3.75 (3H, 
s, C6-OCH3), 3.76 (3H, s, C3’-OCH3), 4.00 (1H, d, 
J = 5.9 Hz, C4-H), 6.48 (1H, dd, J6’,2’ = 2.0 Hz, 
J6’,5’ = 8.1 Hz, C6’-H), 6.51 (1H, s, C5-H),  6.67 
(1H, d, J = 2.0 Hz, C2’-H), 6.74 (1H, d, J = 8.1 
Hz, C5’-H), 7.41 (1H, s, C8-H); ESI-MS m/z 343 
[M+H]+ 
 
S2.2 (2S,3S,4R)-Arisantetralone B (2) (Cheng et 
al., 2009; da Silva and Lopes, 2004) 
[α]20D: -90.7° (CHCl3; c 0.12); CD (MeOH, c = 
1.46 × 10-4 M, 1 cm pathlength): [θ]213 +21 218, 
[θ]233 +3 533, [θ]241 +6 937, [θ]256 0, [θ]274 +7 334, 
[θ]283 0, [θ]290 -6 737, [θ]304 -2 755, [θ]317 -2 539, 
[θ]328 0, [θ]341 +1 515; 13C NMR (shifts from 
HSQC and HMBC experiment; MeOD): δ 11.8 
(CH3-2), 16.12 (CH3-3), 43.2 (C-3), 44.8 (C-2), 
50.7 (C-4), 56.4 (OCH3-7), 56.5 (OCH3-3’), 109.6 
(C-8), 113.8 (C-2’), 116.2 (C-5’), 117.6 (C-5), 
122.7 (C-6’), 125.5 (C-9), 135.1 (C-1’), 142.4 (C-
10), 144.8 (C-4’), 148.9 (C-7 and C-3’), 152.8 (C-
6), 202.7 (C-1); 1H NMR (500.13 MHz, MeOD): δ 
0.95 (3H, d, J = 7.2 Hz, C3-CH3), 1.10 (3H, d, J = 
7.2 Hz, C2-CH3), 2.43 (1H, ddq, J3,2 = 4.1 Hz, J3,4 
= 6.5, J = 7.2 Hz, C3-H), 2.71 (1H, dq, J = 4.1 Hz, 
J = 7.2 Hz, C2-H), 3.77 (3H, s, C3’-OCH3), 3.80 
(3H, s, C7-OCH3), 3.91 (1H, d, J = 6.5 Hz, C4-H), 
6.39 (1H, s, C5-H), 6.50 (1H, dd, J6’,2’ = 1.8 Hz, 
J6’,5’ = 8.1 Hz, C6’-H) 6.67 (1H, d, J = 1.8 Hz, 
C2’-H), 6.74 (1H, d, J = 8.1 Hz, C5’-H), 7.52 (1H, 
s, C8-H); ESI-MS m/z 343 [M+H]+ 
 
S2.3 (2S,3S,4R)-Arisantetralone C (3) (Cheng et 
al., 2009; da Silva and Lopes, 2004) 
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[α]20D: -36.9° (CHCl3; c 0.61); CD (MeOH, c = 
1.40 × 10-4 M, 1 cm pathlength): [θ]213 +21 559, 
[θ]226 +7 680, [θ]238 +20 568, [θ]256 +2017, [θ]274 
+7 346, [θ]287 +428, [θ]298 +2 518, [θ]320 0, [θ]325 
-376, [θ]333 0; 13C NMR (shifts from HSQC and 
HMBC experiment; MeOD): δ 11.9 (CH3-2), 16.0 
(CH3-3), 43.5 (C-3), 44.0 (C-2), 51.3 (C-4), 56.3 
(OCH3-6 and OCH3-3’), 56.5 (OCH3-4’), 113.1 
(C-5, C-8, and C-5’), 113.9 (C-2’), 122.4 (C-6’), 
126.3 (C-9), 137.5 (C-1’), 139.4 (C-10), 146.8 (C-
7), 149.4 (C-4’), 150.5 (C-3’), 154.3 (C-6), 
202.3 (C-1); 1H NMR (500.13 MHz, MeOD): δ 
0.98 (3H, d, J = 7.0 Hz, C3-CH3), 1.09 (3H, d, J = 
7.0 Hz, C2-CH3), 2.72 (1H, dq, J = 4.0 Hz, J = 7.0 
Hz, C2-H), 2.43 (1H, ddq, J3,2 = 4.0 Hz, J3,4 = 5.7, 
J = 7.0 Hz, C3-H), 3.75 (3H, s, C6-OCH3 and C3’-
OCH3), 3.81 (3H, s, C4’-OCH3), 4.04 (1H, d, J = 
5.7 Hz, C4-H), 6.52 (1H, s, C5-H), 6.58 (1H, dd, 
J6’,2’ = 1.9 Hz, J6’,5’ = 8.1 Hz, C6’-H), 6.73 (1H, d, 
J = 1.9 Hz, C2’-H), 6.88 (1H, d, J = 8.1 Hz, C5’-
H), 7.42 (1H, s, C8-H); ESI-MS m/z 357 [M+H]+ 
 
S2.4 (2R,3S,4R)-Arisantetralone D (4) (Cheng et 
al., 2009; da Silva and Lopes, 2004) 
[α]20D: +2.7° (CHCl3; c 1.00); CD (MeOH, c = 
1.46 × 10-4 M, 1 cm pathlength): [θ]214 +27 701, 
[θ]225 +9 144, [θ]241 +20 771, [θ]256 +4 273, [θ]270 
+10 375, [θ]284 0, [θ]288 -1 950, [θ]295 -372, [θ]304 
-1 188, [θ]313 0, [θ]331 +9 437; 13C NMR (shifts 
from HSQC and HMBC experiment; MeOD): δ 
11.6 (CH3-2), 16.9 (CH3-3), 43.8 (C-3), 48.3 (C-2), 
52.8 (C-4), 54.6 (OCH3-6), 55.3 (OCH3-3’ and 
OCH3-4’), 111.1 (C-5), 111.5 (C-8), 111.8 (C-5’) 
112.8 (C-2’), 122.0 (C-6’), 125.7 (C-9), 136.9 (C-
1’), 141.3 (C-10), 145.3 (C-7), 147.9 (C-4’), 149.9 
(C-3’), 152.6 (C-6), 199.5 (C-1); 1H NMR (500.13 
MHz, MeOD): δ 0.93 (3H, d, J = 7.0 Hz, C3-CH3), 
1.26 (3H, d, J = 7.0 Hz, C2-CH3), 2.37 (1H, dq, J 
= 12.2 Hz, J = 7.0 Hz, C2-H), 2.43 (1H, ddq, J3,2 = 
12.2 Hz, J3,4 = 10.5, J = 7.0 Hz, C3-H), 3.59 (3H, 
s, C6-OCH3), 3.73 (1H, d, J = 10.5 Hz, C4-H), 
3.77 (3H, s, C3’-OCH3), 3.84 (3H, s, C4’-OCH3), 
6.21 (1H, s, C5-H), 6.73 (1H, d, J = 1.8 Hz, C2’-
H), 6.77 (1H, dd, J6’,2’ = 1.8 Hz, J6’,5’ = 7.8 Hz, 
C6’-H), 6.98 (1H, d, J = 7.8 Hz, C5’-H), 7.38 (1H, 
s, C8-H); ESI-MS m/z 357 [M+H]+ 
 
 
 
 
S2.5 Meso-dihydroguaiaretic acid (5) (Schrecker, 
1957; Wang et al., 2006) 
[α]20D: +4.1° (CHCl3; c 1.00); 13C NMR (shifts 
from HSQC and HMBC experiment; MeOD): δ 
15.1 (C-9 and C-9’), 38.3 (C-7 and C-7’), 38.7 (C-
8 and C-8’), 55.1 (OCH3-3 and OCH3-3’), 112.4 
(C-2 and C-2’), 114.5 (C-5 and C-5’), 121.2 (C-6 
and C-6’), 133.5 (C-1 and C-1’), 144.1 (C-4 and 
C-4’), 147.3 (C-3 and C-3’); 1H NMR (500 MHz, 
MeOD) δ 0.83 (6H, d, J = 6.7 Hz, C9-H, C9’-H), 
1.74 (2H, dqdd, J = 9.0, 6.7, 5.4, 5.0 Hz, C8-H, 
C8’-H), 2.26 (2H, dd, J = 13.5, 9.0 Hz, C7-Hb and 
C7’-Hb), 2.70 (2H, dd, J = 13.5, 5.4 Hz, C7-Ha and 
C7’-Ha), 3.78 (6H, s, C3-OCH3 and C3’-OCH3),  
6.58 (2H, dd, J = 8.0, 1.8 Hz, C5-H and C5’-H), 
6.65 (2H, d, J = 1.8 Hz, C2-H and C2’-H), 6.71 
(2H, d, J = 8.0 Hz, C6-H and C6’-H); Critical 
NOESY correlations: 7.28 ↔ 1.03, 1.22, 2.47; 
2.47 ↔ 0.52; ESI-MS m/z 331 [M+H]+ 
 
S2.6 Quasi-meso-monomethyl dihydroguaiaretic 
acid (8) (Miyazawa et al., 1997) 
[α]20D: 0° (CHCl3; c 0.09); 13C NMR (shifts from 
HSQC and HMBC experiment; MeOD): δ 15.1 
(C-9 and C-9’), 38.2 (C-7 and C-7’), 38.7 (C-8 and 
C-8’), 55.2 (OCH3-3, OCH3-3’, and OCH-4’), 
112.1 (C-5)a, 112.5 (C-2’)b, 113.0 (C-2)b, 114.5 
(C-5’)a, 121.2 (C-6’)c, 121.3 (C-6)c, 133.4 (C-1’)d, 
134.8 (C-1)d, 143.9 (C-4 and C-4’), 147.2 (C-3’)e, 
148.9 (C-3)e; 1H NMR (500 MHz, MeOD) δ 0.84 
(3H, d, J = 6.7 Hz, C9-H)f, 0.85 (3H, d, J = 6.7 Hz, 
C9’-H)f, 1.76 (2H, m, C8-H and C8’-H), 2.28 (1H, 
dd, J = 13.5, 9.1 Hz, C7-Hb)g, 2.30 (1H, dd, J = 
13.5, 9.1Hz, C7’-Hb)g, 2.71 (1H, dd, J = 13.5, 5.1 
Hz, C7-Ha)h, 2.74 (1H, dd, J = 13.5, 5.1 Hz, C7’-
Ha)h, 3.77 (3H, s, C3-OCH3)i, 3.79 (3H, s, 
C3’-OCH3)i, 3.80 (3H, s, C4’-OCH3)i, 6.59 (1H, 
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dd, J = 8.0, 1.9 Hz, C6’-H)j, 6.67 (1H, d, J = 1.9 
Hz, C2’-H)k, 6.69 (1H, d, J = 1.9 Hz, C2-H) k, 6.70 
(1H, dd, J = 8.0, 1.9 Hz, C6-H)j, 6.70 (1H, d, J = 
8.0 Hz, C5’-H)l, 6.84 (1H, d, J = 8.0 Hz, C5-H)l; 
ESI-MS m/z 345 [M+H]+  
a-l Interchangeable 
 
S2.7 Anwulignan (11) (Nakatani et al., 1988) 
[α]20D: +1.1° (CHCl3; c 1.0); 13C NMR (shifts from 
HSQC and HMBC experiment; CDCl3): δ 16.1 (C-
9 and C-9’), 38.9 (C-7’), 39.3 (C-7), 39.4 (C-8 and 
C-8’), 55.8 (OCH3-3’), 100.6 (-OCH2O-), 107.9 
(C-5), 109.3 (C-2), 111.7 (C-2’), 114.1 (C-5’), 
121.7 (C-6), 121.7 (C-6’), 133.7 (C-1’), 135.7 (C-
1), 143.9 (C-4’), 145.4 (C-4), 146.3 (C-3’), 147.5 
(C-3); 1H NMR (500 MHz, CDCl3) δ 0.84 (3H, d, 
J = 6.7 Hz, C9-H), 0.85 (3H, d, J = 6.7 Hz, C9’-H), 
1.74 (2H, m, C8-H and C8’-H), 2.25 (1H, dd, J = 
13.5, 9.6 Hz, C7’-Hb), 2.28 (1H, dd, J = 13.5, 9.6 
Hz, C7-Hb), 2.72 (2H, dd, J = 13.5, 4.8 Hz, C7’-Ha 
and C7-Ha), 3.85 (3H, s, C3’-OCH3), 5.90 (2H, m, 
C3,C4-OOCH2), 6.60 (1H, dd, J = 8.0, 1.4 Hz, C6-
H), 6.62 (1H, d, J = 1.4 Hz, C2’-H), 6.64 (1H, dd, 
J = 8.0, 1.4 Hz, C6’-H), 6.65 (1H, d, J = 1.4 Hz, 
C2-H), 6.72 (1H, d, J = 8.0 Hz, C5-H), 6.82 (1H, 
d, J = 8.0 Hz, C5’-H); ESI-MS m/z 329 [M+H]+  
 
S2.8 Saururenin (13) (Wang et al., 2000) 
[α]20D: +2.3° (MeOD; c 0.33); 13C NMR (shifts 
from HSQC and HMBC experiment; CDCl3): δ 
16.2 (C-9 and C-9’), 39.0 (C-7 and C-7’), 39.5 (C-
8 and C-8’), 55.9 (OCH3-3’ and OCH3-4’), 100.6 
(-OCH2O-), 108.0 (C-5), 109.0 (C-2), 112.5 (C-
2’), 111.9 (C-5’), 121.5 (C-6), 121.2 (C-6’), 134.5 
(C-1’), 135.6 (C-1), 147.6 (C-4’), 145.6 (C-4), 
149.4 (C-3’), 147.8 (C-3); 1H NMR (500 MHz, 
CDCl3) δ 0.84 (3H, d, J = 6.7 Hz, C9-H)a, 0.85 
(3H, d, J = 6.7 Hz, C9’-H)a, 1.70 – 1.80 (2H, m, 
C8-H and C8’-H), 2.26 (1H, dd, J = 13.3, 9.0 Hz, 
C7’-Hb), 2.29 (1H, dd, J = 13.3, 9.0 Hz, C7-Hb), 
2.71 (2H, dd, J = 13.3, 6.2 Hz, C7-Ha), 2.73 (2H, 
dd, J = 13.3, 6.2 Hz, C7’-Ha), 3.82 (3H, s, C4’-
OCH3), 3.83 (3H, s, C3’-OCH3), 5.86 (2H, s, 
C3,C4-OOCH2), 6.59 (1H, dd, J = 8.2, 1.3 Hz, C6-
H), 6.64 (1H, d, J = 1.3 Hz, C2-H), 6.67 (1H, dd, J 
= 7.8, 1.4 Hz, C6’-H), 6.70 (1H, d, J = 8.2 Hz, C5-
H), 6.65 (1H, d, J = 1.4 Hz, C2’-H), 6.77 (1H, d, J 
= 8.2 Hz, C5’-H); ESI-MS m/z 343 [M+H]+  
a Interchangeable 
 
 
 
S2.9 Deoxyschizandrin (9) (Ikeya et al., 1980; 
Ikeya et al., 1979) 
CD (MeOH, c = 1.20 × 10-4 M, 1 cm pathlength): 
[θ]213 -39 102, [θ]223 0, [θ]238 +45 446 sh., [θ]249 
+56 876, [θ]272 +14 681 sh.; 13C NMR (shifts from 
HSQC and HMBC experiment; MeOD): δ 12.9 
(C-9), 21.9 (C-9’), 35.2 (C-8), 36.4 (C-7’), 40.0 
(C-7), 42.2 (C-8’), 56.5 (OCH3-5 and OCH3-5’), 
60.8 (OCH3-3 and OCH3-3’), 61.3 (OCH3-4 and 
OCH3-4’), 108.9 (C-6’), 112.4 (C-6), 123.3 (C-2’), 
124.4 (C-2), 135.5 (C-1), 140.5 (C-1’), 140.8 (C-
4’), 141.4 (C-4), 152.3 (C-3’), 152.3 (C-3), 152.9 
(C-5), 154.0 (C-5’); 1H NMR (500 MHz, MeOD) δ 
0.74 (3H, d, J = 7.2 Hz, C9-H), 1.01 (3H, d, J = 7.2 
Hz, C9’-H), 1.78 (1H, dqdd, J8’,7’a = 9.5 Hz, J8’,9’ = 
7.2 Hz, J8’,8 = 2.9 Hz, J8’,7’b = 1.4 Hz, C8’-H), 1.92 
(1H, dqdd, J8,7a = 7.7 Hz, J8,9 = 7.2 Hz, J8,8’ = 2.9 
Hz, J8,7b = 1.8 Hz, C8-H), 2.10 (1H, dd, J = 13.3, J 
= 1.4 Hz, C7’-Hb), 2.26 (1H, dd, J = 13.3 Hz, J = 
9.5 Hz, C7’-Ha), 2.48 (1H, dd, J = 13.6, J = 1.8 
Hz, C7-Hb), 2.63 (1H, dd, J = 13.6, J = 7.7 Hz, 
C7-Ha), 3.47 (6H, s, C3-OCH3 and C3’-OCH3), 
3.83 – 3.84 (6H, s, C4-OCH3 and C4’-OCH3), 3.87 
(6H, s, C5-OCH3 and C5’-OCH3), 6.66 (1H, s, 
C6’-H), 6.68 (1H, s, C6-H); ESI-MS m/z 417 
[M+H]+   
 
 
 
S2.10 (+)-Zuihonin A (10) (Lee, 1981; Sadhu et 
al., 2003; Urzua et al., 1987) 
[α]20D: +104.8° (CHCl3; c 0.99); CD (MeOH, c = 
5.9 × 10-4 M, 0.1 cm pathlength): [θ]200 -17 295, 
[θ]207 +85 087, [θ]224 +3 031, [θ]239 +9 702, [θ]270 
+10 375, [θ]260 0, [θ]294 +3 875, [θ]304 0; 13C NMR 
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(shifts from HSQC and HMBC experiment; 
CDCl3): δ 9.2 (C-9’), 11.7 (C-9), 47.3 (C-8’), 43.3 
(C-8), 84.7 (C-7’), 85.6 (C-7), 100.3 (-OCH2O-), 
106.2 (C-2), 107.0 (C-2’), 107.6 (C-5 and C-5’), 
119.3 (C-6 and C-6’), 134.5 (C-1’), 137.5 (C-1),  
147.3 (C-3, C-3’, C-4, and C-4’); 1H NMR (500 
MHz, CDCl3) δ 0.62 (3H, d, J = 7.4 Hz, C9’-H), 
0.99 (3H, d, J = 7.4 Hz, C9-H), 2.39 (1H, m, C8’-
H), 2.40 (1H, m, C8-H),  4.60 (1H, d, J = 9.6 Hz, 
C7-H), 5.34 (1H, d, J = 4.4 Hz, C7’-H), 5.90 (4H, 
m, OCH2O), 6.75 – 6.82 (4H, m, C5-H, C6-H, 
C5’-H, and C6’-H), 6.85 (1H, br s, C2’-H), 6.92 
(1H, br s, C2-H); ESI-MS 703 m/z [2M+Na] 
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Figure S1. Experimental ECD curves for compounds 1-4 and 8 in MeOH.  
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Figure S2. Calculated ECD spectra in the gas-phase and in MeOH (CPCM) of each minimized 
conformer (DFT/B3LYP/6-31G**) of e6 occurring within an energy range of 2 kcal/mol from 
the global minimum. 
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Figure S3. Calculated ECD spectra in the gas-phase and in MeOH (CPCM) of the minimized 
conformers (DFT/B3LYP/6-31G**) of e7 with a cisoid enone conformation occurring within an 
energy range of 1 kcal/mol. 
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Figure S4. Calculated ECD spectra in the gas-phase and in MeOH (CPCM) of the minimized 
conformers (DFT/B3LYP/6-31G**) of e7 with a transoid enone conformation occurring within 
an energy range of 1 kcal/mol. 
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Figure S5. Calculated ECD spectra in the gas-phase and in MeOH (CPCM) of each minimized 
conformer (DFT/B3LYP/6-31G**) of e12 occurring within an energy range of 2 kcal/mol. 
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Table S1. Conformational analysis of compound e7, e12, and e6 in the gas phase. 
Compound e7  Compound e12  Compound e6 
Speciesa ΔEb PE%c  Speciesd ΔEa PE%b  Speciesd ΔEa PE%b
C1 1.2 4.8  C1 0.0 26.6  C1 0.0 15.4 
C2 2.8 0.3  C2 0.3 15.1  C2 0.0 15.4 
C3 3.8 0.1  C3 0.1 22.6  C3 0.0 15.6 
C4 1.3 4.1  C4 0.4 14.3  C4 0.0 16.7 
C5 2.6 0.5  C5 0.7 7.9  C5 0.4 8.6 
C6 1.2 4.6  C6 0.4 12.6  C6 0.4 8.4 
C7 1.7 2.1  C7 2.0 0.9  C7 0.4 8.9 
C8 2.9 0.3      C8 0.4 8.3 
C9 1.0 7.2      C9 1.9 0.7 
C10 2.8 0.3      C10 1.9 0.7 
C11 2.3 0.8      C11 1.9 0.7 
C12 1.0 6.8      C12 1.9 0.7 
C13 0.0 36.3         
C14 2.7 0.4         
C15 2.5 0.5         
C16 2.1 1.0         
C17 0.2 25.6         
aOccurring within a 1 kcal/mol window in the conformational search using OPLS 2005 force field. bRelative energy 
(kcal/mol) ab initio calculated. cBoltzmann weights for different conformers calculated by using DFT/B3YLP/6-
31G** in the gas phase. d Occurring within a 2 kcal/mol window in the conformational search using OPLS 2005 
force field. 
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Table S2. Dihedral angles causing diene helicity in compound e12.  
Species C1-C2-C3-C4 Helicity 
C1 15.9 P 
C2 15.8 P 
C3 -14.8 M 
C4 -14.5 M 
C5 -14.5 M 
C6 -14.8 M 
C7 -15.6 M 
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The extracts of Piper nigrum fruits, Angelica pubescens roots, Acorus calamus roots, Biota 
orientalis leaves and twigs, and Kadsura longipedunculata fruits fulfilled the selection criteria for 
an investigation of their GABAA receptor modulating constituents due to the following reasons: 
(i) they all exhibited pronounced potentiation of the GABA induced chloride current in the 
screening, (ii) they all originated from plants related to TCM, and (iii) the plants belong to 
different families of distinct orders. These are good preconditions to afford pharmacologically 
favorable, GABAA receptor modulating compounds from diverse secondary metabolite classes.  
The HPLC-based activity profiling approach [1] was used for the identification of the active 
constituents of all extracts investigated in this study. The virtues of this miniaturized approach 
were exemplified with the piperamides from Piper nigrum (Chapter 3.1). Using only milligram 
amounts of extract, we were able to identify compounds responsible for the activity (piperine (1) 
as main new scaffold) along with other, structurally related, inactive constituents. The generation 
of this “virtual” library allowed preliminary structure-activity considerations useful for further 
medicinal chemistry efforts (Chart 4). Structure elucidation using minute amounts of material 
could only be realized due to off-line use of highly sensitive microprobe NMR for semi-
preparative HPLC fractions and on-line HPLC-PDA-TOF-MS. Our work on Piper nigrum 
demonstrated that these are core analytical tools for the HPLC-based activity profiling approach.  
In the case of Angelica pubescens (Chapter 3.2), HPLC-based activity profiling allowed the 
early dereplication of the coumarin osthol as a major active compound. Despite being aware of 
the neurotoxicity of this compound, we decided to pursue further the investigation with A. 
pubsecens since reports on GABAA receptor activity of coumarins were fairly limited [2]. 
Preliminary in vitro tests using the Xenopus assay, however, revealed only moderate GABAA 
receptor modulation by all compounds isolated from A. pubescens, and the project was 
discontinued.  
Determination of the configuration of a chiral compound is difficult and often complicates the 
process of structure elucidation as it is shown by the examples of Acorus calamus (Chapter 3.3) 
and Kadsura longipedunculata (Chapter 3.5). With (+)-dioxosarcoguaiacol from A. calamus, we 
demonstrated the applicability of in silico conformational analysis and geometrical optimization 
as complementary for determining the relative configuration by NMR experiments. Hence, we 
were able to rectify and complete the previously reported relative configuration of this compound 
(Figure 10) [3].  
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After full elucidation of the covalent structure 
by NMR experiments, we were able to identify the 
absolute configuration of the isoprenoids isolated 
from K. longipedunculata. Again, experimental 
data (ECD) could be interpreted with the aid of 
conformational analysis and quantum-chemical 
calculations. Both examples highlight the value of 
a multidisciplinary approach for successful 
structure elucidation.  
The ultimately identified novel GABAA 
receptor modulators within this study belong to 
distinct classes of secondary metabolites, as assumed from the targeted choice of active extracts 
for investigation (Figure 11). Scaffold similarities allowed insights into structural features critical 
for GABAA receptor modulation (Chart 4). Several compounds fulfilled the criteria for being a 
relevant hit for further pharmacological investigations (Figure 11, Table 2, Chart 4). These 
criteria include (i) adequate potency and efficiency at the target in comparison with known drugs 
(Figure 11), (ii) “drug-likeness” by answering Lipinski’s rule-of-five [4] and physico-chemical 
properties favorable for blood-brain barrier (BBB) penetration [4, 5] (Table 2), (iii) scaffold 
novelty, and not unimportant, (iv) the possibility of resupply for in vivo experiments and 
medicinal chemistry efforts.  
Table 2: Physico-chemical properties of “drug-like” scaffolds isolated within this thesis with 
potential for further investigation at the GABAA receptor.a 
Compound H-acceptors H-donors MW (g/mol) cLogP Rotatable bonds PSA
1 4 0 285 3.3 0 38.8 
2 2 1 302 4.2 2 37.3 
4 4 1 328 5.6 6 47.9 
5 4 0 342 5.6 7 36.9 
6, 7 5 2 342 3.6 3 76.0 
8 5 1 356 4.1 4 65.0 
10 1 0 220 4.6 3 17.1 
12 1 0 220 4.4 1 17.1 
a Physico-chemical properties favorable for oral bioavailability and blood-brain barrier penetration were enunciated 
by Pajouhesh and Lenz, 2005 [5], on the basis of Lipinski’s rule-of-five [4]. They include: H-acceptors ≤ 7, H-
donors ≤ 3, MW ≤ 450 g/mol, cLogP ≤ 5, rotatable bonds ≤ 8, polar surface area (PSA) ≤ 60-70 (-90) Å2 
 
 
 
Figure 10: 4R*8S*10R*-(+)-dioxosarcoguaiacol 
191
  
 
Chart 4: Selected novel scaffolds at the α1β2γ2S GABAA receptor from natural origin. Structural features positively 
influencing potency and efficiency are highlighted in green, structural features impairing GABAA receptor activity, 
are indicated in red. 
As a consequence of our findings, the GABAA receptor subtype specificity of piperine (1) has 
been characterized, the scaffold was used for medicinal chemistry, and in vivo experiments 
assessing the sedative-like and anxiolytic-like activity of this natural product have been 
conducted. These soon to be published data will provide more information about the relevance of 
this scaffold for further development. Piperine (1) is, however, a pharmacologically promiscuous 
compound and inhibits phase I and phase II metabolism [6-10] hence auguring side effects and 
drug-drug interactions. Therefore it must be investigated to what extent structural modifications 
of the piperine scaffold can positively influence target selectivity.  
Sandaracopimaric acid (2) equally answered the criteria for being a relevant hit (Table 2). It 
binds as well independently from the BZD binding site, thus presenting an interesting scaffold for 
the development of GABAA receptor modulating drugs.  
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Figure 11: Overview on GABAA receptor modulatory efficiency and potency at the α1β2γ2S subtype by compounds 
isolated from Piper nigrum fruits, Acorus calamus roots, Biota orientalis leaves and twigs, and Kadsura 
longipedunculata fruits. The compounds are grouped according to their structure. Compounds from Angelica 
pubescens are missing since potencies and efficiencies were not determined. Numbers indicate the compounds 
shown in Chart 4: piperine (1), sandaracopimaric acid (2), isopimaric acid (3), anwulignan (4), saururenin (5), 
arisantetralones A-D (6-9), sesquiterpenes of A. calamus (10-12). Potentiation of the GABA-induced chloride current 
(IGABA) was measured at a GABA EC5-10. Reference data of benzodiazepines (triazolam, midazolam, clotiazepam) 
are taken from Khom et al. 2006 [11]. Etomidate and Alphaxalone values were measured by Pau et al. 2003 [12]. 
Pentobarbitone was investigated by Thompson et al, 1996 [13], however, using a GABA EC20 which means that 
pentobarbitone efficiency is underestimated compared to the rest. 
We conducted experiments to investigate GABAA receptor subtype specificity with 2 and 
assessed pharmacological effects in preliminary animal experiments (Chapter 3.4). However, a 
rather strong efficiency in vitro occurring at α2, α3, or β2 subunit-containing receptors, could not 
be confirmed in vivo, reflected by comparatively weak anxiolytic-like effects. Further in vivo 
experiments using different paradigms complementary to ours might give deeper insight into the 
pharmacological action and the potency and efficiency of this molecule. Despite slightly superior 
efficiencies at the above mentioned receptors, it is advisable to further improve subtype 
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selectivity of 2 by medicinal chemistry. An important issue is pharmacokinetics and toxicity, 
which should soon be addressed for sandaracopimaric acid (2) with appropriate experiments. 
Intraperitoneal drug administration has been chosen by many researchers for in vivo 
behavioral experiments investigating GABAA receptor related effects, inclusively our publication 
(Chapter 3.4). However, this route of drug administration is disputable, since the liver first-pass 
is disregarded. Oral administration is a much more realistic route including all pharmacokinetic 
hurdles for a drug to leap and is well applicable when investigating GABAA receptor active drugs 
or extracts [2]. 
Anwulignan (4) and saururenin (5) showed favorable potencies and efficiencies at the α1β2γ2S 
GABAA receptor (Chapter 3.5, Figure 11). Moreover, compounds 4 and 5 were devoid of 
agonistic effects, can be isolated in reasonable amounts, and show “drug-like” physico-chemical 
properties (except for a slightly high clogP value of 5.6) (Table 2). Therefore, they present new 
candidates to be evaluated for GABAA receptor subtype specificity. Other lignans, such as the 
arisantetralones A-D (6-9), attracted attention due to their exceptional influence on IGABA kinetics 
(Chapter 3.5). Such compounds are interesting from the perspective of possibly exploring yet 
unknown binding sites and mode of interactions at the GABAA receptor.  
Shyobunone (10) and acorenone (12), isolated from A. calamus, are promising in terms of 
their GABAA receptor modulatory activity and they also fulfill the criteria for orally available 
CNS drugs (Figure 11, Table 2). However, careful evaluation of whether further efforts with 
these compounds are worthwhile is advised. Their small size is a drawback for high affinity 
hydrophobic interactions [14] but could possibly be overcome by structural modification. Double 
bonds as well as the carbonyl group may be targeted for this purpose. 
The “privileged” scaffolds summarized in Table 2 and Chart 4 are highly lipophilic 
compounds which are indeed favorable for BBB penetration and oral availability, but implicate 
solubility problems at sample preparation. For this purpose, often dimethyl sulfoxide is used 
despite of influencing BBB permeability and brain metabolism [15]. Alternative pharmaceutical 
formulations for drug delivery devoid of DMSO may be considered for further animal studies. 
The compounds that were isolated, structurally characterized, and pharmacologically 
evaluated in an in vitro functional assay enlarge the spectrum of natural products acting as 
positive GABAA receptor modulators at the α1β2γ2S subtype (Figure 11). On the whole, a few 
highlights could be identified which should be pursued further. We can conclude that the 
pharmacologic potential of some of these compounds is smaller than of others due to known 
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toxicity (β-asarone, osthol, and linear furanocoumarins), low to moderate activity [angular 
furanocoumarins, bisabolangelone, isoshyobunone (11), piperanine, and arisantetralone D (9)] 
and/or very low potency [preisocalamenediol and isopimaric acid (3)], or difficulty in resupply 
[(+)-dioxosarcoguaiacol (Fig. 1), cuparenes, dihydroguaiaretic acids, zuihonin A, 6-cinnamoyl-7-
hydroxymyrcene) (see Chapters 3.2, 3.3, and 3.5 for structures). In the latter case, literature 
research for alternative source material might be helpful.  
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